AU2007201854A1 - Pharmaceutically active sulfanilide derivatives - Google Patents

Description

I

AUSTRALIA

Patents Act 1990 COMPLETE SPECIFICATION Standard Patent Applicant(s): APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

Invention Title: PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES The following statement is a full description of this invention, including the best method for performing it known to me/us: WO 02/32864 PCT/EP01/11865 (q -1A- Pharmaceutically Active Sulfanilide Derivatives n00

OO

Field of the invention CN The present invention is related to sulfanilide derivatives, in particular for use as Smedicaments, as well as pharmaceutical Formulations containing such sulfanilide CI derivatives. Said sulfanilide derivatives are useful in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion ofvasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. Preferably, the sulfanilide derivatives display a modulatory, notably an antagonist activity of the oxytocin and/or vasopressin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin and/or vasopressin, including preterm labor, premature birth, inappropriate secretion ofvasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome, hypertension and dysmenorrhea.

Background of the invention Arginine vasopressin (AVP) and oxytocin (OT) are cyclic nonapeptides whose actions are mediated by activation of specific G protein-coupled receptors currently classifid into V 1 vascular (VIR), V 2 -renal (V 2 R) and V 3 -pituitary (V 3 R) AVP receptors, as well as OT receptors (OT-R).

Oxytocin (OT) is a peptide hormone that causes the contraction of the uterus of mammals during labor. The corresponding oxytocin receptor belongs to the family of G-proteincoupled receptors and is similar to Vi and V 2 vasopressin receptors. OT receptors increase dramatically during the course of pregnancy. The concentration of OT receptors has been shown to correlate with spontaneous uterine activity Maggi et al. J. Clin.Endocrinol Metabol; 70; 1142, 1990). Premature labor, though, and premature birth is undesired as it WO 02/32864 PCT/EP01/11865 S-2- ¢c represents a major cause of perinatal morbidity and mortality. Hence, the management of preterm labor represents a significant problem in the field of obstetrics.

oO Vasopressin is a cyclic nonapeptide hormone that exhibits a series of physiological effects 0 including free water reabsorption, vasoconstriction, cellular proliferation and S 5 adrenocorticotrophic hormone (ACTH) secretion. In a healthy organism, vasopressin plays San important role in the homeostasis of fluid osmolality and volume status. However, in several diseases or conditions such as the syndrome of inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome, dysmenorrhea and ocular hypertension, vasopressin is assumed to play an important role (Thibonnier et al. Adv. Rev.Pharmacol. Toxicol., 2001; 41: 175-202; Thibonnier et al. Adv.Exp.Med.Biolog.; 1998; 449: 251-203).

In recent years, strong evidence has accumulated indicating that the hormone oxytocin plays a major role in iniating labor in mammals, in particular in humans. Thereby, it is assumed that oxytocin exerts said effect in a direct as well as an indirect way, by contracting the uterine myometrium and by enhancing the synthesis and release of contractile prostaglandins from the uterine endometrium/decidua. These prostaglandins may furthermore play a role in the cervical ripening process. This "up-regulation" of oxytocin receptors and increased uterine sensitivity seems to be due to trophic effects of rising plasma levels of estrogen towards term. By down-regulating oxytocin, it is expected that both the direct (contractile) and indirect (increased prostaglandin synthesis) effects of oxytocin on the uterine could be blocked. An oxytocin modulator, e.g. blocker or antagonists would likely be more efficacious for treating preterm labor than current regimens. Moreover, as oxytocin at term has only an effect on the uterus, such an oxytocin modulator would have only few or no side effects.

A further condition being related to oxytocin is dysmenorrhea, which is characterised by cyclic pain associated with menses during ovulatory cycles. Said pain is believed to result from uterine contractions and ischemia, probably mediated by the effect of prostaglandins WO 02/32864 PCT/EP01/11865 -3- Sproduced in the secretory endometrium. By blocking both the indirect and direct effects of oxytocin on the uterus, an oxytocin antagonist is belived more efficacious for treating dysmenorrhea than current regimens.

00 Some agents counteracting the action of oxytocin are currently used in clinical studies.

Such tocolytic agents uterine-relaxing agents) include beta-2-adrenergic agonists, Smagnesium sulfate and ethanol. The leading beta-2-adrenergic agonists is Ritodrine, which causes a number of cardiovascular and metabolic side effects, including tachycardia, increased renin secretion, hyperglycemia and reactive hypoglycemia in the infant. Further beta-2-adrenergic agonists, including terbutaline and albuterol have side effcts similar to those ofritodrine. Magnesium sulfate at plasma concentrations above the therapeutic range of 4 to 8 mg/dL can cause inhibition of cardiac conduction and neuromuscular transmission, respiratory depression and cardiac arrest, thus making this agent unsuitable when renal function is impaired. Ethanol is as effective as ritodrine in preventing premature labor, but it does not produce a corresponding reduction in the incidence of fetal respiratory distress that administration ofritodrine does.

The principal drawback to the use of peptide antagonists including also atosiban is the problem of low oral bioavailability resulting from intestinal degradation. Hence, they must be administered parenterally.

The development ofnon-peptide ligands for peptide hormone receptors are expected to overcome this problem. Small molecule selective oxytocin antagonists have been reported by Merck. In addition to cyclic hexapeptides, Merck suggested indanylpiperidines and tolyl-piperazines as orally deliverable OT antagonists (Evans et al. JMed.Chem., 35, 3919 (1992). In WO 96/22775 and US-5,756,497 Merck reported benzoxazinylpiperidines or benzoxazinones as OT receptor antagonists.

WO 02/32864 PCT/EP01/11865 -4- -Specific sulfonamides have been reported to antagonize ocytocin at the ocytocin receptor.

Elf Sanofi's EP-A-0469984 and EP-A-0526348 report N-sulfonyl indolines acting as antagonists of the vasopressin and the oxytocin receptors.

00 It is an object of the present invention to provide substances which down-regulate up to antagonizing the function of OT and/or V a in disease states in animals, preferably mammals, especially in humans. It is another object of this invention to provide a method of antagonizing the functions of the OT and/or Via receptors in disease states of mammals.

It is also an objective of the present invention to provide small molecule chemical compounds for the modulation, preferably the down-regulation or even antagonisation of the oxytocin receptor. Moreover, it is an objective of the present invention to provide methods for preparing said small molecule chemical compounds. It is furthermore an object of the present invention to provide a new category of pharmaceutical formulations for the treatment ofpreterm labor and dysmenorrhea, and/or diseases mediated by the oxytocin receptor. It is finally an object of the present invention to provide a method of treating or prevent disorders mediated by the oxytocin receptor, like preterm labor, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome, dysmenorrhea and ocular hypertension with oxytocin and/or vasopressin antagonists, acting for example by antagonising the binding of oxytocin and/or vasopressin to their receptor.

Description of the invention The following paragraphs provide definitions of the various chemical moieties that make up the compounds according to the invention and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a broader definition.

WO 02/32864 WO 0232864PCT[EP01/11865

"C

1

-C

6 -alikyl" refers to monovalent ailkyl groups having 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tertbutyl, n-hexyl and the like.

00 "Aryl" refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms 5 -having a single ring phenyl) or multiple condensed rings naphthyl). Preferred aryl include phenyl, naphthyl, phenantrenyl and the like.

"CI-C

6 -alcyl aryl" refers to CI-C 6 -alkyl groups having an aryl substituent, such as, for example, benzyl, phenethyl and the like.

"Heteroaryl" refers to a monocyclic heteromatic, or a bicyclic or a tricyclic fused-ring heteroaromatic group. Particular examples of heteroaromatie groups include optionally substituted pyridyl, pyrrolyl, fiuyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1 ,2,5-oxadiazolyl, 1,3 ,4-oxadiazolyl, 1,3,4-triazinyl, 1 ,2,3-triazinyl, benzofiiryl, [2,3dihydro]benzoftuyl, isobenzofuiryl, beuzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[ 1,2-allpyriclyl, benzothiazolyl, benzoxazolyl, quinolizinyl, quinazolinyl, pthalazinyl, quinoxalinyl, cinnnolinyl, napthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3 ,2-b]pyridyl, pyrido[4,3-blpyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5 ,6,7,8-teirehydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl or benzoquinolyl and the like.

"Cl-C 6 -allcyl heteroaryl" refers to CI-C 6 -alkyl groups having a heteroaryl substituent, such as, for example, 2-fuirylmnethyl, 2-thienylmethyl, 2-(lH-indol-3-yl) ethyl and the like.

"Alkenyl" refers to alcenyl groups preferably having from 2 to 6 carbon atoms and having one or more sites of alkenyl unsaturation. Preferred alkenyl groups include ethenyl

CH=CH

2 n-2-propenyl (allyl, -CH 2

CH=CH

2 and the like.

WO 02/32864 WO 0232864PCT/EPO1/1 1865 CK1 -6- "Ailcynyl" refers to alkynyl groups preferably having from 2 to 6 carbon atoms and having one or more sites of allcynyl unsaturation. Preferred alcynyl groups include ethynyl CECH), propargyl (-CH 2 CmCH), and the like.

00 "Acyl" refers to the group -C(O)R where R includes "C 1

-C

6 -alkyl", "aryl", "heteroaryl", 5 "CI-C 6 -allc aryl" or "C 1

-C

6 -alkyl heteroaryl".

"Acyloxy" refers to the group -OC(O)R where R includes "C 1

-C

6 -alkyl", "aryl", "heteroaryl", "Ci -C 6 -ll.yl aryl" or "Ci -C 6 -alcyl heteroaryl".

"Alkoxy" refers to the group -0-R where R includes "C 1

-C

6 -alkyl" or "aryl" or "heternaryl" or "CI-C 6 -alkyl aryl" or "Cl-C 6 -alkyl heteroaryl". Preferred alkoxy groups include by way of example, methoxy, ethoxy, phenoxy and the like.

"Alkoxycarbonyl" refers to the group -C(O)OR where R includes "C,-C 6 -alkyl" or "aryl" or "heteroaryl" or "Ci-C 6 -alcyl aryl" or "Cl-Q-alcyl heteroaryl".

"Aminocarbonyl" refers to the group -C(O)NRR' where each R, R' includes independently hydrogen or C 1

-C

6 -alkyl'or aryl or heteroaryl or "C 1

-C

6 -allcyl aryl" or "Ci-C 6 -alkyl heterois aryl".

"Acylamino" refers to the group -NR(CO)R' where each R, R' is independently hydrogen or "C 1

-C

6 -alkyl" or "aryl" or "heteroaryl" or "C 1

-C

6 -alkyl aryl" or "Ci-C 6 -alkyl heteroaryl".

"Halogen" refers to fluoro, chioro, bromo and iodo atoms.

"Sulfonyl" refers to a group -S0 2 wherein R is selected from H, "Cl-C 6 -alkyl", "Cl-

C

6 -alkyl" optionally substituted with halogens, such as, for example, an -S0 2

-CF

3 group, "aryl" "heteroaryl", "CI-C 6 -alcyl aryl" or "Ci-C 6 -alkyl heteroaryl".

WO 02/32864 PCT/EP01/11865 S-7c. "Sulfoxy" refers to a group wherein R is selected from H, "Ci-C 6 -alkyl", "C 1 C6-alkyl" optionally substituted with halogens, such as, for example, an -SO-CF 3 group, "aryl", "heteroaryl", "Ci-Cs-alkyl aryl" or "C 1

-C

6 -alkyl heteroaryl".

00 0 "Thioalkoxy" refers to groups -S-R where R includes "CI-C 6 -alkyl" or "aryl" or "hetero- 5 aryl" or "C 1

-C

6 -alkyl aryl" or "C 1

-C

6 -alkyl heteroaryl". Preferred thioalkoxy groups include 0thiomethoxy, thioethoxy, and the like.

"Substituted or unsubstituted" Unless otherwise constrained by the definition of the individual substituent, the above set out groups, like "alkyl", "alkenyl", "alkynyl", "aryl" and "heteroaryl" etc. groups can optionally be substituted with from 1 to 5 substituents selected from the group consisting of "Ci-C 6 -alkyl", "C 1

-C

6 -alkyl aryl", "Cl-C 6 -alkyl heteroaryl",

"C

2

-C

6 -alkenyl", "C 2

-C

6 -alkynyl", primary, secondary or tertiary amino groups or quarternary ammonium moieties, "acyl", "acyloxy", "acylamino", "aminocarbonyl", "alkoxycarbonyl", "aryl", "heteroaryl", carboxyl, cyano, halogen, hydroxy, mercapto, nitro, sulfoxy, sulfonyl, alkoxy, thioalkoxy, trihalomethyl and the like. Within the framework of this invention, said "substitution" is meant to also comprise situations where neighboring substituents undergo ring closure, in particular when vicinal functional substituents are involved, thus forming e.g. lactams, lactons, cyclic anhydrides, but also acetals, thioacetals, aminals formed by ring closure for instance in an effort to obtain a protective group.

"Pharmaceutically acceptable salts or complexes" refers to salts or complexes of the belowidentified compounds of Formula I that retain the desired biological activity. Examples of such salts include, but are not restricted to, acid addition salts formed with inorganic acids hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalene sulfonic acid, naphthalene disulfonic acid, and poly-galacturonic acid. Said compounds can also be administered as pharmaceutically acceptable quaternary salts known by a person skilled in the art, which WO 02/32864 PCT/EP01/11865 (N -8c specifically include the quarternary ammonium salt of the Formula Z, wherein R, R" is independently hydrogen, alkyl, or benzyl, and Z is a counterion, I including chloride, bromide, iodide, -O-alkyl, toluenesulfonate, methylsulfonate, sulfonate, 00 phos-phate, or carboxylate (such as benzoate, succinate, acetate, glycolate, maleate, malate,

O

C 5 fumarate, citrate, tartrate, ascorbate, cinnamoate, mandeloate, and diphenylacetate).

0 "Pharmaceutically active derivative" refers to any compound that upon administration to the recipient, is capable of providing directly or indirectly, the activity disclosed herein.

"Enantiomeric excess" (ee) refers to the products that are obtained by an asymmetric synthesis, i.e. a synthesis involving non-racemic starting materials and/or reagents or a synthesis comprising at least one enantioselective step, whereby a surplus of one enantiomer in the order of at least about 52% ee is yielded. In the absence of an asymmetric synthesis, racemic products are usually obtained that do however also have the inventive set out activity as OT-R antagonists.

The term "preterm labor" or the term "premature labor" shall mean expulsion from the uterus of a viable infant before the normal end of gestation, or more particularly, onset of labor with effacement and dilation of the cervix before the 37 h week of gestation. It may or may not be associated with vaginal bleeding or rupture of the membranes.

The term "dismenorrhea" shall mean painful menstruation.

The term "cesarean delivery" shall mean incision through the abdominal and uterine walls for delivery of a fetus.

It has now been found that sulfanilide derivatives according to Formula I, set out below, are suitable pharmaceutically active agents, by effectively modulating, in particular by effectively inhibiting the OT-R function and more specifically by antagonising the oxytocin receptor. When compounds according to Formula I are used, oxytocin is antagonised by being prevented to interact with its receptor and is therefore unable to exert its biologic or WO 02/32864 PCT/EP01/11865 (C1 -9cN pharmacological effects. The compounds of the present invention are therefore particularly useful in the treatment and/or prevention of oxytocin-related disorders of mammals and in particular of humans. Disorders mediated by the oxytocin receptor are primarily preterm 00 labor and dysmenorrhea.

The present invention thus provides the use of sulfanilides of Formula I: ciR 1

R

3 R4 O R R O for the treatment of preterm labor, premature birth, dysmenorrhea, inappmropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension.

Compounds of Formula include also their geometrical isomers, their optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein: R' and R2 are "aryl" or "heteroaryl" groups, which may be fused with 1-2 further cycloalkyl or aryl or heteroaryl groups.

Said "aryl" or "heteroaryl" may be substituted with 1 to 5 substituents independently selected from the group consisting of: "C 1

-C

6 -alkyl", "CI-C 6 -alkyl aryl", "Ci-C 6 -alkyl heteroaryl", "C 1

-C

6 -alkyl cycloalkyl", "C 2

-C

6 -alkenyl", "C 2

-C

6 -alkynyl", primary, secondary or tertiary amino groups or quarternary ammonium moieties, "acyl", "acyloxy", "acylamino", "aminocarbonyl", "alkoxycarbonyl", "aryl", "heteroaryl", carboxyl, cyano, halogen, hydroxy, mercapto, nitro, sulfoxy, sulfonyl, alkoxy, thioalkoxy, trihalomethyl, 2alkoxyethoxy, 2-(2-alkoxyethoxy)ethoxy, 2-hydroxyethoxy, 2-(2-hydroxyethoxy)ethoxy, 2- WO 02/32864 WO 0232864PCTIEPO 1/11865 c-K1 c-I (dimethylarnino)ethoxy, 2-(2-(dirnethylamino)ethoxy)ethoxy, 2-carboxyethoxy, 2-(2carboxyethoxy)ethoxy, carboxymethoxy, 2-sulfoxyethoxy, 2-(2-sulfoxyethoxy)ethoxy, 2- [(2-methoxyethyl)sulfanyl]ethoxy, 2-[(2-hydroxyethyl)sulfanyllethoxy, 00 carboxyethyl)sulfanyl]ethoxy, 2-[(2-carboxymethyl)sulfanyl]ethoxy, Nl 5 sulfoxyethyl)sulfanyl]ethoxy and the like.

Ris selected from the group consisting of H, "Cl-C 6 -allcyl", such as, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, carboxymethyl, (aminocarbonyl)methyl, 2-carboxyethyl, 2-aminocarbonylethyl, 3-aminopropyl, 4-aminobutyl, 3-guanidinopropyl and the like, "C 1

C

6 -alkyl aryl", such as, e.g. phenylmethyl, 2-phenylethyl, hydroxy(phenyl)methyl and the like, "C 1

-C

6 -allcyl heteroaryl", such as, (imidazol-4-yl)methyl, (indol-3-yl)methyl, (pyrid-2-yl)methyl, (pyrid-3-yl)methyL, (pyrid-4-yl)methyl, (thien-2-yl)methyl, (thien-3yl)methyl and the lie, "C 2

-C

6 ,-alkenyl", "C 2

-C

6 -alkynyl". Preferred are H and "CI-C 6 alcyl", like a methyl or a ethyl group.

R

4 and W 5 are independently selected from the group consisting of hydrogen, C 1

I-C

6 alkyl,

C

2

-G

6 alkenyl, C 2

-C

6 alkynyl, saturated or unsaturated 3-8-membered cycloalkyl which may contain 1 to 3 heteroatoms selected from N, 0, S, aryl, heteroaryl, CI-C 6 -allcyl aryl,

C

1

-C

6 -alkyl heteroaryl and the like.

Alternatively, R 4 and R 5 may form together with the N atom to which they are attached a 3-8 membered saturated or unsaturated heterocyclic ring which may contain 1-2 further heteroatoms. Said heteroatoms are preferably selected from N, S and 0. Said heterocyclic ring may optionally be fused with an aryl, heteroaryl or 3-8 membered saturated or unsaturated cycloalkyl ring.

According to a fur-ther embodiment, R 4 can be H or C I-C 6 alkyl, and R 5 may be -N=CR 6

R

7 wherein: R is an "aryl" or a "heteroaryl" group optionally substituted with from 1 to 5 substituents selected from the group consisting Of "Cl-C 6 -alkyl", "CI-C 6 -alkYl aryl", "C 1

-C

6 -ally WO 02/32864 PCTIEP01/11865 (N -11- 7 heteroaryl", "C 2

-C

6 -alkenyl", "C 2

-C

6 -alkynyl", primary, secondary or tertiary amino groups, "acyl", "acyloxy", "acylamino", "amino-carbonyl", "alkoxycarbonyl", "aryl", "heteroaryl", carboxyl, cyano, halogen, hydroxy, mercapto, nitro, sulfoxy, sulfonyl, alkoxy, o00 thioalkoxy, trihalomethyl, 2-alkoxyethoxy, 2-(2-alkoxyethoxy)ethoxy, 2-hydroxyethoxy, 2- N 5 (2-hydroxyethoxy)ethoxy, 2-(dimethylamino)ethoxy, 2-(2-(dimethyl-amino)ethoxy)ethoxy, 2-carboxyethoxy, 2-(2-carboxyethoxy)ethoxy, carboxymethoxy, 2-sulfoxyethoxy, 2-(2- N sulfoxyethoxy)ethoxy, 2-[(2-methoxyethyl)sulfanyl]ethoxy, 2-[(2-hydroxyethyl)sulfanyl]ethoxy, 2-[(2-carboxyethyl)sulfanyl]ethoxy, 2-[(2-carboxymethyl)-sulfanyl]ethoxy, sulfoxyethyl)sulfanyl] ethoxy and the like;

R

7 is selected from the group consisting of H, "Ci-C 6 -alkyl", "Cl-C 6 -alkyl aryl", "C 1

-C

6 alkyl heteroaryl", "C 2

-C

6 -alkenyl", "C 2

-C

6 -alkynyl", "acyl", "aminocarbonyl", "alkoxycarbonyl", "aryl", "heteroaryl", carboxyl, cyano, sulfonyl and the like.

Alternatively, R 6 and R 7 may form together with the C atom to which they are attached a 3- 8 membered saturated or unsaturated heterocyclic ring which may contain 1-2 further heteroatoms selected from N, S and O and which is optionally fused with an aryl, heteroaryl or 3-8 membered saturated or unsaturated cycloalkyl ring.

Preferably, the compounds according to Formula I are suitable for the modulation of the oxytocin and/or vasopressin (in particular the Via) function, thus specifically allowing the treatment and/or prevention of disorders which are mediated by the oxytocin and/or vasopressin receptor. Said treatment involves the modulation in particular the down regulation or the antagonisation of the oxytocin and/or vasopressin receptor.

More specifically, the compounds of the present invention are useful for the treatment of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome, ocular hypertension and for stopping labor prior to cesarean delivery. The compounds of the WO 02/32864 WO 0232864PCT/EPO1/1 1865 (NI -12- Cl present invention are in particular useful for the treatment of preterm labor, premature birth, dysmenorrhea.

00 Preferred R' and R 2 groups are aryl and heteroaryl rings, whereby either or both of said 0 rings are substituted with 1 or 2 substituents selected from the group consisting of halogens, 5 cyano, CI-C 6 -alkyl, primary, secondary amines or CI-C 6 -alkoxy groups. Particularly preferred substituents are alkoxy groups such as, for example, inethoxy, ethoxy groups and substituted ethoxy groups such as, for example, 2-alkoxyethoxy, 2-(2-alkoxyethoxy)ethoxy, 2-hydroxyethoxy, 2-(2-hydroxyethoxy)ethoxy, 2-(dimethylamino)ethoxy, 2-(2- (dimethylamnino)ethoxy)ethoxy, 2-carboxyethoxy, 2-(2-carboxyethoxy)ethoxy, carboxymethoxy, 2-sulfoxyethoxy, 2-(2-sulfoxyethoxy)ethoxy, methoxyethyl)sulfanyl]ethoxy, 2-[(2-hydroxyethyl)sulfanyl]ethoxy, 2-[(2-carboxyethyl)sulfanyl] ethoxy, 2-[(2-carboxymethyl)sulfanyl]ethoxy, 2-Ij(2-sulfoxyethyl)sulfanyl]ethoxy.

Preferred sulfanilide derivatives are compounds according to Formula 1, wherein R' and R 2 are unsubstituted or substituted aryl and mor particularly preferrTed are sulfanilides of Formula I wherein R' and R 2 are unsubstituted or substituted phenyl.

Particularly preferred sulfanilides are compounds according to Formula I wherein R1 and

R

2 are unsubstituted or substituted phenyl rings, R 3 .adR 4 are H, and R 5 is a group N--0RVR thus giving sulfanilides of the Formula HI: N N R

III

Rn- WO 02/32864 PCT/EP01/11865 (Nu -13- N Formula (II) also comprises tautomeric forms, such as, for example, the keto-enol form of the carbonyl group or the different forms of the group -N=CR 6

R

7 its geometrical isomers, Io its optically active forms as enantiomers, diastereomers and its racemate forms, as well as 00 pharmaceutically acceptable salts thereof. In Formula (II) the substituents are as follows:

R

6 is an "aryl" or "heteroaryl" group.

R

7 of Formula II is selected from the group consisting of H, "Cl-C 6 -alkyl", "Cl-C6-alkyl aryl", "C 1

-C

6 -alyl heteroaryl", "C 1

-C

6 -alkyl cycloalkyl, "C 2 -C-alkeyl", "C 2

-C

6 -alkynyl", "acyl", "aminocarbonyl", "alkoxycarbonyl", "aryl", "heteroaryl", carboxyl, cyano, sulfonyl.

Alternatively, R6 and R 7 form together with the C atom to which they are attached a 3-8 membered saturated or unsaturated heterocyclic ring which may contain 1-2 further heteroatoms selected from N, S and O and which may be fused with an aryl, heteroaryl or 3-8 membered cycloalkyl ring.

Further particularly preferred sulfanilide derivatives of Formula II are compounds wherein R6 is an phenyl and R' is hydrogen or CI-C 6 -alcyl; or R6 and R 7 form together a tetrahydroisoquinoline or oxindole group. Most preferred are compounds of Formula II wherein or R6 and R7 are together an oxindole group.

R8 and R9 selected from the group consisting of "C 1

-C

6 -alkyl", "C 1

-C

6 -alkyl aryl", "C 1

-C

6 alkyl heteroaryl", "C 1

-C

6 -alkyl cycloalkyl, "C 2

-C

6 -alkenyl", "C 2

-C

6 -alcynyl", primary, secondary or tertiary amino groups or quarternary ammonium moieties, "acyl", "acyloxy", "acylamino", "aminocarbonyl", "alkoxycarbonyl", "aryl", "heteroaryl", carbonyl, carboxyl, cyano, halogen, hydroxy, mercapto, nitro, sulfoxy, sulfonyl, C 1

-C

6 -alkoxy, thioalkoxy, with the proviso that R8 is not a carbonyl moiety in the 2 position (ortho).

Alternatively, 2 substituents of R 8 and/or of R9 may undergo ring closure, in particular when vicinal functional substituents are involved, thus forming e.g. lactams, lactons, cyclic WO 02/32864 WO 0232864PCT[EPO 1/11865 (Nj -14anhydrides, but also acetals, thioacetals, aminals formed by ring closure for instance in an effort to obtain a protective group. n and n' are independently selected from 1 to 00 More preferred R(8 and R(9 are halogen, CI-C 6 -alkyl or C 1

-C

6 -aikoxy groups. Particularly preferred are alkoxy groups such as, for example, methoxy, ethoxy groups and substituted ethoxy groups such as, for example, 2-allcoxyethoxy, 2-(2-alkoxyethoxy)ethoxy, 2hydroxyethoxy, 2-(2-hydroxyethoxy)ethoxy, 2-(dimethylamino)ethoxy, 2-(2-(dimethylaniino)ethoxy)ethoxy, 2-carboxyethoxy, 2-(2-carboxyethoxy)ethoxy, carboxymethoxy, 2sulfoxyethoxy, 2-(2..sulfoxyethoxy)ethoxy, 2-[(2-methoxyethyl)sulfanyl~ethoxy, hydroxyethyl)sulfanyl] ethoxy, 2-[(2-carboxyethyl)sutfanyl] ethoxy, 2-Ij(2-carboxymethyl)sulfanyl] ethoxy, 2-[(2-sulfoxyethyl)sulfanyl]ethoxy.

Further particularly preferred sulfanilides are compounds according to Formula I wherein R1 and 1(2 are unsubstituted or substituted phenyl rings, R 3 is H thus giving sulfarilides of the Formula la: RN n N

R

O O 0 Ia 1(4 and 1(5 of Formula Ia are independently selected from the group consisting of H, "C 1

-C

6 alkyl", "C 1

-C

6 -alkYl aryl", C 1

-C

6 -allcyl heteroaryl","Ci -C-alkyl cycloalkyl, "C 2

-C

6 alkenyl", "C 2

-C

6 -allcynyl", "acyl, "aminocarbonyl", "alkoxycarbonyl", "aryl" "heteroaryl", carboxyl, cyano, sulfonyl.

WO 02/32864 WO 0232864PCT/EPOI/1 1865 CI Alternatively, W 4 and 1( form together with the C atom to which they are attached a 3-8 membered saturated or unsaturated heterocyclic ring which may contain 1-2 further heteroatoms selected from N, S and 0 and which may be fused with an aryl, heteroaryl or 00 3-8 membered cycloalkyl ring.

Further particularly preferred sulfanilide derivatives of Formula Ia are compounds wherein

R

4 is hydrogen or "C 1

-C

6 -allcyl", and R 5 is an acetamide, propionic amiide, propionic acid moiety, being substituted by "Cl-C 6 -alkyl", "Cl-C 6 -alkoxy", "CI-C 6 -alkyl arYl", "C 1

-C

6 ailcyl heteroaryl","Cl-C6-alcyl cycloalcyl. Alternatively preferred compounds of Formula (Ia) are those wherein R 4 and R 5 form together a pyrrolidine, piperidine, tetrahydroisoquinoline, isoindole or indole ring, optionally carrying an acetamide, propionic amide or propionic acid moiety and which may be substituted by "Cl-C 6 -akl"

"C

1

-C

6 -alkoxy", "C 1

-C

6 -alkyl aryl", "C 1

-C

6 -alkyl heteroaryl","Ci -C 6 -alkyl cycloalcyl.

R

8 and R! are selected from the group consisting of "C I-C 6 -allcYl", "C I-C 6 -allcyl aryl", "C 1

I-

C

6 -alkyl heteroaryl", "C 2

-C

6 -alkenyP', "C 2 -C-alkynyl", primary, secondary or tertiary amino groups or quarternary amnmonium moieties, "acyl", "4acyloxy", "acylamino", "aminocarbonyl", "alkoxycarbonyl", "aryl", "heteroaryl", carbonyl, carboxyl, cyano, halogen, hydroxy, mercapto, nitro, sulfoxy, sulfonyl, C 1

C

6 -alkoxy, thioalkoxy.

Alternatively, IR! and R 9 may undergo ring closure, in particular when vicinal functional substituents are involved, thus forming e.g. lactanis, lactons, cyclic anhydrides, but also acetals, thioacetals, aminals formed by ring closure for instance in an effort to obtain a protective group. n and n' are independently selected from I to More preferred R 8 and R 9 are halogen, CI-C 6 -allcyl or C 1

-C

6 -alkoxy groups. Particularly preferred are alkoxy groups such as, for example, methoxy, ethoxy groups and substituted ethoxy groups such as, for example, 2-allcoxyethoxy, 2-.(2-alicoxyethoxy)ethoxy, 2hydroxyethoxy, 2-(2-hydroxyethoxy)ethoxy, 2-(dimethylamino)ethoxy, 2-(2-(dimethylamino)ethoxy)ethoxy, 2-carboxyethoxy, 2-(2-carboxyethoxy)ethoxy, carboxymethoxy, 2- WO 02/32864 PCT/EP01/11865

CU

N -16c sulfoxyethoxy, 2-(2-sulfoxyethoxy)ethoxy, 2-[(2-methoxyethyl)sulfanyl]ethoxy, hydroxyethyl)sulfanyl]ethoxy, 2-[(2-carboxyethyl)sulfanyl]ethoxy, 2-[(2-carboxymethyl)tn sulfanyl]ethoxy, 2-[(2-sulfoxyethyl)sulfanyl]ethoxy.

00 O Preferred pharmaceutically acceptable salts of compounds of Formulae I, Ia and II containing a basic residue such as, for example, a primary, secondary, or tertiary amine or a O pyridyl moiety, are acid addition salts formed with pharmaceutically acceptable acids like hydrochloride, hydrobromide, sulfate or bisulfate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulfonate, benzenesulfonate, and para-toluenesulfonate salts.

The compounds of Formulae I, Ia and II may contain one or more asymmetric centers and may therefore exist as enantiomers or diasteroisomers. It is to be understood that the invention includes both mixtures and separate individual isomers or enantiomers of the compounds of Formula I and Formula II. In a particularly preferred embodiment the sulfanilide derivatives according to Formula I or Formula II containing an asymmetric centre are obtained in an enantiomeric excess of at least 52 ee, preferably of at least 92- 98% ee. Also both mixtures and separate individual E/Z geometrical isomers with regard to the sulfanilide derivatives of the present invention, for example hydrazones of Formula II wherein R 8 and R 9 are are different from each other, are comprised within the scope of the present invention. Tautomeric forms with regard to the sulfanilides of the present invention, such as those present in the hydrazones or in the keto-enol forms of the carbonyl of compounds of Formula II, are also comprised within the scope of the present invention.

A further aspect of the present iunvention consists in the actually novel compounds of Formula I. They are specified by the ensuing Formulae (Ha) and WO 02/32864 PCTIEP01/11865 17- (Ila) whereby:

R

3 is either H or "C 1

-C

6 -alkyl", more preferrd H.

R R of Formula II are independently selected from the group consisting of H, "CI-C 6 alkyl", "C,-C 6 -alkyl aryl", "C -C 6 -alkyl heteroaryl", "C 1

-C

6 -alkyl cycloalkcyl", "C 2

-C

6 alkenyl", "C 2

-C

6 -allcynyl", "acyl", "aminocarbonyl", "alkoxycarbonyl", "aryl", "heteroaryl", carboxyl, cyano, sulfonyl.

Alternatively, R 6 and R 7 form together with the C atom to which they are attached a 3-8 membered saturated or unsaturated cyclic or heierocyclic ring which may contain 1-2 further heteroatoms selected from N, S and O and which may be fused with an aryl, heteroaryl or 3-8 membered cycloalkyl ring.

Further particularly preferred sulfanilide derivatives of Formula II are compounds wherein R6 is phenyl and R 7 is hydrogen or C 1

-C

6 -alkyl; or R 6 and R 7 form together a tetrahydroisoquinoline or oxindole group. Most preferred are compounds of Formula IIa wherein or R 6 and R7 form together an oxindole ring.

R

8 is H, halogen or "C 1

-C

6 -alkyl".

R

9 is selected from the group consisting of -C 6 -alkyl)-Y, whereby X is a bond, 0, NR, -CONR; Y is a 3-8-membered cycloalkyl, a 3-8-membered cycloalkyl containing 1-3 WO 02/32864 WO 0232864PCT/EP01/1 1865 -18heteroatoms selected from N, 0, S, aryl, heteroaryl, OR, NRR', with R, R' independently being H, "C 1

-C

6 -alyl", "Cl-C 6 -alkyl aryl", "CI-C 6 -allcyl heteroaryl","C 1

-C

6 alkyl cycloalkyl", "C I -C 6 -alkoxy" or R, R' form together with the N atom to which they 00 are attached a 3-8 membered saturated or unsaturated heterocyclic ring which may contain 1-2 fturther heteroatoms selected from N, S and 0 and which may be. fused with an aryl, heteroaryl or 3-8 membered cycloallcyl ring.

Novel compounds of Formula Th are as follows:

"N

R

9

R

8 and R 9 are independently selected from H, halogen, "Cl-C 6 -alkoxy" or "C,-C 6 -allcYl".

R

4 is hydrogen or "Cl-C 6 -allcyl" and R 5 is an acetamide, a propionic amnide, a propionic acid moiety, being substituted by "CI-C 6 -alkyl", "C I-C 6 -alcyl aryl", C 1 -Q-alkyl heteroaxyl", "C 1

-C

6 -alkoxy".

Alternatively, R 4 and R 5 form together with the nitrogen atom to which they are attached a pyrrolidine, piperidine, tetrahydroisoquinoline, isoindole or indole ring carrying an acetarnide, propionic amnide or propionic acid moiety. Said acetanide, propionic anide or propionic acid moiety may be substituted by "CI-C 6 -alkyl", "CI-C 6 -alkyl aryl", "CI-C 6 alkyl heteroaryl", "C 1

-C

6 -alkoxy".

WO 02/32864 WO 0232864PCT/EPO1/1 1865 -19- Specific examples of compounds of Formula I include the following: 00 4-ethoxy-N-(2- -(2-hydroxyphenyl)ethylidene]hydrazino }-2-oxoethyl)-N-(4methylphenyl)benzenesulfonamide 4-ethoxy-N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro--3H-indol-3ylidene)hydrazinollethyl~benzenesutfonamide 4-ethoxy-N- {2-oxo-2-[(2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3-ylidene)hydrazino]ethyl}

-N-

phenylbenzenesulfonamide 4-ethoxy-N-[2-{(2E)-2- {5-[hydroxy(oxido)amino]-2-oxo- 1,2-diihydro-3H-indol-3ylidene} hydrazino)-2-oxoethyl]-N-phenylbenzenesulfonamide 4-ethoxy-N- {2-[(2E)-2-(5-iodo-2-oxo-1 ,2-dihydro-3H-indol-3-ylidene)hydrazino]-2oxoethyl} -N-phenylbenzenesulfonamide 4-ethoxy-N-(2-hydrazino-2-oxoethy)-N-(4-ethylphel)bezeleulfoflanliide N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl} -1 -naplithalenesulfonamide N-(4-methylphenyl)-N- {2-oxo-2-II(2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl} -2-naphthalenesulfonamide 4-chloro-N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl) benzenesulfonamide 4-methoxy-N-(4-methylphenyl)-N- {2-oxo-2-II(2E)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl) benzenesulfonamide WO 02/32864 WO 0232864PCTIEPOI/1 1865 4-methyl-N-(4-methylphenyl)-N- {2-oxo-2-II(2E)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl) benzenesulfonaniide 00 4-cyano-N-(4-methylphenyl)-N- {2-oxo-2-II(2E)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl~benzenesulfonamide 4-ethoxy-N- {2-[(2Z)-2-(2-fluorobenzylidene)hydrazino]-2-oxoethyl) methylphenyl)benzenesulfonamide {[(4-ethoxyphenyl)sulfonyl]-4-methylanilino) acetyl)hydrazono]-2-oxo-2,3dihydro- 1 H-indole-5 -sulfonic acid N-(4-.methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3 ylidene)hydrazino] ethyl) [1,1 '-biphenyl]-4-sulfonamide N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl) -4-phenoxybenzenesulfonamide 4-ethoxy-N- {2-[(2Z)-2-(2-hydroxybenzylidene)hydrazino]-2-oxoethyl} methylphenyl)benzenesulfonamide {(2Z)-2.-[4-(diethylainino)-2-hydroxybenzylidene]hydrazino} -2-oxoethyl)-4-ethoxy- N-(4-methylphenyl)benzenesulfonaniide 4-ethoxy-N-(2- {(2Z)-2-[(2-hydroxy- 1 -naphthyl)methylene]hydrazino} -2-oxoethyl)-N-(4methylphenyl)benzenesulfonamide 4-ethoxy-N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(3-oxo-2,3-dihydro- 1H-inden- 1ylidene)hydrazino] ethyl)benzenesulfonamide 4'-methoxy-N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo-1 ,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl) 1,1 '-biphenyl]-4-sulfonaniide WO 02/32864 WO 0232864PCT/EPO 1/11865 -21- 4-ethoxy-N-{2-[(2Z)-2-( 1-methyl-2-oxo-1 ,2-dihydro-3H-indol-3-ylidene)hydrazino]-2oxo ethyl) -N-(4-methylphenyl)benzenesulfonamide 00N-(2- {(2E)-2-[l1-(2,4-dihydroxyphenyl)ethylidene]hydrazino} -2-oxoethyl)-4-ethoxy-N-(4methylphenyl)benzenesulfonamide C) 5 3,4-dimethoxy-N-(4-methylphenyl)-N- 1,2-dihydro-311-indol-3ylidene)hydrazino]ethyl~benzenesulfonamide 4-ethoxy-N-.(2- {(2Z)-2-[l1-(2-hydroxy- 1 -naphthyl)ethylidene]hydrazino} -2-oxoethyl)-N-(4methylphenyl)benzenesulfonamide 4-ethoxy-N-(2- 1 -hydroxy-2-naphthyl)ethylidenejhydrazino} -2-oxoethyl)-N-(4methylphenyl)benzenesulfonamide 4-tert-butyl-N-(4-chlorophenyl)-N- {2-oxo-2-II(2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl) benzenesulfonamide N-(4-chlorophenyl)--3,4-diniethoxy-N- {2-oxo-2-[(2E)-2-(2-oxo- 1,2-dihydro-3H-indo-3 ylidene)hydrazino] ethyl} benzenesulfonaniide 4-tert-butyl-N-(4-methylphenyl).-N- {2-oxo-2-[(2E)-2-(2-oxo-1 ,2-dihydro-3H-indol-3ylidene)hydrazilo] ethyl) benzenesulfonamide N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3 ylidene)hydrazino] ethyl} -4-propylbenzenesulfonamide 4-butoxy-N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl}benzenesulfonamide 4-butoxy-N-(4-chlorophenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino]ethyl}benzenesulfonamide WO 02/32864 WO 0232864PCTIEPOI/1 1865 -22- N-(4-chlorophenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3 ylidene)hydrazino] ethyl} -4-propoxybenzenesulfonamnide 00 N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo-1 ,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl) -4-tert-pentylbenzenesulfonamide C) 5 N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo-1 ,2-dihydro-3F1-indol-3 ylidene)hydrazino] ethyl} -4-propoxybenzenesulfonaxnide N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo-1 ,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl} -2-thiophenesulfonamide N-(4-chlorophenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo-1 ,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl} -2-thiophenesulfonamide N-(4-clilorophenyl)-N- {2-[(2E)-2-(2-hydroxybenzylidene)hydrazino] -2-oxoethyl} -3,4dixnethoxybenzenesulfonamnide N-(4-chlorophenyl)-4-ethoxy-N- {2-[(2E)-2-(2-hydroxybenzylidene)hydrazino]-2oxo ethyl) benzenesulfonamide N-(4-chlorophenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3 ylidene)hydrazino] ethyl) -4-tert-pentylbenzenesulfonamide N-(4-chlorophenyl)-4-ethoxy-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl)benzenesulfonaniide N-(4-chlorophenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl) benzenesulfonamnide N-(4-clorophenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl) -4-propylbenzenesulfonamide WO 02/32864 WO 0232864PCTIEPOI/1 1865 -23- 4-ethoxy-N- {11-methyl-2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl} -N-(4-methylphenyl)benzenesulfonamide 00 4-ethoxy-N- {l1-(hydroxymethyl)-2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl} -N-(4-methylphenyl)benzenesulfonamide C) 5 N-(4-chlorophenyl)-4-ethoxy-N- {2-[(2E)-2-(1H-imidazol-2-yrnethylene)hydrazinol-2oxoethyl~benzenesulfonamide N-(4-chlorophenyl)-4-ethoxy-N- pyridinylmethylene)hydrazino] ethyl) benzenesulfonamnide 4-fluoro-N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl} benzenesulfonamide 4-fluoro-N- {2-[(2E)-2-(2-hydroxybenzylidene)hydrazino]-2-oxoethyl} methylphenyl)benzenesulfonainide 4-ethoxy-N-[2-((2E)-2- {2-[hydroxy(oxido)amino]benzylidene} hyclrazino)-2-oxoethyl] -N- (4-methylphenyl)benzenesulfonamide N- {2-[(2E)-2-(2-amninobenzylidene)hydrazino] -2-oxoethyl} -4-ethoxy-N-(4methylphenyl)benzenesulfonamnide {[(4-ethoxyphenyl)sulfonyl]-4methylanilino} acetyl)hydrazono]methyl} phenyl)acetainide N-(4-chlorophenyl)-4-[2-(4-morpholinyl)ethoxy] {2-oxo-2- [2-(2-oxo- l,2-diliydro-311indol-3-ylidene)hydrazino] ethyl) benzenesulfonamide N-(4-methylphenyl)-4-[2-(4-morpholinyl)ethoxy] {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro- 311-indol-3 -ylidene)hydrazino] ethyl) benzenesulfonamnide WO 02/32864 WO 0232864PCT[EP01/1 1865 24- N-(4-chlorophenyl)-4-[2-(dimnethylamino)ethoxy]-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1 ,2-dihydro- 3H-indol-3 -ylidene)hydrazino] ethyl} benzenesulfonamide 00 4-[2-(dimethylamino)ethoxy]-N-(4-methylphenyl)-N- 1,2dihydro-3H-indol-3-ylidene)hydrazino] ethyl} benzenesulfonaiide C) 5 4-[3 -(dimnethylamino)propoxy]-N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2dihydro-3H-indol-3-ylidene)hydrazino]ethyl~benzenesulfonamide N-(4-chlorophenyl)-4-[3-(dimethylamino)propoxy]-N- {2-oxo-2-[(2Z)-2-(2-oxo-1 ,2dihydro-3H-indol-3 -ylidene)hydrazino] ethyl} benzenesulfonamide N-(4-chlorophenyl)-4-ethoxy-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-pyrrolo[3,2c]pyridin-3 -ylidene)hydrazino] ethyl) benzenesulfonaxnide N-(4-chlorophenyl)-4- {[2-(4-morpholinyl)ethyl]amino} {2-oxo-2-[(2Z)-2-(2-oxo- 1,2dihydro-3H-indol-3-ylidene)hydrazino] ethyl} benzenesulfonamid~e 3 {4-[(4-methyl {2-oxo-2-II(2Z)-2-(2-oxo-1 ,2-dihydro-3H-indol-3 ylidene)hydrazino~ethyl) anilino)sulfonyl]phenyl}propanamide N-(4-chlorophenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl} -4-(2-thienylmethoxy)benzenesulfonamide N-(4-chlorophenyl)-4-[2-(2-methoxyethoxy)ethoxy]-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2dihydro-3H-indol-3 -ylidene)hydrazino] ethyl) benzenesulfonaniide N-(4-chlorophenyl)-4-(2-methoxyethoxy)-N- {2-oxo-2-[(2Z)-2-(2-oxo-1 ,2-dihydro-311indol-3 -ylidene)hydrazino]ethyl)benzenesulfonamnide N-(4-chlorophenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl} -pyridinyl)propoxy]benzenesulfonamide WO 02/32864 WO 0232864PCT/EPO 1/11865 N-(4-chlorophenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3ylidene)hydrazinol ethyl) 4-[3-(2-pyridinyl)propoxy]benzenesulfoflaiflde 00 4-(2-methoxyethoxy)-N-(4-methylphenyl)-N- {2-oxo-2- [(2Z)-2-(2-oxo-1 ,2-dihydro-3Hindol-3-ylidene)hydrazino] ethyl) benzenesulfonamide C) 5 4-ethoxy-N- {2-.[(2E)-.2-(1H-indol-3-yhnethylene)hydrazinol-2-oxoethYl} methylphenyl)benzenesulfonamide 4-ethoxy-N-(2- {(2E)-2-[(2-methyl- LH-indol-3-yl)methylene]hydrazino} -2-oxoethyl)-N-(4methylphenyl)benzenesulfonamide N-(4-chlorophenyl)-4-[3-(dinethylaflno)propoxy]N {2-oxo-2-II(2Z)-2-(2-oxo- 1,2dihydro-3H-.pyrrolo[3,2-c]pyridil-3-ylidene)hydazino~ethyl~belzeneleSffofalide {14-chloro( (dimethylamino)propoxy]phenyl} sulfonyl)anilino] acetyl) hydrazono)-2-oxo-2,3-dihydro- 1H-indole.-7-carboxylic acid methyl {[4-chloro({ 4-[3- (dimethylamino)propoxy]phenyl} sulfonyl)anilino] acetyl} hydrazono)-2-oxo-2,3-dihydro- 1H-indole-7-carboxylate 4-ethoxy-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3 -ylidene)hydrazilo] ethyl} -N- (2-pyrimidinyl)benzenesulfolafllde 3- {4-[(4-chloro {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino] ethyl) anilino)sulfonyllphenyl} (dimethylamino)propyl]propananiide N-(4-chlorophenyl)-4- [3 -(4-methyl-i -piperazinyl)-3-oxopropyl-N- oxo- 1 ,2-dihydro-3H-indol-3-ylidele)hydrazio] ethyl) benzenesulfonamide WO 02/32864 WO 0232864PCT/EPO 1/11865 -26- 3-Qbenzyloxy)-2-[( {4-chloro ,4dimiethoxyphenyl)sulfonyl] anilino} acetyl)amino]propanamide 00 3-(benzyloxy)-2-( {[4-chloro(phenylsulfonyl)anilino] acetyl) aniino)propanamide {[(4-ethoxyphenyl)sulfonyl-4-methylalililo} acetyl)amnino]-2-phenylacetamide S 5 3-(3,4-dchlorophenyl)-2-[( {[(4-fluorophenyl)sulfonyl]-4methoxyanilino}I acetyl)amino]propanamide {[(4-ethoxyphenyl)sulfonyl] -4-methoxyanilino} acetyl)-1 ,2,3,4-tetrahydro-3isoquinoliny]acetainide {[(4-ethoxyphenyl)sulfonyl]-4-methoxyanilino} acetyl)-1 -isoindolinecarboxamide ,4-dirnethoxyphenyl)sulfonyl]-4-methoxyanilino} acetyl)-1 ,2,3 ,4-tetrahydro-3isoquinolinyllacetamide {4-chloro[(4-ethoxyphenyl)sulfonyl] anilino} acetyl)valine [(4-ethoxyphenyl)sulfonyl]-4-fluoroanhno} acetyl)aniino]-3-(1H-indol-3 yl)propanamide {[(4-ethoxyphenyl)sulfonyl]-4-fluoroanilino} acetyl)amino]-2-phenylacetamide ,4-dimethoxyphenyl)sulfonyl]-4-fluoroanilino} acetyl)valine 1 {[(4-ethoxyphenyl)sulfonyl] -4-methylanilino} acetyl)-5-phenyl-2pyrrolidinecarboxamide {[(4-ethoxyphenyl)sulfonyl] anilino) acetyl)- 1,2,3,4-tetrahydro-3isoquinolinyl]acetaxuide WO 02/32864 PCT/EP01/11865 -27-

C

2-[2-({[(4-ethoxyphenyl)sulfonyl]-4-methylanilino acetyl)-1,2,3,4-tetrahydro-3isoquinolinyl]acetamide 00 [(4-ethoxyphenyl)sulfonyl]-4-methoxyanilino} acetyl)amiho]-4-phenylbutanamide S [(4-ethoxyphenyl)sulfonyl]-4-methoxyanilino} acetyl)-1,2,3,4-tetrahydro-3- 0 5 isoquinolinecarboxamide 2-[({[(4-ethoxyphenyl)sulfonyl]-4-methoxyanilino}acetyl)amino]-3-(1H-indol-3yl)propanamide [(4-ethoxyphenyl)sulfonyl]-4-fluoroanilino} acetyl)-5-phenyl-2-pyrrolidinecarboxamide 3-(3,4-dichlorophenyl)-2-({[4-fluoro(phenylsulfonyl)anilino]acetyl} amino)propanamide A further object of the present invention is a process for preparing the sulfanilide derivatives according to Formula I, Ia, Ib and Formula II as well as Ia.

The sulfanilide derivatives exemplified in this invention may be prepared from readily available or previously described starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred experimental conditions reaction temperatures, time, moles of reagents, solvents, etc.) are given, other experimental conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the parti-cular reactants or solvents used, but such conditions can be determined by one skilled in the art by routine optimisation procedures.

Generally, the sulfanilide derivatives according to the general Formula I and/or II may be obtained by several processes, using both solution-phase and solid-phase chemistry protocols. Depending on the nature of R-R 9 certain processes will, in some instances, be preferred over others, and it is assumed that the choice of the most suitable process will be known to the practitioner skilled in the art.

WO 02/32864 PCT/EP01/11865 -28- According to one process, sulfanilide derivatives according to the general Formula I, whereby C(O)-NR 4

R

5 represents an amide moiety, with R 4 and R 5 being defined as above, are prepared from the corresponding carboxylic acids III (R H) and primary or secondary 00 amines IV, following solution-phase chemistry protocols such as described in the Examples and shown in Scheme 1, using conditions and methods well known to those skilled in the art to prepare an amide bond from an amine and a carboxylic acid or a carboxylic acid derivative, with standard peptide coupling agents, such as e.g. DIC, EDC, TBTU, DECP, or others.

According'to another process, sulfanilide derivatives according to the general Formula I, whereby C(O)-NR 4

R

5 represents an acyl hydrazone moiety C(O)-NII-N=CRR 9 (general Formula II), with R 8 and R? being defined as above, are prepared from the corresponding

CI-C

6 -alkyl esters 111 (R Me, for example), which are first converted to the corresponding hydrazides by treatment with hydrazine, followed by reaction with ketones or aldehydes V, using standard solution-phase chemistry protocols such as those described in the Examples and shown in Scheme 1. The ketones or aldehydes, V, are either commercial or can be prepared from readily available starting materials according to published litterature procedures (see Rivalle, Bisagni, E. J Heterocyclic Chem. 1997, 34, 441. Deady, L. Kaye, A. Finlay, G. Baguley, B. Denny, W. A. J. Med. Chein.

1997, 40, 2040), standard protocols, as hereinafter described in. the Examples, or by other current methods well known to the practitioner skilled in the art.

Other derivatives of Formula I and/or of Formula II are prepared using known modifications to the Scheme 1 reaction sequence.

WO 02/32864 PCTIEPO1/11865 (N -29- Clq Scheme 1

H

00 W, R 0

N

Y-"N'R'

peptide coupling agent R R 0 1

I

RO

R2 R3 R R

III

0 8 1) H 2

N-NH

2 N .N R 2) RsR R R

V

Compounds of Formula III may be converted to alternative compounds if R 2 is bearing an appropriate reactive group G and by employing suitable interconversion techniques as described in Scheme 2 and hereinafter in the Examples. G can be substituted by activated unsaturated chains, using Pd catalysed Heck reaction under usual reaction conditions described in the litterature as shown in Scheme 2 and reported hereinafter in the Examples.

This unsaturated substituted alkyl chain, such as in compound lla, can optionally be hydrogenated and further transformed (reduction, saponification, amide formation, substitution, etc) following standard conditions well known to the person skilled in the art and as it is described below in the Examples. Resulting alternative intermediate II* can be converted into I or II following procedures described on Scheme 1 and hereinafter described in the Examples.

WO 02/32864 PCT/EP01/11865 Scheme 2

R

1

R

1

O

00 O YOR 3- OSN OR R R R2 3 R R O e.g. =SNH R e.g. OS _N OR

[R=NH

2 OAlkyl] R )G Pd-catalyst, base.

[G=CI Br, I, OMs, OTs] Ila Compounds of Formula In, whereby the substituents R 1

R

2 and R 3 are as above defined, can be prepared from the corresponding N-aryl- or N-heteroaryl a-aminoacids or aminoacid esters, VI, by sulfonylation with aryl or heteroaryl sulfonyl chlorides VII, using standard synthetic techniques, as hereinafter described in the Examples and shown in Scheme 2.

The aryl or heteroaryl sulfonyl chlorides, VII, are either commercial or may be prepared from readily available starting materials according to standard protocols, such as by chlorosulfonylation (see Ramage, Green, Blake, A. J. Tetrahedron, 1991, 47, 6353), as hereinafter described in the Examples, or by other current methods well known to the practitioner skilled in the art.

The corresponding N-aryl- or N-heteroaryl a-aminoacids or aminoacid esters, VI, can be prepared from the corresponding N-unsubstituted precursors VI, using a variety of synthetic strategies, of which some selected examples are shown in Scheme 3 and described hereinafter in the Examples. Thus, the amino group of compounds of Formula VIII can for example be cross-coupled with aryl or heteroaryl halides and sulfonates, IX, using a base and an appropriate Pd-catalyst, the correct choice of will depend on the molecular context, as appreciated by one skilled in the art and as recently reviewed in extenso (Wolfe, Tomori, Sadighi, Yin, Buchwald, S.L. J.Org.Chem., 2000, WO 02/32864 PCT/EP01/11865 -31- 1158). The N-unsubstituted precursors VIII are notably naturally occuring and/or synthetic a-amino acids including Glycine, Serine, Tyrosine, Alanine, Valine, Leucine etc..

Alternatively, to get access to compounds of general Formula VI, compounds of Formula S VIII can be reacted with electron-deficient aryl or heteroaryl fluorides and/or chlorides, X, under conditions suitable for SNAr-type reactions. If the aryl component X contains a nitrogroup, as shown in Scheme 3 and described hereinafter in the Examples, the resulting compound VI can optionally be carried on to nitro group reduction and further functionalization (acylation, sulfonylation, alkylation) of the resulting primary amino group, before eventually being converted to III by sulfonylation with VII.

As a further alternative, compounds of general Formula VI can be prepared from corresponding precursors of general Formula XI containing a suitable leaving group Z, by displacement of the latter with aryl or heteroaryl amines anilines), XII, under standard conditions well known to the person skilled in the art. Compounds of Formula XI are either commercially available per se or readily accessible from commercial starting materials. In one particularly preferred synthetic approach, compounds of Formula XI whereby Z =Br and n 1 are made from suitably side-chain protected a-amino acids by treatment with NaNO 2 and HBr, as shown in Scheme 3 and described hereinafter in the Examples (see Souers, Schuerer, Kwack, Virgilio, Ellman, J.A.

Synthesis, 1999, 583).

WO 02/32864 WO 0232864PCTJEP01/11865 -32- Scheme 3 R1-X, g. i [X=CI,Br,OTfl F Ix Pd-catalyst, base 0 H2 r--OR Rk 3 Vill

R

1 e'g. F [Y=F,CI] R'-CI

>N

x

NO

Base R 10 R 2"'CI ViI HN Y-

OR

R 3 (Base)

VI

e.g.: NaNO 2 HBr (n=I ,R=H)

RI-NH

2

XII

3s R e.g. zNH leaving group, R40 e.g. Br,OTs,OMS] As a further alternative, compounds of general Formula III can be prepared from intermediates of general Formula XI (see Scheme 2) containing a suitable leaving group Z, by displacement of the latter with preformed anions of N-sulfonylated aryl or heteroaryl amnines or heteroaryl amiines, XII, using standard synthetic techniques as shown in Scheme 4 and hereinafter described in the Examples. Alternatively, compounds of general Formula 1111 can be prepared from N-sulfonylated aryl or heteroaryl amines or heteroaryl arnines, =II with intermediates of general Formula M~a by Mitsunobu reaction, using standard reaction conditions, as depicted in Scheme 4.

WO 02/32864 PCT/EP01/11865 -33c Scheme 4 1) Base NaH) oo2) 00

S

Z

-Y OR R R 1 XI R 1

O

O O R-NH 2 ,NH [Z leaving group, 0 ,N

SR

2 S'CI I O=S e.g. Br,OTs,OMs] O=S OR c N

R

2

R

2

R

3 VII XII XIII O III 1

OR

R XIa Mitsunobu Reaction Said N-sulfonylated aryl or heteroaryl amines or heteroaryl amines, XIII, are obtained from reactions between aryl or heteroaryl sulfonyl chlorides, VII, and aryl or heteroaryl amines, XII, using conditions and methods well known to those skilled in the art to form a sulfonamide bond from an amine and a sulfonyl chloride, as shown in Scheme 4 and hereinafter described in the Examples.

According to a further general process, intermediate XIII can be converted to alternative intermediate XIII*, if R2 is bearing an appropriate reactive group G and by employing suitable interconversion techniques as described in Scheme 5 and hereinafter in the Examples. Under conditions suitable for SNAr-type reactions, G can be displaced by preformed anions of the appropriate alkohol or amine Rio, as shown in Scheme (compound XIIIb) and hereinafter described in the Examples. Alternatively, G can be substituted by activated unsaturated chains, using Pd catalysed Heck reaction under usual reaction conditions described in the litterature as shown in Scheme 5 and reported hereinafter in the Examples. This unsaturated substituted alkyl chain, such as in compound XIIb, can optionally be hydrogenated and further transformed (reduction, saponification, amide formation, substitution, etc) following standard conditions well known to the person skilled in the art and as it is described below in the Examples. Resulting alternative WO 02/32864 WO 0232864PCTIEPO 1/11865 -34intermediate XIII or XIIP can be converted into MI following procedures described on Scheme 5 and hereinafter described in the Examples.

00 Scheme I

I

R

CIXIII

I*

RIO, e.g. substituted alcohol or amine 0 Base 0a \\A.H Y=Ieavlng group, F, Br] I3~1 e'g.

'NH

.NH

RIO, eg. R OS

[R=NH

2 QAlkyl] Pd-catalyst, base.

[G=CI Br, 1. ONs, OTs] XII1b 0 According to another process, compounds of Formula III, whereby the substituents R 1

R

2 and W 3 are as above defined, are prepared from the corresponding N-sulfonylated ccaminoacid esters, XlV (R Me), by N-arylation, using cuprate/boromic acid methodologies (see Combs, A.P. et al. J. Comb. Chem., 2000, 2, 29), as shown in Scheme 6 and described hereinafter in the Examples. The appropriate N-sulfonylated ct-aminoacid esters, )UV, are obtained from reactions between aryl or heteroaryl sulfonyl chlorides, VII, and aaninoacid esters, VIII (R Me) using conditions and methods well known to those skilled in the art to form a sulfonamide bond from an amnino group and a sulfonyl chloride.

WO 02/32864 PCT/EP01/11865 Scheme 6 R-B(OH)2,

XV

H e.g.

H

2 OR OR OR R3 R R 2

R

3 Cu(OAc)z, base R 2

R

VIII VII XIV III The processes hitherto presented provide compounds of general Formula e I and II by initial elaboration of the N-terminal portion of the central a-aminoacid core, followed by ultimate transformation of the carboxy terminus into the corresponding amides and/or acylhydrazones. As will be appreciated by the person skilled in the art, it may, depending on the molecular context, sometimes be preferable to inverse the order of the above reaction sequence. Thus, suitably N-protected a-aminoacids or amino acid esters, XVI, are subjectd to the reaction conditions outlined in Scheme 1 and the associated text, to provide the corresponding N-protected amides and/or acyl hydrazones XVII, as shown in Scheme 7.

After N-deprotection, the resulting free amino groups are then elaborated according to the conditions and methods summarized in Schemes 3 and 6 and the associated text above, to afford the final products of general Formulae I, Ia, Ib, II, IIa.

By virtue of analogy, compounds of general Formula XI containing a suitable leaving group Z, which are either commercially available per se or readily accessible from commercial starting materials, as described in Scheme 3 and the associated text, may first be subjected to the reaction conditions outlined in Scheme 1 (see also the inserted text), to provide the corresponding amides and/or acyl hydrazones of Formula XVIII, as shown in Scheme 7 below. Subsequent displacement of the leaving group Z from compounds XVIII, either using aryl or heteroaryl amines anilines), XII (Scheme followed by Nsulfonylation, or using preformed anions of N-sulfonylated aryl or heteroaryl amines or heteroaryl amines, XIII (Scheme affords the final products of general Formulae I, Ia, Ib, II, Ha.

WO 02/32864 PCT/EP01/11865 36- Scheme 7 H 0 PN OR

R

3

XVI

see Scheme 1 [P suitable protecting group 1) N-deprotection H 2) see Schemes 2, 4 PN N R

R

3

R

XVII

pJ

R

1

O

NR

O R 0 R R R 3

R

II (R 4

-N=CRR

9 see Schemes 2, 3

OR

R

XI

see Scheme 1 [Z appropriate leaving group] 0

R

3

R

5

XVIII

According to yet another process, sulfanilide derivatives according to the general Formula e I and/or II, whereby the substituents R'-R 9 are as above defined, are prepared by solidphase and/or mixed solid-/solution-phase synthesis protocols such as, those described in the examples and shown in Schemes 8 and 9 below. It will be appreciated by the practitioner skilled in the art that basically the same conditions, methods and reagents as above described in Schemes 1-4 for the solution-phase synthesis of compounds of Formula e I and/or II can be applied to the solid-phase and/or mixed solid-/solution-phase synthesis of said compounds. In the context of such a solid-phase and/or mixed solid-/solution-phase synthesis protocol, the R-group contained in the C(0)-OR moiety of the compounds III, VI, VIII, XI and XIV shown in Schemes 1-4, represents a suitable resin comprising the appropriate cleavable linker. The circles within the below Schemes 8 and 9 illustrate the resin beads to which the corresponding compounds are linked during the solid phase synthesis. It is to be understood that further to the below mentioned resin types, other WO 02/32864 PCT/EP01/11865 -37- C suitable reagents, notably resins, known to a person skilled in the art, could be employed for the solid-phase synthesis of compounds of general Formula e I and/or II.

S Thus, in one preferred scenario, suitably N-protected a-aminoacids are coupled to an acidc" labile resin, such as, Wang resin, XIX, using standard carbodiimide-mediated coupling S 5 conditions well known to the practitioner skilled in the art, followed by N-deprotection, to 0C afford resin-bound intermediates of Formula VIla. According to the methods outlined in Scheme 2, the latter intermediates Vilma can then be reacted with electron-deficient aryl or heteroaryl fluorides and/or chlorides, X, under conditions suitable for SNAr-type reactions.

If the aryl component X contains a nitro-group, as shown in Scheme 8 and described hereinafter in the Examples, the resulting compound VIa can optionally be carried on to nitro group reduction and further functionalization (acylation, sulfonylation, alkylation) of the resulting primary amino group, before eventually being converted to 111 by sulfonylation with VII, and subsequent acid-catalyzed cleavage from the resin. The resulting acids Il can directly be captured onto a further, nucleophile-labile, resin, such as, e.g. Kaiser oxime resin, XX, to give intermediates of Formula IIlb, which upon cleavage with either primary or secondary amines IV, and/or hydrazones of Formula XXI, will yield compounds of general Formula I and/or II, respectively, as shown in Scheme 8 and described hereinafter in the Examples.

WO 02/32864 WO 0232864PCT/EPO 1/11865 -38- Scheme 8 H 0 PNY? OR

R

3 l

XVI

HO~

e.g. Wang-resin xIX 0 Villa e.g.

NO,

Villa Base R 0R 2- Cl 0R 0 HN~r ol VII OH R 3 (Base) R2 R3 Via 2) Cleavage III from resin 0R 0 0. N OH HO"

P

'2 R 3 :N1p Ill e.g. Kaiser Oxime-resin xx ,OA I Ph

H

R3 R 0R 0 N N 2 3 '4 R R R N'

NH

2 R8!' R 9 Illb 1

XXI

0 2

R

3

R

r WO 02/32864 PCT/EP01/11865 -39- According to another preferred process, compounds of general Formula XI containing a suitable leaving group Z, which are either commercially available per se or readily l accessible from commercial starting materials, as described in Scheme 3 and the associated text, can first be coupled to a resin presenting a hydroxyalkyl moiety, XXII, such as, e.g., TentaGel S OH, or hydroxymethyl-PS, using standard carbodiimide-mediated coupling Sconditions well known to the practitioner skilled in the art. Subsequent displacement of the leaving group Z from the resulting resin-bound intermediates XIc, either using aryl or heteroaryl.amines anilines), XII (Scheme followed by N-sulfonylation, or using preformed anions of N-sulfonylated aryl or heteroaryl amines or heteroaryl amines, XIII (Scheme affords the resin-bound intermediates of general Formula mc. Cleavage from the resin is effected, e.g. by hydrazine, affording the corresponding hydrazides, XXIII, which can ultimately be transformed into the corresponding acyl hydrazones, II, by treatment with a ketone and/or aldehyde component, V, as described hereinafter in the Examples and shown in Scheme 9.

w"MIM WO 02/32864 PCT/EPOI/1 1865 .S cheme 9 0

'YOR

Rk 3 [Z leaving group]

XI

HO'

e.g. TentaGel S OH, Hydroxymethyl-PS

XXII

0 R3

XIC

VII 0

N

(Base) R 2

R

3 I1iC R1 -NH 2

XXII

eX g Nc

R

1 0 H N Y R 3 Vic 0 \\-NHBase NaH) RAl

H

2 N' N-2 11iC 0 R 0

NH

2 R\ Rk 0 1 N R" H V R 2 R 3 R 11 XXIII According to another preferred process, Fmoc-protected P3-, cyclic and acylic amnino acids, which are either commercially available per se or readily accessible from commercial starting materials, as described in Scheme 10, may first be coupled to a resin presenting a amine moiety, XXIV, such as, Rink resin, using standard carbodiimidemediated coupling conditions well known to the practitioner skilled in the art. Subsequent Fmoc deprotection and coupling with carboxylic acid XMa, using stardard carbodiimide- WO 02/32864 WO 0232864PCT/EP0 1/11865 -41mediated coupling conditions, are affording intermediate XXVI. Displacement of the leaving group Z from the resulting resin-bound intermediates XXVI, either using aryl or heteroaryl amines anilines), XII (Scheme followed by N-sulfonylation, or using preformed anions of N-sulfonylated aryl or heteroaryl amines or heteroaryl amines, XIII (Scheme affords the resin-bound intermediates of general Formula XXVIII Cleavage from the resin is effected under acidic conditions, affording the corresponding acetamide Ha as described hereinafter in the Examples and shown in Scheme Scheme H2N.

e.g. Rink

XXIV

aX-, V3, cyclic and acyclic aa's (Fmoc-protected) e.g.0 fmoc-N-amino acid-

OH

fmoc 0 N-amino acid-/< 1. Fmoc deprotection 2.Z XO leaving group] [R H] N-kamino acdd 0

R

3 0 1

INH

R xiii Base NaH) Ri-NH 2 HN 0 XII N-amino acid-k 3

N

e~g. NHXXVII H

VII

(Base) Acid TFA) R'0 2 N-amino acid-\ R R Ila NH 2

XXVIII

The term "finoc-N-amino acid-COOH"' as used in the above Scheme 10, denotes an cc-, cyclic and acylic amino acid which is protected by the protective group "Fmoc".

WO 02/32864 PCT/EP01/11865 'q N -42- The reaction sequences outlined in the above Schemes provides enantiomerically pure compounds of Formula I, if enantiomerically pure starting materials are used. as well as (S) S enantiomers can be obtained depending upon whether or forms of commercially 00 available starting materials are used.

O

According to a further general process, compounds of Formula I can be converted to alter- Snative compounds of Formula I, employing suitable interconversion techniques such as hereinafter described in the Examples.

If the above set out general synthetic methods are not applicable for obtaining compounds according to Formula I and/or necessary intermediates for the synthesis of compounds of Formula I, suitable methods of preparation known by a person skilled on the art should be used. In general, the synthesis pathways for any individual compound of Formula I will depend on the specific substitutents of each molecule and upon the ready availability of intermediates necessary; again such factors being appreciated by those of ordinary skill in the art. For all the protection, de-protection methods, see Philip J. Kocienski, in "Protecting Groups", Georg Thieme Verlag Stuttgart, New York, 1994 and, Theodora W. Greene and Peter G. M. Wuts in "Protective Groups in Organic Synthesis", Wiley-Interscience, 1991.

Compounds of this invention can be isolated in association with solvent molecules by crystallization from evaporation of an appropriate solvent. The pharmaceutically acceptable acid addition salts of the compounds of Formula I, which contain a basic center, may be prepared in a conventional manner. For example, a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. Pharmaceutically acceptable base addition salts may be obtained in an analogous manner by treating a solution of compound of Formula I with a suitable base. Both types of salt may be formed or interconverted using ion-exchange resin techniques.

WO 02/32864 PCT/EP01/11865 -43- A final aspect of the present invention relates to the use of the compounds according to Formula I and Formula II for the preparation of pharmaceutical compositions for the modulation of the oxytocin receptor and/or the vasopressin receptor as well as the Formula oO tions containing the active compounds according to Formula I and Formula II. The modulation of the oxytocin receptor is viewed as a suitable approach for the treatment of Spreterm labor and dysmenorrhea. The modulation of the vasopressin receptor is viewed as a suitable approach for the treatment of congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. When employed as pharmaceuticals, the sulfanilide derivatives of the present invention are typically administered in the form of a pharmaceutical composition. Hence, pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier, diluent or excipient therefore are also within the scope of the present invention. A person skilled in the art is aware of a whole variety of such carrier, diluent or excipient compounds suitable to Formula te a pharmaceutical composition. Also, the present invention provides compounds for use as a medicament. In particular, the invention provides the compounds of Formula I for use as antagonists of the oxytocin receptor, for the treatment or prevention of disorders mediated by the oxytocin receptor in mammals, particularly in humans, either alone or in combination with other medicaments, e.g. in combination with a further OT antagonist.

The compounds of the invention, together with a conventionally employed adjuvant, carrier, diluent or excipient may be placed into the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable WO 02/32864 PCT/EP01/11865 N -44c effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.

00 When employed as pharmaceuticals, the sulfanilide derivatives of this invention are typically administered in the form of a pharmaceutical composition. Such compositions can be 5 prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. Generally, the compounds of this invention are administered in a pharmaceutically effective amount. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

The pharmaceutical compositions of the invention can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. Depending on the intended route of delivery, the compounds are preferably Formula ted as either injectable or oral compositions. The compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include prefilled, premeasured ampoules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the sulfanilide compound is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.

WO 02/32864 PCT/EP01/11865 Liquid forms suitable for oral administration may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors and the like.

Solid forms may include, for example, any of the following ingredients, or compounds of a 00 similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatine; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art. As above mentioned, the sulfanilide derivatives of Formula I in such compositions is typically a minor component, frequently ranging between 0.05 to 10% by weight with the remainder being the injectable carrier and the like.

The above described components for orally administered or injectable compositions are merely representative. Further materials as well as processing techniques and the like are set out in Part 8 of Remington's Pharmaceutical Sciences, 17 th Edition, 1985, Marck Publishing Company, Easton, Pennsylvania, which is incorporated herein be reference.

The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can also be found in the incorporated materials in Remington's Pharmaceutical Sciences.

The present invention shall be illustrated by means of the following examples which are not construed to be viewed as limiting the scope of the invention. The HPLC, NMR and MS data provided in the examples described below were obtained as followed. The following abbreviations are hereinafter used in the accompanying examples: min (minute), hr (hour), g (gram), mmol (millimole), m.p. (melting point), eq (equivalents), mL (milliliter), 4L WO 02/32864 WO 0232864PCTIEPOI/11865 -46- (microliters), mL (milliliters), ACN (Acetonitile), CDC1 3 (deuterated chloroform), cHex (Cyclohexanes), DCM (Dichioromethane), DECP (lDiethylcyanophosphonate),

DIG

tt~~ (Diisopropyl carbodiiniide), DMAP Dimethylarninopyridine) DMF (Dimethylform- 00 amide), DMSO (Dimethylsulfoxide), DMSO-d 6 (deuterated dimethylsul-foxide), EDC (1- (3-Dimethyl-amino-propyl)-3-ethylcarbodiimide), EtOAc (Ethyl acetate), Et 2 O (Diethyl ether), HOBt (1-Hydroxybenzotiazole), K 2 C0 3 (potassium carbonate), Nail (Sodium hydride), NaHCO 3 (Sodium bicarbonate), nBuLi (n Butyllitbiurn), TBTU (0- Benzotriazolyl-N,N,N' ,N'-tefraiuethyluronium-'tetrafluoroborate), TEA (Triethyl amine), TFA (Trifluoro- acetic acid), TBFf (Tetrahydrof'uran), MgSO 4 (Magnesium sulfate), PetEther (Petroleum ether), rt (room temperature).

Examples

N

Intermediate 1: N-Acetyl-2-amino beuzaldehyde a) Synthesis of 2-Aminobenzyl alcohol To a solution of 2-nitrobenzyl alcohol (500 g, 3.2 mol) in MeOHl (2.5 L) was added Pd/C g) under N 2 and refluxed for 30min. Hydrazine hydrate (500 mE) was added slowly with stirring. The resulting mixture was stirred under refiux for another 2 h. The solid formed was filtered, concentrated and the crude residue was extracted with ethyl acetate (2x500 mE). The organic layer was washed with brine and dried over MgSO 4 After evaporation of the solvents, 2-aminobenzyl alcohol (357 g, 89% yield) was isolated as pale yellow solid.

WO 02/32864 WO 0232864PCT/EPO1/1 1865 -47b) Synthesis of N-Acetyl-O-acetyl-2-aminobenzyl alcohol Et 3 N (132g, 1.3mol) was added to a solution of 2-aniinobenzyl alcohol (40g, 0.33 mol) in 0C) dry CH 2 Cl 2 (400 mL). The mixture was stirred for 20 min. and acetic anhydride (1 0g, 0.98mo1) was added slowly. After 12h stirring at room temperature, the reaction mixture was washed with water, brine and dried over MgSO4. The solvents were removed under c-i vacuum to give the crude N-acetyl-O-acetyl-2-aminobenzyl alcohol (55 g, 88% yield).

c) Synthesis of N-Acetyl-2-aminobenzyl alcohol To a solution of N-acetyl-O-acetyl-2-aminobenzyl alcohol (55 g, 0.25 mol) in MeOH (550 mL) was added K 2 C0 3 (200 g, 1.42 mol). After 2 h at room temperature, the resulting solid was filtered and concentrated. The crude product was dissolved in CH 2 Cl 2 (250 mL), washed with water, brine and dried over MgSO 4 The solvent was removed under vacuum, affording N-acetyl-2-aminobenzylalcohol (20g, 47% yield).

d) Synthesis of -Acetyl-2-aminobenzaldehyde To a stirred solution of N-acetyl-2-aniino-benzylalcohol *(20 g) in dry CHC1 3 (500 mL) was added MnO 2 (160 g, 8 equivalents) and allowed to stir at room temperature for 12 h. The reaction mixture was filtered through celite and concentrated. 'The crude product was recrystallised from CHCl 3 /petrol ether to give N-acetyl-2-aminobenzaldehyde (14 g, 73%).

'H NMR (300 MHz, DMSO-d 6 2.01 3H), 7.30 (in, 2H, H arom.), 7.65 (in, 2K1, H arom.), 7.85 (in, 2H, H arom.), 8.09 (in, 2H, H arom.), 9.95 1H1, CHO), 10.70 1H1, N Il).

Example 1: General protocol A for the solution-phase synthesis of sulfanilide derivatives of ,general Formula II with R 3 H (Schemes e.g. 3-r({r(4-ethoxyphenyL)sulfonyll-4methylanilinol acetyl)hydrazonol-2-oxo-2,3-dihydro- 1H-indole-5-sulfonic acid

IWIMMMI

WO 02/32864 PCTIEPO1/1 1865 c-K1 -48cl 0 a) 0 Prtclfrtefraino h -ay-eznsloaid uligbokXI (Schme 4; 4-thox-N-(-metylpNylbneeufnmd 0-mn--ehlezee(.20,1. mmol)wsdsovdi C 2 L.NN Diprpltyaie(.mL181nmil n -tox-eznslolclrd desre Prouct, efg. th omatin-ofmthlpheylbenzenesufonamide (3i087ng, bl4%, was g0 obtine as aolo rles sold, sucin. Th priteyHa L Mx dtction betrwssire twe 230m and 400 n).

'H NMR (300 MfH, CDCI 3 1.39 J= 7.0 Hz, 3H1, OCH 2

CH

3 ),1224 3H, CH 3 ),4.02 J= 7.0 Hz, 2H1, OCH 2

CH

3 6.35 (br s, 1H, NH), 6.84 (in, 2-H, H arom.), 6.91 (in, 2H, H arom.), 7.01 (in, 2H, H aroin.), 7.63 (mn, 2H, H aroin.); 292; Wv(ES): 290.

b) Protocol for the displa cement of the leaving group inUX (Scheme e.g. methyl ethoxyphenyl)sulfonyl]-4-methylanzilino~acetate The crude N-aryl-benzenesulfonainide building block =II e.g. 4-ethoxy-N-(4methylphenyl)benzenesulfonamide (3.087 g, 10.6 mxnol), was dissolved in DMF (10 mL) and was added to a suspention of NaH (13.6 inmol, 0.5 93 mg of NaH 55-65% in oil) in DMIF (30 mE). The mixture was stirred 45 min at room temperature. 2-Broinoacetic acid w-MINO WO 02/32864 PCT/EP01/11865 -49methyl ester (1.45 mL, 15.9 mmol) was added dropwise. The resulting mixture was stirred at room temperature overnight. The solvents were evaporated, affording the desired l n product, e.g. methyl {[(4-ethoxyphenyl)sulfonyl]-4-methylanilino}acetate (3.816 g, quantitative crude yield) as a light yellow solid, in 96.1 purity by HPLC (MaxPlot detection between 230 and 400 nm).

'H NMR (300 MHz, CDC13): 1.42 J= 7.0 Hz, 3H, OCH 2

CH

3 2.29 3H, CH 3 3.67 3H, OCH 3 4.06 J= 7.0 Hz, 2H, OCH 2

CH

3 4.36 2H, NCH 2 CO), 6.87 2H, H arom.), 7.05 (br s, 4H, H arom.), 7.58 2H, H arom.); M+(APCI): 364; M'(APCr): 362.

c) Protocol for the transformation of the carboxylic acid ester into the hydrazide (Scheme e.g. 4-ethoxy-N-(2-hydrazino-2-oxoethyl)-N-(4-methylphenyl)benzenesulfonamide The crude carboxylic acid methyl ester, e.g. methyl {[(4-ethoxyphenyl)sulfonyl]-4-methylanilino}acetate (3.816 g, 10.5 mmol), was dissolved in MeOH (30 mL). Hydrazine hydrate was added (3.3 mL). The reaction mixture was stirred overnight at room temperature. A white precipitate was formed. It was isolated by filtration and rinsed with cold MeOH.

From mother liquors some more compound could be recovered, affording the desired product, e.g. 4-ethoxy-N-(2-hydrazino-2-oxoethyl)-N-(4-methylphenyl)benzenesulfonamide (2.745 g, 72%) as a colorless solid in 99.8 purity by HPLC (MaxPlot detection between 230 and 400 nm).

M.p. 117.5-118.5 OC; IR (neat) v 3326, 2926,1595, 1344, 1154 'H NMR (300 MHz, DMSO-d 6 1.34 J= 7.0 Hz, 3H, OCH 2

CH

3 2.26 3H, CH 3 4.10 J= 7.0 Hz, 2H,

OCH

2

CH

3 4.11 2H, NCH 2 CO), 4.18 (br s, 2H, N-NH 2 6.95-7.15 6H, H arom.), 7.51 2H, H arom.); M'(APCr): 362. Analysis calculated for C17H 21

N

3 0 4 S 07 H20: C, 54.30; H, 6.00; N, 11.17. Found: C, 53.97; H, 5.97; N, 11.03.

WO 02/32864 PCT/EP01/11865 d) Protocol for the formation of the acyl hydrazone, II (Scheme e.g. ethoxyphenyl)sulfonyl]-4-methylanilino)acetyl)hydrazono]-2-oxo- 2 ,3-dihydro-JH- 0 indole-S-sulfonic acid 00 Hydrazide obtained in the precedent step, e.g. 4-ethoxy-N-(2-hydrazino-2-oxoethyl)-N-(4methylphenyl)benzenesulfonamide (73 mg, 0.2 mmol), was dissolved in EtOH 5 AcOH (4 mL). Isatin-5-sulfonic acid sodium salt dihydrate (57 mg, 0.2 mmol) was added. The reaction mixture was stirred overnight at 76 0 C. A yellow precipitate was formed. It was collected by filtration, washed with cold EtOH and dried under vacuo at 40 0 C, affording the desired product, e.g. 3-[(([(4-ethoxyphenyl)sulfonyl]-4-methylanilinoacetyl)hydrazono]-2-oxo-2,3-dihydro-H-indole-5-sulfonic acid (38 mg, 32%; as a yellow solid in 98.4 purity by HPLC (MaxPlot detection between 230 and 400 nm).

M.p. 318-319 C, decomposition; IR (neat) v 2988, 1698, 1595, 1500, 1354, 1222, 1091 cm-; 'H NMR (300 MHz, DMSO-d 6 1.42 J= 7.0 Hz, 3H, OCH 2

CH

3 2.33 3H,

CH

3 4.20 2H, OCH 2

CH

3 4.55 (br s, 2H, NCH 2 CO, minor isomer 4.55 (br s, 2H, NCH 2 CO, major isomer 6.95 1H, H arom.), 7.06-7.30 6H, H arom.), 7.50-7.90 4H, H arom.), 11.38 1H, NH), 12.54 (br s, 1H, CONHN, major isomer 13.64 (br s, 1H, CONHN, minor isomer Mv(APCT): 571. Analysis calculated for C 25

H

24

N

4

O

8

S

2 Na 0.5 H 2 0: C, 49.75; H, 4.01; N, 9.28. Found: C, 49.58; H, 3.93; N, 9.24.

WO 02/32864 PCT/EP01/11865 -51- Example 2: 4-ethoxy-N- {2-oxo-2-[2-(2-oxo- 1 .2-dihydro-3H-indol-3-lidene)hydrazinolethll -N-phenylbenzenesulfonamide 00 NN I Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, aniline, methyl bromoacetate and 1H-indole-2,3-dione, the title compound was precipitated with the addition of water and recristallized from MeOH. A bright yellow solid (74 mg, 62%) was isolated in 99.6 purity by HPLC (MaxPlot detection between 230 and 400 nm).

M.p. 135.5-136.5 OC; IR (neat)v 3168, 1688, 1595, 1495, 1337, 1155, 1122, 1091 cm'; 'H NMR (300 MHz, DMSO-d 6 1.34 J= 7.0 Hz, 3H, OCH 2

CH

3 4.11 J= 7.0 Hz, 2H,

OCH

2

CH

3 4.51 (br s, 2H, NCH 2 CO, major isomer 5.00 (br s, 2H, NCH 2

CO,

minor isomer 6.95 1H, H arom.), 7.03-7.17 3H, H arom.), 7.19-7.43 (m, 6H, H arom.), 7.43-7.70 3H, H arom.), 11.27 1H, NH), 12.50 (br s, 1H, CONHN, minor isomer 13.66 (br s, 1H, CONHN, major isomer M(APCI): 477.

Analysis calculated for C 24 H22N 4 0s 5 S 1 H20: C, 58.05; H, 4.87; N, 11.28. Found: C, 57.71; H, 4.92; N, 11.03.

WO 02/32864 PCTIEPO1/1 1865 -52- Example 3: 4-ethoxy-N- {2-[2-(5-nitro-2-oxo-1 .2-dihvdro-3H-indol-3-ylidene)hydrazinol- 2-oxoethyl} -N-ph.ybenenesulfonaiide 00 Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, aniline, methyl bromoacetate and 5-nitro-1H-indole-2,3-dione, the title compound was precipitated with the addition of water and recristallized in THFIH 2 O. A yellow powder (48 mg, 40%) was isolated in 98.9 purity by HPLC (MaxPlot detection between 230 and 400 n).

M.p. 252-253 'C;IR (neat) v 3107, 1734, 1721, 1624, 1595, 1518, 1337, 1154, 1118, 1084 cm- 1 1H NMIR (300 MHz, DMSO-d 6 1.34 J= 7.0 Hz, 3H, OCH 2

CH

3 4.20 J= Hz, 2H, OCH 2 CHA) 4.68 (br s, 2H, NCH 2 CO, major isomer 5.14 (br s, 2H,

NCH

2 CO, minor isomer 7.12-7.27 (in, 3H, H arom.), 7.30-7.48 (in, 5H1, H arom.), 7.52-7.77 (mn, 2H1, H aroin.), 8.23-8.46 (in, 2H, H arom.), 11.95 IIH, NH), 12.48 (br s, 1H, CONHN, minor isomer 13.58 (br s, 1H, CONHN, major isomer Mf (APcF): 522. Analysis calculated for C 2 4 1{ 2

IN

5 0 7 S: C, 55.06; H, 4.04; N, 13.38. Found: C, 54.92; H, 4.09; N, 13.27.

WO 02/32864 WO 0232864PCTIEPO 1/11865 -53- Example 4: 4-ethoxyIN- 12-r2-5-iodo-2-oxo-l ,2.-dihydro-3H-indol-3-ylidene)hvdrainol-2oxoethyll -N-phenvlbenzenesulfonamide 00 0 0 c-I rAUN N~ N Following the general method as outlined in ltxample 1, starting from 4-ethoxybenzenesulfonyl chloride, aniline, methyl bromoacetate and 5-iodo-1H-indole-2,3-dione, the title compound was precipitated with the addition of water and recristallized in EtOH. A yellow solid (65 mg, 47%) was isolated in 95.1 purity by HPLC (MaxPlot detection between 230 and 400 nm).

M.p. 233-234 IR (neat) v 3371, 2976, 1719, 1693, 1594, 1534, 1338, 1156, 1094 cm; 1 NMR (300 M&z, DMSO-d 6 1.13 J= 7.0 Hz, 3H, OCH 2

CH

3 3.89 J 7.0 Hz, 2H, OCH 2

CH

3 ),4.31 (br s, 2H, NCH 2 CO, major isomer (5 1.80 (br s, 2H, NCH 2

CO,

minor isomer 6.79 (in, 1H, H arom.), 7.07 (in, 2H, H arom.), 7.19-7.41 (in, 5H, H arom.), 7,41-7.92 (in, 4H, H arom.), 11.35 1H, NH), 12.42 (br s, 1H, CONRN, minor isomer 13.58 (br a, 1H, CONIJN, major isomer Mf(APCID: 603. Analysis calculated for C 24

H

21

IN

4 0 5 S 0.1 H 2 0: C, 47.55; H, 3.52; N, 9.24. Found: C, 47.20; H, 3.58; N, 9.26.

WO 02/32864 WO 0232864PCTJEPOI/1 1865 (Nj4 Example 5: 4-ethoxy-N-(4-meth lphenl)-N- f2-oxo-2-r2-(2-oxo- 1 2-dihydro-3H-indol-3ylidene)hydrazinolethyI'lbenzenesulfonarnide 00 r 0 0 Folowig te gnerl ethd a oulind Nml1,satnfrm4ehybnne yellowsid (197enr mho %was iolated in 98amp9 1, purti yo HPLC (Mxt eetio between 230 and 400 nm).

M.p. 130-131 0 IR(neat) v3170, 1682, 1598, 1335, 1262, 1152, 1091 cm'1; 1 H NMR (3 00 MiHz, DMSO-d 6 1.16 J =7.0 Hz, 3H, OCH 2

CH

3 2.07 3H, CH 3 3.93 J Hz, 2H, OCH 2

CH

3 ),4.29 (br s, 2H, NCH 2 CO, major isomer 4.78 (br s, 2H,

NCH

2 CO, minor isomer (3 6.77 (in, 1H, H arom.), 7.0 1-7.20 (in, 7H, H arom.), 7.20 (in, 111, H arom.), 7.43-7.68 (mn, 3H, H arom.), 11.09 1H, NH), 12.31 (br s, 111, CONHN, minor isomer 13.46 (br s, 1H, CONHN, major isomer M+(ES): 493; Mf(ES): 49 1. Analysis calculated for C25H- 24

N

4

O

5 S 1 H 2 0: C, 5 8.8 1; H, 5.13; N, 10.97. Found: C, 58.41; H, 5.19; N, 10.98.

WO 02/32864 WO 0232864PCTIEPOI/1 1865 Expmple 6: N-(4-methylphenfl)-N- (2-oxo-2-[2-(2-oxo- 1 2-dihydro-3H-indol-3vLhdene)hvdraZinolethl 1-1-naphthalenesulfonaniide 00 -0 0

N-N

N/

Following the general method as outlined in Example 1, starting from 1-naphthalenesulfonyl chloride, p-toluidine, methyl bromoacetate and 1lH-indole-2,3-dione, the title compound was isolated by evaporation of the solvents and purified by recrystallization. in MeOH. A yellow powder (52 mg, 52%) was obtained in 98.5 purity by HPLC (MaxPlot detection between 230 and 400 nm).

138-139'C; IR (neat) v 3431, 1698, 1621, 1494, 1465, 1336, 1193, 1161, 1162 cm-1; 1H NMIR (300 MfHz, DMSO-d 6 2.27 3H, CH),4.66 (hr s, 2H, NCH 2 GO, major isomer 5.14 (hr s, 2H, NCH 2 CO, minor isomer 6.98 1 H, H arom.), 6.99-7.15 (in, 5H, H arom.), 7.30-7.70 (in, 5H, H arom.), 8.02-8.19 (in, 2H, H aroin.), 8.21-8.45 (in, 2H, H arom.), 11.30 1H, NIT), 12.54 (hr s, 1H1, CONHN, minor isomer 13.56 (hr s, 1H, CONHN, major isomer Nf(ACr): 497. Analysis calculated for

C

27 H22N 4 0 4 S 0.5 1120: C, 63.89; H, 4.57; N, 11.04. Found: C, 63.73; H, 4.48; N, 11.34.

WO 02/32864 WO 0232864PCT[EPO 1/11865 -56- Example 7: N-(4-methylphenvl)-.N- {2-oxo-2-r2-(2-oxo- 1 2-dihydro-3H-indol-3ylidene~hvdrazinolethvll -2-naphthalenesulfonamide 00 0 c-I 11"0 00

N'

Following the general method as outlined in Example 1, starting from 2-naphthalenesulfonyl chloride, p-toluidine, methyl bromoacetate and LH-indole-2,3-done, the title compound was isolated by evaporation of the solvents and purified by recrystallization in MeOH. An orange powder (52 mg, 55%) was obtained in 94.7 purity by HPLC (MaxIPlot detection between 230 and 400 rn).

1 H NMR (300 M&z, DMSO-d 6 2.24 3H, CH 3 4.60 (br s, 2H, NCH 2 CO, major isomer 5.06 (br s, 2H, NCH 2 CO, minor isomer 6.82-71.19 (mn, 6K, H arom.), 7.38 (mn, 1H, H arom.), 7.46-7.6 1 (mn, 2H, H aroin.), 7.6 1-7.79 (in, 211, H aroin.), 8.02-8.20 (in, 3H, H aroin.), 8.38 1H, H aroin.), 11.27 1H,NHW, 12.51 (hr s, 1H, CONHN, minor isomer 13.66 (br s, 1H, CONIJN, major isomer M-(APCD): 497.

WO 02/32864 WO 0232864PCT/EPOI/1 1865 -57- Example 8: 4-chloro-N-(4-methylnhenv)-N- f2-oxo-2-[2-(2-oxo- 1 2-dibvdro-3H-indol-3ylidene~hydrazinolethyllbenzenesulfonamide 00 0

N

0

N-N

N

Following the general method as outlined in Example 1, starting from 4-chlorobenizenesulfonyl chloride, p-toluidine, methyl bromoacetate and 1H-indole-2,3-dione, the title compound was isolated by evaporation of the solvents and purified by recrystallization in MeOll. A yellow powder (50 mg, 51 was obtained in 98.7 purity by HPLC (MaxPlot detection between 230 and 400 rim).

M.p. 234-235'C;IR (neat) v 3352, 1717, 1693, 1614, 1509, 1463, 1332, 1192, 1152, 1127, 1087 cm-1; 'H NMR (300 Mvffz, DMSO-d 6 2.26 3K, CH 3 ),4.56 (br s, 2H, NCH 2

CO,

major isomer 5.00 (br s, 2H, NCH 2 CO, minor isomer 6.94 (in, 1H, H aroin.), 7.03-7.19 (in, 5H, H arom.), 7.38 (in, 1L H aroin.), 7.46-7.7 1 (in, 51L H aroin.), 11.27 1H, NIH), 12.49 (br s, 1H, CONHN, minor isomer 13.59 (br s, 11-L CONHN, major isomer Mf(APCr): 48 1. Analysis calculated for C 23 HI 9

CIN

4 0 4

S

0.4 H 2 0: C, 56.36; H, 4.07; N, 11.43. Found: C, 56.54; H, 4.11; N, 11.43.

WO 02/32864 WO 0232864PCT/EPOI/1 1865 -58- ExaMple 9: 4-methoxy-N-(4-methyl hnv)-N- f2-oxo-2-r2-(2--oxo- 1 2-dih dro-3H-indol- 3 -ylidene)hydrazinol ethl benzenesulfoflami~de 00 0 N t0 0

N-N

N/

Following the general method as outlined in Example 1, starting from 4- methoxybenzenesulfonyl chloride, p-toluidine, methyl bronioacetate and 1Hl-indole-2,3--dione, the title compound was isolated by evaporation of the solvents and purified by recrystallization in MeOH. A yellow powder (60 mg, 63%) was obtained in 97.0 purity by HPLC (MaxPlot detection between 230 and 400 n).

M.p. 134-135*C;IR (neat) v 33 53, 1691, 1613, 1503, 1464, 1334, 1152, 1123, 1089 cm- 1 'H NMIR (300 M&z, DMSO-d 6 2.25 311, CHA) 3.84 311, OCH 3 4.47 (br s, 2H,

NCU

2 CO, major isomer 4.96 (br s, 211, NCH 2 CO, minor isomer 6.84-7.01 (in, 1H, H arom.), 7.06-7.18 (in, 7H, H arom.), 7.38 (mn, 1H, H arom.), 7.44-7.68 (mn, 3H1, H arom.), 11.27 1H, NH), 12.49 (br s, 1H, CONHN, minor isomer 13.65 (br s, IH, CONHN, major isomer M+(APC~I7): 479; 477. Analysis calculated for

C

24 H12N 4 0 5 S 1.5 H 2 0: C, 57.02; H, 4.98; N, 11.08. Found: C, 57.02; H, 4.93; N, 11. w WO 02/32864 PCT/EPOI/1 1865 -59- Example 10: 4-methyl-N-(4-methvlphenyrl)-N- f2-oxo-2-r2-(2-oxo- 1 2-dihydro-3H-indol-3ylidene)hydrazinolethyllbenzenesulfonaniide 00 0

N-N

N

Following the general method as outlined in Example 1, starting from 4-methylbenzenesulfonyl chloride, p-toluidine, methyl. bromoacetate and 1H-indole-2,3-dione, the title compound was isolated by evaporation of the solvents and purified by recrystallization in MeOH. A yellow powder (37 mg, 40%) was obtained in 98.0 purity by HPLC (MaxPlot detection between 230 and 400 nm).

M.p. 243-244'C; JR (neat) v 3350, 1715, 1692, 1614, 1508, 1462, 1328, 1150, 1124, 1091 cm'1; 'H NMR (300 MIHz, DMSO-d 6 2.25 3H, CHA) 2.39 3H, CHA) 4.49 (br s, 21HL

NCH

2 CO, major isomer 4.97 (br s, 2H, NCH 2 CO, minor isomer 6.95 (in, 1H, H arom.), 7.04-7.19 (in, 5H, H arom.), 7.34-7.64 (mn, 6H, H aroin.), 11.27 1H, Nil, 12.49 (br s, 1H, CONRN, minor isomer 13.63 (hr s, 1H, CONHN, major isomer M+(APCP'): 463; Mf(APCIf): 46 1. Analysis calculated for C 24

H

22

N

4 0 4 S 0.3 H 2 0: C, 61.60; H, 4.87; N, 11.97. Found: C, 61.48; H, 4.87; N, 12.02.

WO 02/32864 WO 0232864PCT/EP01/1 1865 Example 11: 4-cyano-N-(4-methylphenyl)-N- f2-oxo-2-r2--(2-oxo- 1 2-dihydro-3H-indol-3ylidene)hydrazinolethvflbenzenesulfonamide 00 0 N N\

N/

Following the general method as outlined in Example 1, starting from 4- cyanobenzenesulfonyl chloride, p-toluidine, methyl bromoacetate and 1lH-indole-2,3-dione, the title compound was isolated by evaporation of the solvents and purified by recrystallization in MeOH. A yellow powder (59 mg, 63%) was obtained in 93.0 purity by HIPLC (MaxPlot detection between 230 and 400 nmn).

'H NMR (300 MHz, DMSO-d 6 2.25 3H, CHA) 4.62 (hr s, 2H, NCH 2 CO, major isomer 5.04 (hr s, 2H, NCH 2 CO, minor isomer 6.94 (in, 1 H, H arom.), 7.03-7.22 (mn, 5H, H arom.), 7.38 (mn, 1H, H arom.), 7.46-7.62 (in, 1H, Harom.), 7.72-7.92 (in, 2H, H arom.), 8.08 (in, 211,11 aroin.), 11.27 111, WH?, 12.49 (hr s, 111, CONHN, minor isomer 13.52 (hr s, 1H, CONHN, major isomer M-(APCF): 472.

WO 02/32864 WO 0232864PCT/EPOI/1 1865 C~1 -61- Example 12: 4-ethoxy-N- f2-r2-(2-fluorobenzvlidejehydrazinol-2-oxoethvlI methylphpnylbenzenesulfonamide 00

N

N-N

F

Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, p-toluidine, methyl bromoacetate and 2-fluorobenzaldehyde, the title compound precipitate in the reaction mixture. It was collected by filtration, washed with cold EtOH and dried under vacuo at 40*C, affording a colorless powder (72 mg, 77%) in 96 purity by HPLC (MaxPlot detection between 230 and 400 rn).

M.p. 183-184 0 C; JR (neat) v 3286, 2987, 1673, 15 94, 1537, 1454, 1343, 1256, 1152, 109 1, 1073 cmn 1 'H NMR (300 Mhfz, DMSO-d 6 1.34 J 7.0 Hz, 3H, OCH 2

CII

3 2.24 (s, 3H, CH 3 4. 10 J 7.0 Hz, 2H, OCH 2 CHA) 4.31 2H, NCH 2 CO, minor isomer 4.80 2H, NCH 2 CO, major isomer 6.95-7.15 (in, 6H, H arom.), 7.20- 7.33 (in, 2H, H arom.), 7.42-7.64 (in, 3HL H arom.), 7.75-7.95 (in, 1H, H arom.), 8.15 (s, 1H, CH=N, major isomer 8.42 1H, CIP=N, minor isomer 11.56 1H, CONIIN, major isomer 11.60 1H, CONHN, minor isomer MT(APCF): 468. Analysis calculated for C 24

H

24

FN

3 0 4 S 0.1 H 2 0: C, 61.16; H, 5.17; N, 8.92. Found: C, 60.92; HK 5.21; N, 8.95.

WO 02/32864 WO 0232864PCTIEP01/1 1865 -62- Example 13: N-44-m2thylphenYl)-N- f2-oxo-2-[2-(2-oxo-1 .2-dihydro-3H-indol-3ylidene~hydrazinol ethyl) r 1.1'-biphenyll-4-sulfonamide 00 0 0

N-N

N/

Following the general method as outlined in Example 1, starting from 4-phenylbenzenesulfonyl chloride, p-toluidine, methyl bromoacetate and 1 H-indole>-2,3-dione, the title compound precipitate in the reaction mixture. It was collected by filtration, washed with cold EtOH and dried under vacuo at 40"C, affording a yellow-orange powder (76 mng, in 99 purity by KPLC (MaxPlot detection between 230 and.400 inn).

M.p. 246-247'C; JR (neat) v 3098, 1698, 1616, 1506, 1468, 1317, 1148, 1117 cm'1; 1

H

NMR (300 MHz, DMSO-d 6 2.26 3H, CH 3 4.57 (br s, 2H, NCH 2 CO, major isomer 5.04 (hr s, 2H, NCH 2 CO, minor isomer 6.94 (in, 1H, H aroin.), 7.08 (in, 1H, H aroin.), 7.16 (in, 4H, H arom.), 7.34-7.60 (in, 5H, H aroin.), 7.60-7.83 (mn, 4H, H arom.), 7.90 (in, 2K, H aroin.), 11.27 1H, NH), 12.52 (hr s, 1H, CONIJN, minor isomer 13.64 (br s, 1H, CONJJN, major isomer M-(APCI): 523. Analysis calculated for C 29 H24N 4 0 4 S: C, 66.40; H, 4.61; N, 10.68. Found: C, 66.25; H, 4.63; N, 10.59.

WO 02/32864 PCT/EPOI/1 1865 -63- ExaMle 14: N-(4-methylphenfl-N- {2-oxo-2-[2-(2-oxo-l .2-dihydro-3H-indol-3ylidene')hydrazinolethvl} -4-phenoxybenzenesulfonaxnide 00 0 \0 0 N-N Following the general method as outlined in Example 1, starting from 4-phenoxybenzenesulfonyl chloride, p-toluidine, methyl bromoacetate and 1H-indole-2,3-dione, the title compound precipitate in the reaction mixture. It was collected by filtration, washed with cold EtOH and dried under vacuo at 40TC, affording a yellow powder (84 rug, 78%) in 98 purity by HPLC (MaxPlot detection between 230 and 400 urn).

M.p. 245-246'C; IR(neat) v2987, 1698, 1616, 1506, 1468, 1317, 1248, 1148, 1117, 1078 cm'1; 1 H N'R (300 M&z, DMSO-d 6 2.26 311, CH 3 4.57 (hr s, 2H, NCH 2 CO, major isomer 5.04 (hr s, 21L, NCH 2 CO, minor isomer 6.95 (in, 11-L H arom.), 7.08 (in, 1H, H arom.), 7.16 (in, 411, H arom.), 7.34-7.61 (in, 5H, H arom.), 7.61-7.84 (mn, 411, H arom.), 7.90 (mn, 2H, H arom.), 11.27 1H, NH, 12.52 (hr s, 1H, CONHN, minor isomer 13.64 (hr s, 1H, CONRN, major isomer [M-CH 3 ]ftAPCr): 523.

WO 02/32864 WO 0232864PCTIEP01/1 1865 -64- ExaMple 15: 4-ethoxy:-N- {2-[2-(2-hydroxybenzyLidene)hydrazinoI -2-oxoehylI methyl henyl)benzenesulfonamide 00 0

N-N

Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, p-toluidine, methyl bromo acetate and 2-hydrbxybenzaldehyde, the title compound precipitate in the reaction mixture. It was collected by filtration, washed with cold EtOH and dried under vacuo at 40 0 C, affording a colorless powder (63 mg, in 83 purity by HPLC (MaxP lot detection between 230 and 400 nm).

'H NMR (300 MHz, DMSO-d 6 1.34 J= 7.0 Hz, 3H, OCH 2

CH

3 2.24 3H, CHA) 4. 10 J 7.0 Hz, 2H, OCH 2 CHA) 4.32 2H, NCH 2 CO, major isomer 4.77 (s, 2H, NCH 2 CO, minor isomer 6.81-7.16 (in, 8H, H arom.), 7.18-7.31 (mn, 1H, H arom.), 7.45-7.72 (in, 3H, H arom.), 8.23 1H, CH=N, minor isomer 8.39 1H, CH=N, major isomer 9.98 1H, OH, minor isomer 10.92 1H, OH, major isomer 11.37 lH, CONIJN, minor isomer 11.68 lH, CONBN, minor isomer M-(APCr-): 466.

WO 02/32864 WO 0232864PCTIEP01/11865 ExaMple 16: f2-r4-(diethylamino)-2-hvdy benLhdenelhydrazinol -2-oxoethyl)-4ethoxy-N-(4-methylphenyl)benzenesulfonanmide 00

%N

N-N

Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, p-toluidine, methyl bromoacetate and 4-(dicithylaniino)-2-hydroxybeuzaldehyde, the title compound precipitate in the reaction mixture. It was collected by filtration, washed with cold EtOH and dried under vacuo at 40'C, affording a peach powder (91 mg, 85%) in 98 purity by HPLC (MaxPlot detection between 230 and 400 nm).

M.p. 227-228*C; JR (neat) v 3338, 2978, 1687, 1633, 1592, 1510, 133 8, 1242, 1154, 1092, 1043 cm-1; 'H NMR (300 MlHz, DMSO-d 6 1.00-1.17 (in, 6H1, NCH 2

CH

3 1.34 J= Hz, 3H, OCH 2

CH

3 2.24 3H, CH 3 3.20-3.43 (Mi 4H, NCH 2

CH

3 4. 10 J 7.0 Hz, 2H1, OCH 2 CHA) 4.27 2H, NCH 2 CO, major isomer 4.68 211, NCH 2 CO, minor isomer 6.06 IHR H arom, major isomer (75 6. 10 IHR H arom, minor isomer 6.22 (in, 1H, H arom.), 6.95-7.40 (in, 7H, H arom.), 7.45-7.65 (in, 2K1 H arom.), 8.02 1H, CH=N, minor isomer 8.15 1H, CH=N, major isomer 9.75 1H, OH, minor isomer 11.06 111, OH, major isomer 11.10 111, CONIIN, minor isomer 11.36 1H1, CONIIN, major isomer MC(APCD:. 537. Analysis calculated for C 2 SH34N 4

O

5 S: C, 62.43; H, 6.36; N, 10.40. Found: C, 62.3 1; HL 6.40; N, 10.4 1.

WO 02/32864 WO 0232864PCT/EP01/11865 -66- ExaMple 17: 4-ethoxy-N-(2-1f2-[(2-hyclroxy-1 -naphthvl~methylenelhydrazino1 -2oxoethyl)-N-(4-methlphenyl~benzenesulfonamide 00 0

N-N

0// Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, p-toluidine, methyl bromoacetate and 2-hydroxy-1 -naphtbaldehyde, the title compound precipitate in the reaction mixture. It was collected by filtration, washed with cold EtOll and dried under vacuo at 40*C, affording a bright yellow powder (71 mg, 68%) in 92 purity by ILPLC (MaxPlot detection between 230 and 400 m).

'H NMv~R (300 iHz, DMSO-d 6 1.34 J= 7.0 Hz, 3H, OCH 2

CH

3 2.25 3HK CH 3 4.11 J 7.0 Hz, 2H, OCH 2 CHA) 4.39 2H, NCH 2 CO, major isomer 4.81 (s, 2H, NCH 2 CO, minor isomer 7.05-7.65 (in, 1 1H, H arom.), 7.82-7.95 (mn, 2H, H aroin.), 8.25 (in, 111,1 aroin., major isomer 8.64 (in, 11-1 H arom., minor isomer 8.78 11L, CH=N, minor isomer 9.26 1Hl, CH=N, major isomer 10.70 1H, OH, minor isomer 11.41 1H, CONIJN, minor isomer 11.77 1H, OH, major isomer 11.33 111, CONIJIN, major isomer Mf(APCF-): 516.

WO 02/32864 WO 0232864PCTIEP0 1/11865 -67- Examle 18: 4-ethoxy-N-(4-methvlphenvil)-N-1.2-oxo-2-[2-(3-oxo-2,3-dihydro- 1H-inden- 1ylidene)hydraino] ethlbenzenesulfonamide 00 '0

%N

N-N

0-b Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, p-toluicline, methyl bromoacetate and flH-indene-1,3(2H)-dione, the title compound precipitate in the reaction mixture. It was collected by filtration, washed with cold EtOH and dried under vacuo at 40 0 C, affording a grey brown powder (60 mg, 62%) in 93 purity by HPLC (MaxPlot detection between 230 and 400 rn).

'H NMR (300 MFIz, DMSO-d 6 1.35 J= 7.0 Hz, 3H, OCH 2

CH

3 2.24 3H, CH 3 lo 3.39 (in, 2H, (C=N)CH 2 4.11 J= 7.0 Hz, 2H, OCH 2

CH

3 ),4.44 2H,

NCH

2 CO, minor isomer 4.88 2H, NCH 2 CO, major isomer (62 6.98-7.16 (in, 6H, H arom.), 7.5 1-7.68 (in, 3H, H arom.), 7.70-7.86 (mn, 2H, H aroin.), 7.90 (in, 1K1 H arom., minor isomer 7.99 (in, 1H, H arom., major isomer 10.52 LH, CONRN, minor isomer (3 10.92 IH, CONIJN, major isomer MC(APCIF): 490.

WO 02/32864 WO 0232864PCTJEPOI/1 1865 -68- Exampple 19: 4'-methoxv-N-(4-methylphelyl)-N- f2-oxo-2-[2-(2-oxo-1 .2-dihydro-3H-indol- 3-3Lhdene)hvdaio tyl[. -ihni -4-sulfonamide 00 0 S- N~

-I

0 6N Following the general method as outlined in Example 1, starting 4'-methoxy[1,1'-biphenyl]- 4-sulfonyl chloride, p-toluicline, methyl bromoacetate and 1H-indole-2,3-dione, the title compound precipitate in the reaction mixture. It was collected by filtration, washed with cold EtOH and dried under vacuo at 40*C, affording a yellow-orange powder (106 mg, 92%) in 98 purity by HPLC (MaxPlot detection between 230 and 400 run).

M.p. 235-236'C; IR (neat) v 3204, 1717, 1688, 1595, 1504, 1466, 1337, 1249, 1155, 1125, 1092 cm-1; 'H NMR (300 M&z, DMSO-d 6 2.26 3H, CHA) 3.81 3H, OCHA) 4.5 (br s, 2H, NCH 2 CO, major isomer 5.03 (br s, 2H, NCH 2 CO, minor isomer 6.95 (in, 1H, H arom.), 7.01-7.22 (in, 7H, H arom.), 7.38 (in, 1H, H arom.), 7.46-7.78 (in.

H arom.), 7.85 (in, 2H, H aroin.), 11.27 1H, 12.51 (br s, 11-L CONHN, minor isomer 13.64 (br s, 1H, CONBN, major isomer MW(APCI): 553. Analysis calculated for C 3 oH 26

N

4 0 5 S: C, 64.97; H, 4.73; N, 10. 10. Found: C, 64.60; H, 4.70; N, 9.94.

WO 02/32864 WO 0232864PCT/EPO 1/11865 -69- Example 20: 4-ethoxy-N- 12-[2-(1 -methyl-2-oxo-1I.2-dihydro-3H-indol-3-vlidene)hydrazinol-2-oxoethfl -N-(4-methylphenyl)benzenesulfonamide 00 00 Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, p-toluidine, methyl bromoacetate and I1-methylisatin, the title compound was isolated by evaporation of the solvents and purified by rectystallization in MeOH. A yellow powder (79 mg, 79%) was obtained in 99% purity by HIPLC (MaxPlot detection between 230 and 400 inn).

M.p. 109-1 10'C;IR (neat) v 2987, 1694, 1616, 1592, 1505, 1470, 1356, 1338, 1261, 1153, 1116,1097,1041 cm-1; 1H NMVR(300 MHz, DMSO-d 6 1.34 J= 7.0 Hz, 3H,

OCH

2

CH

3 2.26 3H, CR 3 3.31 3H, CR 3 4. 11 J= 7.0 Hz, 2H, OCH 2

CH

3 4.48 2H, NCH 2 CO, major isomer 4.96 2H, NCH 2 CO, major isomer 7.02- 7.23 (in, 8H, H arom.), 7.43-7.67 (mn, 4H, H arom.), 12.42 1H, CONHN, minor isomer 13.60 1H, CONHN, major isomer M-(APCf): 505. Analysis calculated for C 26

H

26

N

4 0 5 S 0.2 H 2 0: C, 61.21; H, 5.22; N, 10.98. Found: C, 60.96; HL 5.23; N, 10.92.

WO 02/32864 WO 0232864PCTIEP0 1/11865 Example 21: N-(2-1f2-fl -(2,-dihydroxvphenvl)ethylidenelhydrazinol -2-oxoethyl)-4ethoxyjN-4-methylphen l)benzenesulfonamide 00 N-.0

N

K-

Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, p-toluidine, methyl bromoacetate and 2,4-dihydroxyacetophenone, the title compound was isolated by evaporation of the solvents and purified by recrystallization in MeOH. A light yellow powder (33 mg, 33%) was obtained in 93% purity by I{PLC (MaxPlot detection between 230 and 400 nm).

'H NMVR (300 Mh1z, DMSO-d 6 1.34 J= 7.0 Hz, 3H, OCH2CH 3 2.21 3H, Gil 3 2.25 3H1, CHA) 4. 10 J 7.0 Hz, 2H, OCH 2

CH

3 4.45 2H, NCH 2 CO), 6.20 (in, lIH, H arom.), 6.28 (mn, 1H, H arom.), 6.95-7.18 (in, 611, H arom.), 7.35 (mn, IL H arom.), 5 (mn, 2H1, H aroin.), 9.81 IlH, OH), 10. 79 1 H, OH), 13.12 lI-L, CONHN); Mf (APCL): 496.

WO 02/32864 WO 0232864PCT/EPOI/1 1865 -71- Exa!mple 22: 4-ethoxy-N-(2- 12-[ 1-(2-hydroxyphenvlethylidenelh'vdrzinol-2-oxoethvh- N-(4-rnthylphenyl)benzenesulfonamide 00 0 c-I 0 S=O-

N-N

Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, p-toluidine, methyl. bromoacetate and 2-hydroxyacetophenone, the title compound was isolated by evaporation of the solvents and purified by recrystallization. in MeGH. A colorless powder (59 mg, 61%) was obtained in 99% purity by HPLC (MaxPlot detection between 230 and 400 nin).

M.p. 199-200'C; IR (neat) v 2986, 1669, 1592, 1534, 1493, 1351, 1304, 1244, 1203, 1161, 1084 cm-1; 'H NMR (300 MHz, DMSO-d 6 1.34 J= 7.0 Hz, 3H, OCH 2

CH

3 2.25 (s, 3H, CH 3 2.30 3H, CH),4.10 J= 7.0 Hz, 2H, OCH 2 CHA) 4.49 2H, NCH 2

CO,

major isomer 4.72 2H, NCH 2 CO, minor isomer 6.81-6.90 (mn, 2H, H arom.), 7.00-7.16 (mn, 6H, H arom.), 7.26 (mn, 1H, H aroin.), 7.55 (mn, 3H, H arom.), 10.77 1H, CH=N, minor isomer 10.98 1H, CH=N, major isomer 12.94 (s, 1H, CONIIN); M-(APCD): 480. Analysis calculated for C25H 27

N

3

O

5 S: C, 62.35; H, 5.65; N, 8.73. Found: C, 62.16; H, 5.60; N, 8.74.

WO 02/32864 WO 0232864PCT/EP01/1 1865 -72- Examle 23: 3 ,4-dimethoxv-:N-(4-methylphenyl)-N-1f2-oxo-2-r2-(2-oxo-1 .2-dihydro-3Hindol-3-yLhdene')hydrazinolethyllbenzelesulfoflaflde 00 /0 0 I N 0 N-N Following the general method as outlined in Example 1, starting from 3,4-dimethoxybenzenesulfonyl chloride, p-toluidine, methyl. bromoacetate and 1lH-indole-2,3 -dione, the title compound was isolated by evaporation of the solvents and purified by recrystallization in EtOAc. A dark orange powder (35 mg, 35%) was obtained in 92% purity by HI.PLC (MaxPlot detection between 230 and 400 nm).

'H NMR (300 MHz, DMSO-d 6 2.08 3H, CHO), 3.54 3H, OCH 3 3.66 3H,

OCH

3 4.31 2H, NCH 2 CO, major isomer 4.79 2H, NCH 2 CO, minor isomer 6.68-6.85 (in, 2H, H arom.), 6.85-7.10 (in, 7H, H arom.), 7.20 (in, 1H, H arom.), 7.35 (in, 1H, H arom.), 11.09 1H, NH), 12.32 1H-, CONRN, minor isomer 13.48 1H, CONHN, major isomer m+(Apcri): 509, Mc(APCr): 507.

WO 02/32864 WO 0232864PCTIEP01/1 1865 73- Examle 24: 4-ethoxy-N-(2- 12-ri -(2-hydroxy-l1-naphthylbethylidenelhvdrazinol -2oxoethyl)-N-(4-methylphenylbenzenesulfonaniide 00 0 c-I 0 S0-

%N

-N

Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, p-toluidine, methyl bromoacetate and 2-hydroxy-l-acetonaphthone, the title compound was isolated by evaporation of the solvents and purified by recrystallization .in AcOEt. A light yellow powder (5 5 mg, 52%) was obtained in 90% purity by HPLG (MaxPlot detection between 230 and 400 rn).

1H NMR (300 M&z, DMSO-d 6 1.34 (in, 3H, OCH 2

CH

3 2.25 (in, 6H, 2 CHA) 3.904.15 (in, 4H, OCH 2

CH

3 and NCH 2 CO, minor isomer 4.79 2H, NCH 2 CO, major isomer 6.25 (in, 1H, H atom.), 6.80 (in, 1H, H atom.), 6.88-7.65 (in, lOH, H atom.), 7.76-8.04 (in, 2H, H atom.), 9.13 1H, OH, minor isomer 9.30 1H, OH, major isomer 10.07 1H, CONIIN, minor isomer (3 10.23 1H, CONHN, major isomer M-(APCF): 530.

WO 02/32864 WO 0232864PCT/EPO 1/11865 74- Example 25: 4-Ethoxv-N-(2- ff2E')-2-[1 1-hydroxy-2-naphthvl)ethlidenelhydrazino1 -2oxoethl'l)-N-(4-methylphenyl)benzenesulfonamide 00 >X~yN~t0 Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, 4-toluidine, methyl bromoacetate and 1'-hydroxy-2'-acetophenone, the title compound was isolated by evaporation of the solvents and purified by crystallization in EtOIAcOH A light beige solid (18.9 mg, 18%) was obtained in 98.18% purity by HPLC (MaxPlot detection between 230 and 400 nm).

'H NMIR (DMSO-46, 300* MILz) d 1.37 3H, J=6.8Hz), 2.22 3H7), 2.43 3H), 4.14 (q, 2H, 1=6.8Hz), 4.56 2H), 7.05-7.18 (in, 6HD, 7.39 11H), 7.47-7.70 5H), 7.85 (in, 1H), 8.29 1H), 11. 1 1H, OH). (APCF): 530.2. (APCC): 532.2.

WO 02/32864 PCT/EP01/11865 (N Example 26: 4-tert-Butyl-N-(4-chlorophenyl)-N- 12-oxo-2-[(2E)-2-(2-oxo-1,2-dihdro-3Hindol-3-vlidene)hydrazinolethvl}benzenesulfonamide 00

O

rN Following the general method as outlined in Example 1, starting from 4-tertbutylbenzenesulfonyl chloride, 4-chloroaniline, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by crystallization in MeOH. A yellow powder (72.7 mg, 69%) was obtained in 99.35% purity by HPLC (MaxPlot detection between 230 and 400 nm).

M.p. 194-195 0 C. IR(neat)v 2966, 1698, 1620, 1469, 1366, 1170, 1084 cm'. 'H NMR (DMSO-d 6 300 MHz) d 1.30 9H), 4.57 (br s, 2H, NCH2CO, major isomer 5.04 (br s, 21H, NCH2CO, minor isomer 6.94 1H), 7.09 1H11), 7.25-7.67 (m, 11.27 1H, NH), 12.52 (br s, 1H, CONHN, minor isomer 13.56 (br s, 1H, CONHN, major isomer (ESI): 523. Analysis calculated for C 26

H

2 5ClN40 4

H

2 0OC, 58.48; H, 4.91; N, 10.49. Found: C, 58.37; H, 4.97; N, 10.57.

WO 02/32864 PCT/EPO1/11865 -76- Example 27: N-(44-chlorophenyl)-3 .4-dimethoxy-N- 12-oxo-2-(2E)-2-(2-oxo- 1,2-dihydro- 3H-indol-3 -vlidene)hvdrazinolethyl}benzenesulfonamide 00

IIN

O

Following the general method as outlined in Example 1, starting from 3,4dimethoxybenzenesulfonyl chloride, 4-chloroaniline, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by crystallization in MeOH. A yellow powder (91.0 mg, 86%) was obtained in 97.58% purity by HPLC (MaxPlot detection between 230 and 400 nm).

M.p. 132-133 0 C. IR (neat) v 3188, 2966, 1714, 1622, 1506, 1464, 1337, 1139, 1016 cmn 1 'H NMR (DMSO-d, 300 MHz) d 3.74 3H, OCH3), 3.83 3H, OCH3), 4.55 (br s, 2H, NCH2CO, major isomer 5.03 (br s, 2H, NCH2CO, minor isomer 6.90- 7.60 11H, H arom.), 11.27 1H, NH), 12.52 (br s, 1H, CONHN, minor isomer 13.62 (br s, 1H, CONHN, major isomer Analysis calculated for C24H21CIN406S'l.8 H 2 0C, 51.35; H, 4.42; N, 9.98. Found: C, 51.12; H, 4.08; N, 10.05.

WO 02/32864 PCT/EPOI/11865 C( -77- Example 28: 4-tert-Butyl-N-(4-methylphenyl)-N- f2-oxo-2- (2E)-2-(2-oxo-1 .2-dihvdro-3Hindol-3-vlidene)hvdrazinol ethylibenzenesulfonamide 00 oO Following the general method as outlined in Example 1, starting from 4-tertbutylbenzenesulfonyl chloride, 4-toluidine, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by crystallization in MeOH. A yellow powder (49.9 mg, 49%) was obtained in 99.44% purity by HPLC (MaxPlot detection between 230 and 400 rnm).

M.p. 139-140 0 C. IR (neat)v 3188, 2968, 1698, 1506, 1465, 1338, 1160, 1084 cnm- 1

H

NMR (DMSO-d 6 300 MHz) d 1.30 9H), 2.25 3H), 4.50 (br s, 2H, NCH2CO, major isomer 4.98 (br s, 2H, NCH2CO, minor isomer 6.94 1H), 7.02-7.20 5H), 7.38 1H), 7.47-7.70 5H), 11.27 1H, NH), 12.52 (br s, 1H, CONHN, minor isomer 13.56 (br s, 1H, CONHN, major isomer (EST): 503. (ESIr7: 505.

WO 02/32864 WO 0232864PCT(EPOIII 1865 -78- Example 29: N-(4-methylnhenyl)-N- f 2-oxo-2-r(2E')-2-(2-oxo- I .2-dihydro-3H-indol-3ylidene)hydrazinol ethyl) -4-propylbenzenesulfonamide 00 Following the general method as outlined in Example 1, starting from 4-npropylbenzenesulphonyl chloride, 4-toluidine, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by crystallization in MeGH. A orange powder (44.5 mg, 45%) was obtained in 96.59% purity by HPLC (MaxPlot detection between 230 and 400 nm).

M.p. 198-199'C. IR (neat) v 3207, 2966, 1698, 1619, 1467, 1314, 1245, 1143, 1116 cm- 1 1H NMR (DMSO-d 6 300 MHz) d 0.88 3H, J=7.54Hz), 1.60 (sex, 2H, J=7.54Hz), 2.25 3H), 2.64 2H, J=7.54Hz), 4.50 2H, NCH2CO, major isomer 4.97 (br s, 2H, NCH2CO, minor isomer 6.94 (in, 1H), 7.05-7.20 (in, 5H), 7.30-7.65 (in, 6H), 11.28 1H, NH), 12.49 (br s, 1H, CONHN, minor isomer 13.63 (br s, 1H, CONHN, major isomer (ESO): 489.2. Analysis calculated for C26H26N404SC, 63.66; H, 5.34; N, 11.42. Found: C, 63.60; H, 5.36; N, 11.49.

WO 02/32864 WO 0232864PCTIEPOI/1 1865 79- Example 30: 4-Butoxv-7N-(4-methylphenyl)-N- {2-oxo-2-r(2E)-2-(2-oxo-l .2-dihvdro-3Hindol-3-yLidene)hydraginol ethyl eznslonamide 00 Following the general method as outlined in Example 1, starting from 4-(nbutoxy)benzenesulfonyl chloride, 4-toluidine, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by crystallization in MeCH. A yellow powder (61.4 mg, 59%) was obtained in 99.3 9% purity by HPLC (MaxPlot detection between 230 and 400 rim).

M.p. I1I1-I12TC. IR (neat) v 2962, 1693, 1622, 1594, 1497, 1466, 1347, 1257, 1152, 1092 cm- 1 1 H NMR (DMSO-d 6 300 MHz) d 0.93 3H, J=7.53Hz), 1.43 (sex, 2H, J=7.53Hz), 1.71 (in, 211, 2.26 311), 4.05 2H, J=6.39Hz), 4.47 2H, NCH2CO, major isomer 4.95 (br s, 2H, NCH2CO, minor isomer 6.95 (mn, 1H), 7.05-7.26 (mn, 7H1), 7.36 (in, 111), 7.38-7.70 (in, 3H1), 11.28 1H, NH), 12.49 (br s, 111, CONHN, minor isomer 13.65 (br s, 111, CONHN, major isomer 519.2. (ES1+): 521.2. Analysis calculated for C271128N405SC, 62.29; H, 5.42; N, 10.76. Found: C, 62.19; H, 5.44; N, 10.67.

WO 02/32864 WO 0232864PCT/EPO 1/11865 Example 31: 4-Butox)v-N-(4-chlorovhenyl)-N- f 2-oxo-2- 1 .2-dihydro-3Hindol-3-ylidene)hydrazinolethyll benzenesulfonamide 00 a0 Following the general method as outlined in Example 1, starting from 4-(nbutoxy)benzenesulfonyl chloride, 4-chioroaniline, methyl. bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by crystallization in MeOH. A yellow powder (26.3 mg, 25%) was obtained in 96. 1% purity by HPLC (MaxPlot detection between 230 and 400 nmn).

1H NMR (DMSO-d( 6 300 MvHz) d 0.93 311, J=7.5Hz), 1.43 (sex, 2H, J=7.5Hz), 1.71 (in, 2H), 4.05 2H, J=6.40Hz), 4.52 211, NCH2CO, major isomer 5.01 (br s, 2H, NCH2CO, minor isomer 6.95 (in, 11H), 7.03-7.14 (in, 3H1), 7.22-7.68 (in, 8H), 11.28 III,NH), 12.51 (br s, 1H, CONHN, minor isomer 13.60 (br s, III, CONHN, major isomer (APCD): 539. (APCI+): 541.

Example 32: N-(4-chlorophenvl)-N- (2-oxo-2-r(2Z')-2-(2-oxo-1 ,2-dih dro-3H-indol-3vlidene)hvdrazinol ethvll -4-lpropoxybenzenesulfonainide WO 02/32864 WO 0232864PCT/EPO1/1 1865 c-I Following the general method as outlined in Example 1, starting from 4-n-propoxy-1 benzenesulfonyl chloride, 4-chioroaniline, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by flash 00 chromatography, using a mixture cyclohexane/ethyl acetate 3:1 as eluent. A yellow powder NI 5 (46.8 mg, was obtained in 98.92% purity by HPLC (MaxPlot detection between 230 and 400 nm).

'H NMR (DMSO-d 6 300 MIHz) d 0.98 311, J=7.53Hz), 1.75 (in, 2H), 4.02 2H, J=6.40Hz), 4.53 2H, NCH2CO, major isomer 5.02 (br s, 2H, NCH2CO, minor isomer 6.95 (in, lIi), 7.05-7.16 (in, 311), 7.28 (in, 211), 7.35-7.70 (in, 611), 11.28 (s, lH, NMl, 12.52 (br s, 1H1, CONHN, minor isomer 13.61 (br s, 111, CONHN, major isomer (APCF): 525.2. (APCf t 527.2.

Expample 33: N-(4-methylphenl)-N- 12-oxo-2-[(2Z)-2-(2-oxo-I.,2-dih dro-3H-indol-3ylidene~hydrazinolethvl 4tert-etvlbenzenesulfonamide Following the general method as outlined in Example 1, starting from 4-tertamylbenzenesulfonyl chloride, 4-toluidine, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by crystallization in EtOH. A orange-yellow powder (14.7 mg, 14.2%) was obtained in 88.22% purity by HPLC (MaxPlot detection between 230 and 400 rim).

1H1 NMR (DMSO-d 6 300 MFz) d 0.98 311, J=7.53Hz), 1.26 6H1), 1.63 2H, J=7.5311z), 2.25 311), 4.51 2H1, NCH2CO, major isomer 4.98 (br s, 2H, WO 02/32864 PCT/EP01/11865 -82c1 NCH2CO, minor isomer 6.95 1H), 7.02-7.18 5H), 7.38 1H), 7.46-7.67 5H), 11.27 1H, NH), 12.49 (br s, 1H, CONHN, minor isomer 13.62 (br s, 1H, CONHN, major isomer (APCT): 517. (APCI): 519.2.

00 O Example 34: N-(4-methvlphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo-1, .2-dihvdro-3H-indol-3ylidene)hydrazino]ethvll -4-propoxbenzenesulfonamide

O%

Following the general method as outlined in Example 1, starting from 4-n-propoxy-1benzenesulfonyl chloride, 4-toluidine, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a mixture cyclohexane/ethyl acetate 3:1 as eluent. A yellow powder (46.9 mg, 46.3%) was obtained in 99.6% purity by HPLC (MaxPlot detection between 230 and 400 nm).

1 H NMR (DMSO-d, 300 MHz) d 0.97 3H, J=7.34Hz), 1.74 2H), 2.25 3H1), 4.01 2H, J-6.40Hz), 4.47 2H, NCH2CO, major isomer 4.95 (br s, 2H, NCH2CO, minor isomer 6.95 1H), 7.03-7.18 7H), 7.38 1H), 7.44-7.68 6H), 11.28 1H, NH), 12.49 (br s, 1H, CONHN, minor isomer 13.65 (br s, 1H, CONHN, major isomer (APCI): 505. (APCT): 507.2.

WO 02/32864 WO 0232864PCTJEPO 1/11865 -83- Example 35: N-(4-methylphenyl)-N- f2-oxo-2-r(2Z)-2-:(2-oxo- I ,2-dih dro-3H-indol-3vlidene)hydrazinolethyfll-2-thiophenesulfonainide Following the general method as outlined in Example 1, starting from 2-thiophenesulfonyl chloride, 4-toluidine, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by crystallization in EtOH. A brown powder (12.9 mg, 14.2%) was obtained in 58.4% purity by HPLC (MaxPlot detection between 230 and 400 nm).

(APCrF): 453. (APCI+): 455.

ExaMple 36: N-(4-chlorovl)-N- {2-oxo-2-r(2Z)-2-(2-oxo-l .2-dihydro-3H-indol-3vlidene~hvdrazino] ethvll -2-thiotphenesulfonamide Following the general method as outlined in Example 1, starting from 2-thiophenesulfonyl chloride, 4-chloroaniline, methyl bromoacetate and isatine, the title compound was +isolated by evaporation of the solvents and purified by flash chromatography, using a mixture WO 02/32864 PCT/EP01/11865 CN -84- C cyclohexane/ethyl acetate 3:1 as eluent. A yellow powder (21.8 mg, 23%) was obtained in 99.2% purity by HPLC (MaxPlot detection between 230 and 400 nm).

00 'H NMR (DMSO-d 6 300 MHz) d 4.59 2H, NCH2CO, major isomer 5.03 (br s, S2-H, NCH2CO, minor isomer 6.94 1H), 7.09 1H), 7.21-7.59 7H), 7.64 5 1H), 8.05 1H), 11.28 1H, NH), 12.52 (br s, 1H, CONHN, minor isomer 0 13.62 (br s, 1H, CONHN, major isomer (APCI): 473. (APCI): 475.

Example 37: N-(4-chlorophenyl)-N- 2-r(2E)-2-(2-hydroxvbenzvlidene)hvdrazinol-2oxoethyl}-3.4-dimethoxybenzenesulfonamide Following the general method as outlined in Example 1, starting from 3,4dimethoxybenzenesulfonyl chloride, 4-chloroaniline, methyl bromoacetate and salicylaldehyde, the title compound was isolated by evaporation of the solvents and purified by crystallization in EtOH/5% AcOH. A colorless solid (232 mg, 80.4%) was obtained in 99.52% purity by HPLC (MaxPlot detection between 230 and 400 nm).

M.p. 188-189 0 C. IR (neat) v 2962, 1673, 1507, 1488, 1351, 1241, 1137, 1020 cm-. 1

H

NMR (DMSO-d, 300 MHz) d 3.74 3H), 3.77 3H), 4.39 2H, NCH2CO, major isomer 4.85 (br s, 2H, NCH2CO, minor isomer 6.80-6.93 2H), 7.05- 7.15 2H), 7.17-7.31 4H), 7.34-7.45 2H), 7.50 1H, major isomer 7.67 1H, minor isomer 8.24 1H, minor isomer 8.41 1H, major isomer 10.00 1H, minor isomer 10.90 1H, major isomer 11.46 1H, minor isomer 11.74 1H, major isomer (APCI): 502.

WO 02/32864 WO 0232864PCTIEPO 1/11865 (NI (1 (APCO+: 504.2. Analysis calculated for C23H22C1N306SC, 54.82; H, 4.40; N, 8.34.

Found: C, 54.48; H, 4.44; N, 8.3 1.

00Examle 38: N-(4-chlorophenvl)-4-ethoxy-N- f2-[(2E)-2 hvdroxvbenzylidene)hvdrazinol-2-oxoethyllbenzenesulfonanide Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, 4-chioro aniline, methyl bromoacetate and sa 'licylaldehyde, the title compound was isolated by evaporation of the solvents and purified by crystallization in EtOH. A colorless powder (64.6 mg, 66.2%) was obtained in 92.2% purity by HPLC (MaxPlot detection between 230 and 400 rn).

IR (neat) v 2988, 1632, 1488,1351,1262,1155, 1084 cm- 1 'H NMR (DMSO- 6 300 MHz) d 1.34 3H, J=7.l4Hz), 4.10 2H, J=7.14Hz), 4.37 2H, NCH2CO, major isomer 4.82 (br s, 2H, NCH2CO, minor isomer 6.81-7.14 (in, 4H), 7.16- 7.32 (in, 3H), 7.35-7.44 (in, 2H), 7.46-7.73 (in, 3H), 8.24 1H, minor isomer 8.40 1H, major isomer 9.99 LH, minor isomer 10.90 lIi major isomer 11.42 1H, minor isomer 11.74 1H, major isomer (APcr): 486. (APCI'}: 488.

WO 02/32864 PCT/EPO1/11865 (Nu -86- Example 39: N-(4-chlorophenl)-N- (2-oxo-2-r(2Z)-2-(2-oxo-. ,.2-dihydro-3H-indol-3ylidene)hvdrazinolethvll -4-tertpentvlbenzenesulfonamide 00 Following the general method as outlined in Example 1, starting from 4-tertamylbenzenesulfonyl chloride, 4-chioroaniline, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by crystallization in EtOH. A brown-orange powder (59.3 mg, 55%) was obtained in 76% purity by HPLC (MaxPlot detection between 230 and 400 nn).

(APCfl: 537. (APC1+): 539.2.

Example 40: N-(L4-clorohenl)-4-ethoxv-N- f2-oxo-2-[(2Z)-2-(2-oxo-1 .2-dihvdro-3Hindol-3-vlidene)hydrazinolethvllbenzenesulfonamide cO~a 0 Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, 4-chioroaniline, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a WO 02/32864 WO 0232864PCT/EPO 1/11865 (NI 87c1 mixture cyclohexane/ethyl acetate 3:1 as eluent. A orange powder (60.3 mg, 59%) was obtained in 95-48% purity by HIPLC (MaxPlot detection between 230 and 400 nm).

00 1 H NMR (DMSO-d 6 300 M&z) d 1.34 3H, J=6.78Hz), 4.10 2H, 3=6.78Hz), 4.52 (s, 2H, NCH2CO, major isomer 5.01 (br s, 2H, NCH2CO, minor isomer 6.94 5 (in, IM1, 7.02-7.14 (in, 3H), 7.26 (in, 2H), 7.33-7.71 (in, 6H), 11.28 1Hi,NH), 12.52 (br s, 1H, CONHN, minor isomer 13.61 (br s, 1H, CONHN, major isomer (APCDF: 511. (APCf'): 513.

Example 41: N-(4-chlorophenyl)-N- f2-oxo-2-[(2Z)-2-(2-oxo- 1 2-dihydro-3H-indol-3ylidene)hydrazinolethyllbenzenesulfonamide 100 Following the general method as outlined in Example 1, starting from benzene-sulfonyl chloride, 4-chioroaniline, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a mixture cyclohexane/ethyl acetate 3:1 as eluent. A yellow powder (15.5 mg, 16.5 was obtained in 98% purity by I{PLC (MaxPlot detection between 230 and 400 fnm).

1 H NMR (DMSO-d 6 300 MIHz) d 4.59 2H, NCH2CO, major isomer 5.06 (br s, 2H, NCH2CO, minor isomer 6.94 (in, 1H), 7.09 (in, 111), 7.26 (in, 2H), 7.33-7.47 (in, 3Hf), 7.49-7.78 (in, 6H), 11.28 1H, NHM, 12.53 (br s, 111, CONHN, minor isomer 13.58 (br s, 1H, CONHN, major isomer (APCl): 466.8. (APC~I): 469.

WO 02/32864 WO 0232864PCT/EPO1/1 1865 (Nj -88- ExaMle 42: N-4-chloropheniyfl-N- [2-oxo-2-[(2Z)-2-(2-oxo- 1 ,2-dihvdro-3H-indol-3ylidene)hydmainolethyl1-4-proplbenzenesulfonamide 00__ Following the general method as outlined in Example 1, starting from 4-n-propoxy-lbenzenesulfonyl chloride, 4-chioroaniline, methyl. bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a mixture cyclohexane/ethyl acetate 3:1 as eluent. A yellow powder (32.8 mg, 32%) was obtained in 67.9% purity by HIPLC (MaxPlot detection between 230 and 400 nm).

(APCI-: 508.8. (APCI): 511.2.

ExgMple 43: N-(4-chlorophenyl)-4-ethoxy-N- {2-[(2E)-2-(lH-imidazol-2vlmethvlene~hydrazinol-2-oxoethyllbenzenesulfonamide Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, 4-chloroaniline, methyl bromoacetate and 2-imidazolecarboxaldehyde, the title compound was isolated by evaporation of the solvents and purified by WO 02/32864 WO 0232864PCT/EP01/1 1865 -89- CI crystallization in EtOHI5% AcOil. A colorless powder (34 mg, 74%) was obtained in 98.73 purity by IHPLC (MaxPlot detection between 23 0 and 400 nm).

00 'H NMR (DMSO-d 6 300 MHz) d 1.34 3H, J=6.OHz), 4.10 2H, J=6.0Hz), 4.35 (s, 0 2H1, NCH2CO, minor isomer 4.89 (br s, 2H, NCH2CO, major isomer 5 6.98-7.44 (in, 8M1, 7.54 (in, 2H1, minor isomer 7.64 (in, 2H, major isomer 7.82 111 major isomer 8.07 1H, minor isomer 11.50 1H, Nil), 12.55 (br s, 1H, CONHN, major isomer 12.72 (br s, 1H, CONHN, minor isomer (APCI): 459.8. (APCfi): 462.

Example 44: N-(4-chlorophenyl)-4-ethoxy-N- {2-oxo-2-r(2E)-2-(2pRgidinyhnethylene)hydrazinolethyll beazenesulfonamide 0 Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, 4-chioroaniline, methyl bromoacetate and 2-pyridinecarboxaldehyde, the title compound was isolated by evaporation of the solvents and purified by crystallization in EtOH!5% AcOH. A colorless powder (26.9 mg, 57%) was obtained in 96.4% purity by IIPLC (MaxPlot detection between 230 and 400 n).

'H NMR (DMSO-d 6 300 MI~z) d 1.34 311, J=6.OHz), 4.11 211, J=6.OHz), 4.38 (s, 211, NCH2CO, minor isomer 4.88 (br s, 2H, NCH2CO, major isomer 7.01-7.66 (in, 911), 7.80-8.22 (in, 311), 8.58 (in, 111), 11.71 (in, 1H1). (APCD): 471. (APCI'):' 473.

WO 02/32864 WO 0232864PCT/EPO 1/11865 CI Example 45: 4-Fluoro-N-(4-methylphenyl)-N- {2-oxo-2-f(2Z')-2-42-oxo- 1 2-dihvdro-3Hindol-3-ylidene~hydrazinol eth llbenzenesulfonamide 00 Following the general method as outlined in Example 1, starting from 4fluorobenzenesulfonyl chloride, 4-toluidine, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by crystallization in AcOH. A yellow powder (26 mg, 59%) was obtained in 94.7% purity by HPLC (MaxiPlot detection between 230 and 400 run).

1HNMR (DMSO-d 6 300 MIHz) d 2.27 3H), 4.54 2H, NCH2CO, major isomer 5.01 (br s, 2H, NCH2CO, minor isomer 6.94 (in, 1H), 7.03-7.22 (in, 5H1), 7.33-7.85 (in, 611), 11.28 1H, NH), 12.49 (br s, LH, CONHN, minor isomer 13.61 (br s, 1H, COINHN, major isomer (ESfl): 464.8.

Example 46: 4-Fluoro-N- {2-[(2E)-2-(2-hydroxybenzvlidene)hydrazinol..2-oxoethyll methylphWny)benzenesulfonanmide %Q0y WO 02/32864 WO 0232864PCTIEP01/1 1865 (NI -91ci Following the general method as outlined in Example 1, starting from 4fluorobenzenesulfonyl chloride, 4-toluidine, methyl bromo acetate and salicylaldehyde, the title compound was isolated by evaporation of the solvents and purified by crystallization in 00 AcOH. A colorless powder (33.5 mg, 76%) was obtained in 87.3% purity by ci 5 ILPLC (MaxPlot detection between 230 and 400 nm).

1H NMR (DMSO-d 6 300 MHz) d 2.25 3H), 4.37 2H, NCH2CO, major isomer 4.81 (br s, 2H, NCH2CO, minor isomer 6.81-6.91 (in, 2H), 7.02-7.32 (mn, 5H1), 7.36-7.78 (in, 511), 8.24 1H, minor isomer 8.40 lH, major isomer 9.98 1H, minor isomer 10.90 lH, major isomer 11.40 1H, minor isomer 11.71 1H, major isomer (ESIT): 440.

ExaMple 47: 4-Ethoxv-N-[2-((2E)-2- 12-[hydroxy(oxido)aminolbenzvlidenelhydrazino)-2oxoethyl] -N-(4-methylphenyl)benzenesulfonamide Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, 4-toluidine, methyl bromoacetate and 2-nitrobenzaldehyde, the title compound was isolated by evaporation of the solvents and purified by crystallization in AcOH. A colorless powder (418.3 mng, 84%) was obtained in 98.62% purity by HPLC (MaxPlot detection between 230 and 400 nin).

'H NMR (DMS0-l 6 300 Mffz) d 1.34 3H, J=6.OHz), 2.24 311), 4.10 2H, J=6.OHz), 4.34 2H, NCH2CO, minor isomer (3 4.78 (br s, 2H, NCH2CO, major isomer 6.88-7.20 (in, 611), 7.50-7.70 (in, 311), 7.77 (in, 111), 7.95-8.10 (in, 211), WO 02/32864 WO 0232864PCT/EPOI/1 1865 (NI -92- C1 8.29 1H, major isomer 8.58 1H, minor isomer 11.74 1H, major isomer 11.81 1H, minor isomer 11.93 1Hi). (APCrF): 494.8. (APCI 4 496.8.

00 0 Example 48: N- f2-r(2E)-2-(2-aniinobenzvlidene)hydrazino]-2-oxoethvul-4-ethoxv-N-(4- 5 methvlphenvl)benzenesulfonamide 4-ethoxy-N-(4-methylphenyl)-N- {2-[(2E)-2-(2-nitrobenzylidene)hydrazino] -2oxoethyl~benzenesulfonamide (99 mg, 0.2 mmol) was dissolved in methylene chloride.

Palladium 5 on charcoal was added (10 mol%). The mixture was stirred under H 2 at atknospheric pressure at room temperature overnight. It was filtered on Celite and solvents were evaporated. The expected product, e.g. N- aminobenzylidene)hydrazino]-2-oxoethyl} -4-ethoxy-N-(4methylphenyl)benzenesulfonamride (71.2 mg, was obtained as a light yellow solid, in 90.9 purity by I{PLC (MaxPlot detection between 230 and 400 nm).

1H NMR (300 MHz, CDCl 3 1.38 J= 6.0 Hz, 3H, OCH 2

CH

3 2.26 3H, CH 3 3.5 (br s, 2ff), 4.01 J= 6.0 Hz, 2H, OCH 2

CH

3 ),4.14 211), 6.62 (in, 1H1), 6.76-6.91 (mn, 5HK H arom.), 6.93 -7.07 (mn, 4H, H aroin.), 7.40 (in, 2H, H aroin.), 7.85 (br s, 11H).

WO 02/32864 WO 0232864PCTIEPO1/1 1865 (Nj 93- Example 49: ffE)[2-(2- fr(4-ethoxyhenl)sulfonvI1--4methlanilinol acetvL)hydrazonolmethyllRphenl)acetamide 00 0" r Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, 4-toluicline, methyl. bromoacetate and N-acetyl-2-aminobenzaldehyde, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a midxture cyclohexane/ethyl acetate 4:1 as eluent. A light yellow solid (18.3 mg, 18%) was obtained in 93.6% purity by }LPLC (MaxPlot detection between 230 and 400 n).

'H NMR (DMSO-d 6 300 MHz) d 1.44 3H1, J=6.OHz), 2.26;(s, 3M1, 2.32 311), 4.08 (q, 2H, J=6.OHz), 4.29 2H, NCII2CO), 6.81-7.16 (in, 711), 7.24 (mn, 111), 7.38 (in, 111), 7.50 (mn, 211), 8.13 111), 8.69 1H, J=611z), 9.82 111), 11.59 111). (EST): 507.

ExaMple 50: N-(4-chlorophenvl)-4-ethoxy-N- (2-oxo-2-r(2Z)-2-(2-oxo- 1.2-dihydro-3Hpvrrolo[F3 2-clpyrdin-3 -ylidene~hydrazinol ethyl benzenesulfonamide r WO 02/32864 WO 0232864PCTIEP0 1/11865 (Nj4 CI Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, 4-chioroaniline, methyl bromoacetate and 5-azaisatine, the title compound was isolated by evaporation of the solvents and purified by flash 00 chromatography, using a mixture DCMiMeOH 20:1 as eluent. A light yellow solid (32.4 mg, 26%) was obtained in 87% purity by HIPLC (MaxPlot detection between 23 0 and 400 rn).

1 H NMR (DMS0-l 6 3 00 MIz) d 1. 12 3H, J=6Hz), 3.88 2H, J=6Hz), 4.3 5 2H, NCH2CO, major isomer 4.80 (br s, 2H, NCH2CO, minor isomer 6.79 (in, 1H), 6.87 (mn, 2H), 7.03 (in, 2ff, 7.19 (in, 2H), 7.32 (in, 2ff), 8.24 1H, MhHz), 8.40 (br s, lIH), 11.45 1H, NH), 12.15 (br s, 1H, CONHN,iminor isomner 13.28 (br s, 1H, CONIIN, major isomer 511.8. 514.

Example 51: 4-Ethoxy-N- r2-r(2E)-2-( 1H-indol-3-ylmethlene~hvdrazinol-2-oxoethvfl -N- (4-inethylphenyl)benzenesulfonamide 0 Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, 4-toluidine, methyl bromoacetate and indole-3-carboxyldeliyde, the title compound was isolated by evaporation of the solvents and purified by crystallization in ethyl acetate. A beige solid (40 mg, 43.3%) was obtained in 93.2% purity by 1{PLC (MaxPlot detection between 230 and 400 rim).

'H NMR (DMSO-6, 300 ~Ivz)d 1.37(in, 3H), 2.24 3H), 4.12(in, 2H),4.29 2H, NCH2CO, minor isomer 4.80 (br s, 2H, NCH2CO, major isomer 7.01- WO 02/32864 WO 0232864PCTIEP0 1/1 1865 C1 7.26 (in, 1H1), 7.42 (in, 1H1), 7.57 (in, 211), 7.77 (in, 111), 7.99 (in, 1H1, major isomer 8.10 (br s, 1H, major isomer 8.12 (mn, 111, minor isomer 8.30 (br s, 111, minor isomer 11.08 1H, CONIIN, minor isomer 11.55 lH, CONI{N, 00 major isomer 11.55 (br s, 1H, NH). (APCD): 489. (APCr): 491.2.

5 Example 52: 4-Ethoxy-N-(2- f(2E')-2-[(2-methvl- lH-indol-3-vl)methylenelhydrazinol -2oxoethyl)-N-(4-methlphenvl~benzenesulfonamide 0 Following the general method as outlined in Example 1, starting from 4-ethoxybenzenesulfonyl chloride, 4-toluidine, methyl bromoacetate and 2-methylindole-3-carboxyldehyde, the title compound was isolated by evaporation of the solvents and purified by crystallization in ethyl acetate. A yellow powder (57.4 mg, 60%) was obtained in 95.2% purity by HPLC (MaxPlot. detection between 230 and 400 nin).

1H NMIR (DMSO-d 6 300 MEz) d 1.36 (in, 311), 2.24 311), 2.43 3H, major isomer 2.45 311, minor isomer 4.12 (in, 211), 4.27 211, NCH2CO, minor isomer 4.78 (hr s, 211, NCH2CO, major isomer 6.95-7.18 (mn, 811), 7.32 (in, 111), 7.56 (in, 211), 7.77 (in, 111), 7.88 (in, 1H, major isomer 8.04 (in, 111 minor isomer 8.18 111, major isomer 8.37 1H1, minor isomer 11.44 (hr s, 111, minor isomer 11.46 (hr s, 111, major isomer 11.90 (hr s, 111, NHT). (APCr): 503.2. (APCri): 505.2.

Example 53: 4-Ethoxy-N- f 2-oxo-2-[(2Z)-2-(2-oxo-1 ,2-dihydro-3H-indol-3ylidene')hydrazinolgthvl} -N-(2-pyriinidinyl)benzenesulfonainide WO 02/32864 WO 0232864PCT(EPO 1/11865 -96- 00 CI Following the general method as outlined in Example 1, starting from 4-ethoxyberizenesulfonyl chloride, 2-amino-pyrimidine, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by crystallization in AcOH. A yellow solid (61.1 mg, 75%) was obtained in 96.63% purity by HiPLC (MaxPlot detection between 230 and 400 rim).

'H NMR (DMSO-d 6 3 00 M11z) d 1.27 3H, J=6Hz), 4.05 2H, J=-6Hz), 5.01 2H1, NCH2CO, minor isomer 5.42 (br s, 2H, NCH2CO, major isomer 6.89 (in, 111), 6.94-7.1B (in, 411), 7.34 (in, 111), 7.42-7.68 (in, 1H), 8.01 (mn, 211), 8.48 (in, 2H), 11.20 (br s, 1H, major isomer 12.55 (hr s, lH, minor isomer (ESD): 479.17.

481.24.

Example 54: General protocol B for the solution-phase synthesis of sulfanilide derivatives of general Formula II with R 3 H (Schemes 3. e.g. 4-(2-methoxyethoxy)-N-(4methylphenMl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazinolethyLlbenzenesulfonaniide.

WO 02/32864 PCT/EP01/11865 C 97- (c a) Protocolfor the formation of the N-aryl-benzenesulfonamide building block, XIII (Scheme 4 and e.g. 4-(2-methoxyethoxy)-N-(4-methylphenyl)-N-{2-oxo-2-[(2Z)-2-(2tI oxo-, 2-dihydro-3H-indol-3-ylidene)hydrazino]ethyl}benzenesulfonamide.

00 4-Toluidine (6.430 g, 60 mmol) was dissolved in pyridine (200 mL). The resulting mixture 1 5 was cooled down to 0°C. 4-fluoro-benzenesulfonyl chloride (7.784 g, 40 mmol) was added Sin portions. The mixture was stirred between 0°C and room temperature overnight.

Solvents were evaporated to dryness. The crude oil was dissolved in ethyl acetate (150 mL) and washed with 10% HCI (2 x 75 mL) and brine (1 x 75 mL). Organic phase was dried over magnesium sulfate before filtering and removal of solvent. The resulting solid was recrystallized in cyclohexane/ethyl acetate 9:1. The desired product, e.g. 4-fluoro-N-(4methylphenyl)benzenesulfonamide (9.4754 g, was obtained as a colorless solid, in 98 purity by HPLC (MaxPlot detection between 230 and 400 nm).

'H NMR (300 MHz, CDC13): 2.26 3H, CH 3 6.63 (br s, 1H, NH), 6.92 2H, H arom.), 6.97-7.14 4H, H arom.), 7.73 2H, H arom.); M+(ESI): 266.20; M-(ESI): 264.18.

b) Protocol for the transformation of the N-aryl-benzenesulfonamide building block XII into XIII* by aromatic nucleophilic substitution with sodium alcoholate (Scheme e.g. 4-(2-methoxyethoxy)-N-(4-methylphenyl)benzenesulfonamide.

To a suspention of NaH (2.2 mmol, 55-65% in oil) in dry dioxane (6 mL) was added 2methoxyethanol (158 il, 2 mmol). The mixture was stirred lh at room temperature. A solution of 4-fluoro-N-(4-methylphenyl)benzenesulfonamide (265.3 mg, 1 mmol) in dry dioxane (2 mL) was added. The resulting mixture was heated 24h at 100 0 C. Solvents were evaporated. NH 4 CI saturated solution in water (5 mL) was added and the desired product was extracted with three portions of ethyl acetate (3x5 mL). Combined organic phases were dried over magnesium sulfate before filtering and removal of solvent. The desired product, e.g. 4-(2-methoxyethoxy)-N-(4-methylphenyl)benzenesulfonamide was obtained as a 1 WO 02/32864 PCT/EP01/11865 (N -98- N colorless oil, in 77% purity by HPLC (MaxPlot detection between 230 and 400 nm). This intermediate was used in the next step without further purification.

00 M+(APCf): 322.

N c) Protocolfor the displacement of the leaving group in XI (Scheme e.g. methyl (2-methoxyethoxy)phenyl]sulfonyl}-4-methylanilino)acetate.

The crude N-aryl-benzenesulfonamide building block XIII* resulting from the precedent step, e.g. 4-(2-methoxyethoxy)-N-(4-methylphenyl)benzenesulfonamide (1 mmol), was dissolved in dry dioxane (5 mL) and was added to a suspention of NaH (1.2 mmol, 55-65% in oil) in dry dioxane (1 mL). The mixture was stirred 1 h at room temperature. 2- Bromoacetic acid methyl ester (133 jiL, 1.4 mmol) was added dropwise. The resulting mixture was stirred at 60 0 C overnight. The solvents were evaporated, affording the desired product, e.g. methyl ({[4-(2-methoxyethoxy)phenyl]sulfonyl}-4-methylanilino)acetate as a light yellow oil, in 74 purity by HPLC (MaxPlot detection between 230 and 400 nm).

This intermediate was used in the next step without further purification.

M+(APCI+): 394.

d) Protocol for the transformation of the carboxylic acid ester into the hydrazide (Scheme e.g. N-(2-hydrazino-2-oxoethyl)-4-(2-methoxyethoxy)-N-(4methylphenyl)benzenesulfonamide.

The crude carboxylic acid methyl ester resulting from the precedent step, e.g. methyl (2-methoxyethoxy)phenyl]sulfonyl}-4-methylanilino)acetate (1 mmol), was dissolved,in MeOH (3.5 mL). Hydrazine hydrate was added (0.385 mL). The reaction mixture was stirred overnight at room temperature. Solvents were evaporated. The crude product was dissolved in ethyl acetate (4 mL) and was washed with water (4 mL). Aqueous phase was extracted with ethyl acetate (3x2 mL) and with methylene chloride (2x2mL). Combined organic phases were dried over magnesium sulfate, filtrated and solvents were evaporated.

WO 02/32864 PCTIEP01/11865 (N1 -99- The desired product, e.g. N-(2-hydrazino-2-oxoethyl)-4-(2-methoxyethoxy)-N-(4methylphenyl)benzenesulfonamide was isolated as a light yellow oil, in 86 purity by In HPLC (MaxPlot detection between 230 and 400 nm). This intermediate was used in the 00 next step without further purification.

M(ESI): 394.33. M(ESr): 392.18.

e) Protocolfor theformation of the acyl hydrazone, II (Scheme e.g. 4-(2methoxyethoxy)-N-(4-methylphenyl)-N-[2-oxo-2-[(2Z)-2-(2-oxo-1,2-dihydro-3H-indol- 3-ylidene)hydrazino]ethyl}benzenesulfonamide.

Hydrazide obtained in the precedent step, e.g. N-(2-hydrazino-2-oxoethyl)-4-(2methoxyethoxy)-N-(4-methylphenyl)benzenesulfonamide (1 mmo was dissolved in EtOH 5 AcOH (3 mL). Isatin (118 mg, 0.8 mmol) was added. The reaction mixture was stirred overnight at 75 0 C. Solvents were evaporated and the desired product was purfied by flash chromatography using a 1:1 mixture ofcyclohexane and ethyl acetate. The expected product, e.g. 4-(2-methoxyethoxy)-N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo-1,2dihydro-3H-indol-3-ylidene)hydrazino]ethyl}benzenesulfonamide (135.6 mg, 26% yield over 4 steps) was isolated as a yellow solid in 96% purity by HPLC (MaxPlot detection between 230 and 400 nm).

'H NMR (300 MHz, DMSO-d 6 2.29 3H, CH 3 3.45 3H, OCH 3 3.76 2H), 4.16 2H), 4.39 (br s, 2H, NCH 2 CO, major isomer 5.00 (br s, 2H, NCH 2 CO, minor isomer 6.87-7.01 3H, H arom.), 7.02-7.21 4H, H arom.), 7.32 1H, H arom.), 7.52 2H, H arom.), 7.66-7.78 21H1, H arom.), 7.92 (br s, 1H, minor isomer 8.34 (br s, 1H, major isomer 12.39 (br s, 1H, minor isomer 14.00 (br s, 1H, major isomer M(APCI): 523.0; MN(APCI): 521.0.

WO 02/32864 WO 0232864PCT/EPO 1/11865 -100- Example 55: N-(4-chlorophenvl)-4-[2-(4-morpholinflethox] [2-oxo-2-[2-2-oxo-1 .2dihydro-3H-indol-3-ylidene)h drazinoleth llbenzenesulfonainide 00__ Following the general method as outlined in Example 54, starting from 4-chloroaniline, 2morpholin-4-yl-ethanol, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a mixture methylene chloride/MeOH 40:1 as eluent. A yellow powder (342.1 mg, 8.2% over four steps) was obtained in 95% purity by HPLC (MaxPlot detection between 230 and 400 rm).

N-(4-chlorophenyl)-4-[2-(4-morpholinyl)ethoxy] {2-oxo-2-[2-(2-oxo-1 ,2-dihydro-3Hindol-3 -ylidene)hydrazino] ethyl} benzenesulfonamide (342.1 mg, 0.572 inmol) was dissolved in DCM (10 mL). A HCl solution in diethylether (LM, 0.58 mL, 0.580 inmol) was added. Solvents were evaporated and the resulting mass was recrystallized in MeOH.

A yellow powder. (307.9 mng, 90% yield of recrystallization) was obtained in 100% purity by HPLC (MaxPlot detection between 230 and 400 rim).

M.p. 255 0 C. IR (neat) v 2971,1682,1506,1492, 1350, 1233, 1159, 1089 cm'. 'HNMIR (DMSO-6, 300 M&z) 8 3.28 (mn, 2H), 3.5 1-3.74 (mn, 4H), 3.84 (in, 2ff), 4.04 (in, 4.48-4.74 (in, 2H 2H, NCH2CO, major isomer 5.12 (br s, 2H, NCH2CO, minor isomer 7.03 (in, lH, H arom.), 7.16 (in, 1H, H aroni.), 7.25 (mn, 2K~ H arom.), 7.35 (in, 211, H arom.), 7.41-7.56 (mn, 311, H aroin.), 7.57-7.82 (in, 3H, H arom.), 10.91 (br s, 111), 11.39 11$, 12.59 (br s, 1K, CONHN, minor isomer 13.68 (hr s, 111 CONHN, major isomer (ESr): 596.4. (ESIi): 598.0.

WO 02/32864 WO 0232864PCT(EPO 1/11865 ExaMple 56: N-(4-methylphenyl)-4-[2-(4-morpholinyl)ethoxyl-N- {2-oxo-2-[(2Zh}2-(2oxo- 1,.2-dihydro-3H-indol-3-vlidene~hvdrazinoletlwfllbenzenesulfonamide 00 CKI0 *0 Following the general method as outlined in Example 54, starting from 4-toluidine, 2morpholin-4yl-ethanol, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a mixture methylene cbloride/MeOH 40:1 as eluent. A yellow solid. (39.7 mg, 7% over 4 steps) was obtained in 95.38% purity by HPLC (MaxPlot detection between 230 and 400 tim).

'H NMVR (CDCI 3 300 MHz) 6 2.28 3H), 2.58.(m, 4M), 2.83 (in, 2H), 3.73 (in, 4M1', 4.15 (in, 211), 4.40 2H, NCH2CO, major isomer 4.99 2H, NCH2CO, minor isomer 6.86-7.22 (in, 8K1 H arom.), 7.29 (mn, 1H1, H arom.), 7.51 (in, 2K, H aroin.), 7.69 (in, 1H, H arom.), 8.85 111, minor isomer 9.32 111, major isomer 12.41 111, minor isomer 14.06 1H, major isomer (ESD): 576.3.

578.5.

ExaMple 57: N-(4-chlorophenyl)-4-r2-(dimethylamino)ethoxvl-N- f2-oxo-2-i(2Z)-2-(2oxo-1 .2-divdro-3H-indol-3-ylidene)hydrazinolethyll betizenesulfonamide WO 02/32864 WO 0232864PCT/EP0I/1 1865 (NI -102- (1 Following the general method as outlined in Example 54, starting from 4-chloroaniline, 2dimethylamino-ethanol, methyl bromoacetate and isatine, the title compound was isolated tn by evaporation of the solvents and purified by flash chromatography, using a mixture 00 methylene chloridelMeOH 20:1 as eluent. A yellow oil. (20.0 mg, 8% over 4 steps) was N1 5 obtained in 97.54% purity by HiPLC (MaxPlot detection between 230 and 400 nm).

'H NMIR (CDCI 3 300 MHz) 8 2.44 6H, N(CH3)2), 2.91 (in, 2H), 4.18 (in, 2H), 4.39 (s, 2H, NCH2CO, major isomer 4.99 2H, NCH2CO, minor isomer 6.86- 6.98 (in, 311 H aroin.), 7.07 (mn, 1H, H arom.), 7.12-7.36 (in, 511 H arom.), 7.49 (mn, 211, H aroin.), 7.69 (mn, 111, H arom.), 9.20 (br s, 1R), 12.45 111, minor isomer 13.98 (s, lo 1H, major isomer 554.1. 556.3.

Exainple 58: 4-[2-(Dimethyjlamino)ethioxy]-N-(4-inetli lphenyl oxo-1 .2-dihydro-311-indol-3-ylidene)hydrazinoleth flbenzenesulfonamide Following the general method as outlined in Example 54, starting from 4-toluidine, 2is dimethylamino-ethanol, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a mixture inethylene chloride/MeOH 20:1 as eluent. A yellow oil. (23.4 mng, 9% over 4 steps) was obtained in 98.42% purity by HPLC (MaxPlot detection between 230 and 400 nm).

'H NMR (CDCI 3 300 M&z) 852.42 6H1, N(C113)2), 2.87 (in, 211), 4.17 (in, 211), 4.40 (s, 211, NCH2CO, major isomer 4.99 211, NCH2CO, minor isomer 6.86- 6.98 (mn, 311, H1 aroin.), 7.02-7.22 (mn, 511, H aroin.), 7.32 (in, 111, H aroin.), 7.50 (in, 211, H1 WO 02/32864 WO 0232864PCT/EPO 1/11865 -103arom.), 7.72 (in-4 IH, H arom.), 8.05 (hr s, 1H, minor isomer 8.60 (hr s, 1H, major isomer 12.37 1H, minor isomer 13.95 1H, major isomer (APCF): 534.0. (APC1+): 536.4.

00 ExamRle 59: 4-43-(Dimethlamino)propox]-N-(4-mehylphell)-N- 12-oxo-2-4(2Z)-2-(2oxo-1,2-dihydro-3H-indol-3ylidene)hdrazilolethLl1benzenesulfonamide 0 Following the general method as outlined in Example 54, starting from 4-toluidine, 3dimethylamino-propan-1-ol, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a l0 mixture methylene chloride/MeOH 10: 1 as eluent. A yellow solid (22.9 mng, 7% over 4 steps) was obtained in 9 7.93% purity by HPLC (MaxPlot detection between 230 and 400 nm).

'H NMR (CDC1 3 300 MHz) 8 2.25 (in, 211), 2.29 3H, CH3), 2.68 6H, N(CH3)2), 2.94 (in, 2H, minor isomer 2.94 (mn, 2H, major isomer 4.08 (in, 2H, minor isomer 4.15 (in, 2H, major isomer 4.32 2H, NCH2CO, major isomer 4.97 (hr s, 2H, NCH2CO, minor isomer 6.78-7.23 (in, 9H, H arom.), 7.32 (mn, 2H, H arom.), 7.70 (in, 1H, H arom.), 8.40 (hr s, 1H, minor isomer 9.60 (hr s, 1H, major isomer 12.36 1H, minor isomer 14.08 1H, major isomer (APCI-): 548.0. (ApcLr): 550.2.

WO 02/32864 WO 0232864PCT[EPOI/1 1865 -104- Example 60: N-(4-chlorohenvl)-N-1f2-oxo-2-r2Z)-2-(2-oxo-l ,2-dihydro-3H-indol-3ylidene)hydrazinolethvll -4-(2-thienylMethoxvyeneeslonamide 00__ Following the general method as outlined in Examp le 54, starting from 4-chloroaniline, thiophen-2-yl-methanol, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a mixture cyclohexane/ethyl. acetate 4:1 as eluent. A yellow soild (149.6 mg, 26% over 4 steps) was obtained in 9 1.11 purity by HPLC (MaxPlot detection between 230 and 400O rim).

'H NMR (CDCI 3 300 MHz) 864.38 2H, NCH2CO, major isomer 5.01 2H, NCH2CO, minor isomer 5.26 (in, 211), 6.90 (in, 1H, H arom.), 7.02 (in, 2H, H arom.), 7.05-7.39 (in, 6H1, H aroin.), 7.47-7.64 (in, 31L H aroin.), 7.68 (in, 21H, H arom.), 7.77 (in, 1H, H arom.), 12.42 III, minor isomer 13.92 1H, major isomer (ESr): 579.0. 581.2.

ExgMple 61: N-44-chlorophenyl)-4-r2-(2-methoxvetoxy)ethoxvl-N- (2-oxo-2-r(2Z)-2-(2oxo- 1 2-d hdro-3H-indol-3 -vlidene)hvdraziol eth llbenzenesulfonamide WO 02/32864 WO 0232864PCT/EPO 1/11865 (Nj -105- Following the general method as outlined in Example 54, starting from 4-chloroaniline, 2- (2-methoxy-ethoxy)-ethanol, methyl bromoacetate and isatine, the title compound was 00 isolated by evaporation of the solvents and purified by flash chromatography, using a mixture cyclohexane/ethyl acetate 1: 1 then 2:3 as eluent. A yellow solid. (447 mg, 38% (1 5 over 4 steps) was obtained in 95.5% purity by HIPLC (MaxPlot detection between 230 and 400 rum).

'H NMvR (CDCl 3 300 MHz) 8 3.38 3H, OCH3), 3.57 (in, 2ff, 3.71 (in, 2ff, 3.87 (in, 2ff, 4.17 (in, 2H), 4.39 2H, NCH2CO, major isomer (5 4.99 2HK NCH2CO, minor isomer 6.88-6.97 (in, 311, H arom.), 7.09 (in, 111, H arom.), 7.14-7.37 (in, 5H, H arom.), 7.52 (in, 2H, H arom.), 7.70 (in, 1H, H arom.), 7.98 (br s, 1H, minor isomer 8.28 (br s, 1H1, major isomer 12.41 1H1, minor isomer 13.91 (s, lH, major isomer (ESI): 586.0. 587.3.

ExaMple 62: N-(4-chloMphenyl')-4-(2-methoxyethoxV)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2dihydro-3H-indol-3-ylidene)hydrazinolethyllbeflzenesulfonamfide 0 Following the general method as outlined in Example 54, starting from 4-chioroaniline, 2methoxy-ethanol, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a mixture cyclohexane/ethyl acetate 1: 1 as eluent. A orange solid. (240 mng, 44% over 4 steps) was obtained in 91.3% purity by HPLC (MaxPlot detection between 230 and 400 m).

WO 02/32864 PCT/EPO1/11865 i -106- 1'H NMR (CDC1 3 300 MHz) 8 3.45 3H1, OCH 3 3.76 2M), 4.16 2H), 4.38 21H, NCH2CO, major isomer 4.99 2H11, NCH 2 CO, minor isomer 6.87-7.01 If 3H, H arom.), 7.03-7.29 5H, H arom.), 7.33 1H, H arom.), 7.53 21H, H 00 arom.), 7.61 1H, H arom.), 7.82 (br s, 1H, minor isomer 8.11 (br s, 1H, major S 5 isomer 12.42 1H, minor isomer 13.94 1H, major isomer O (APCI-): 540.6. (APCI): 543.0.

Example 63: N-(4-chlorophenyl)-N- {2-oxo-2-r(2Z)-2-(2-oxo-1,2-dihvdro-3H-indol-3vlidene)hydrazinolethyl -4-3-(3-pyridinl)propoxy]vlbenzenesulfonamide Following the general method as outlined in Example 54, starting from 4-chloroaniline, 3pyridin-3-yl-propan-1-ol, methyl bromoacetate and isatine, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using pure ethyl acetate as eluent. A yellow solid. (88.9 mg, 15% over 4 steps) was obtained in 99.67% purity by HPLC (MaxPlot detection between 230 and 400 nm).

'H NMR (CDC1 3 300 MHz) 8 2.16 2H), 2.89 2H), 4.02 2H11), 4.42 2H,

NCH

2 CO, major isomer 5.00 2H, NCH 2 CO, minor isomer 6.83-6.99 411, H arom.), 6.08 1H, H arom.), 7.14-7.44 5H, H arom.), 7.46-7.58 211, H arom.), 7.63-7.77 3H11, H arom.), 8.17 1H, minor isomer 8.55 1H11, H arom.), 9.18 1H11, major isomer 12.43 1H, minor isomer 13.92 1H, major isomer (ESI): 602.06. (ES1': 604.11.

WO 02/32864 WO 0232864PCTIEP01/1 1865 -107- NI Example 64: N-(4-chlorophe~nyl)-N- 12-oxo-2-[(2Z')-2-(2-oxo- 1.2-dihydro-3H-indol-3ylidene)hydrazinolethyll- 4 r 3 2 :pRigdinl)propoxlbenzenesulfonan-jde 00 Following the general method as outlined in Example 54, starting from 4-chloroaniline, 3pyridin-2-yl-propan-1I.-ol, methyl bromnoacetate and isatine, the -title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a mixture cyclohexane/ethyl acetate 1: 1 to 1:4 as eluent. A yellow solid (59.4 mg, 10% over 4 steps) was obtained in 95.15% purity by I{PLC (MaxPlot detection between 230 and 400 nm).

'H NMR (CDCI 3 300 MHz) 8 2.27 (in, 2M1, 3.02 (in, 211, 4.06 (mn, 211), 4.42 2H, NCH2CO, major isomer 4.99 211, NCH2CO, minor isomer 6.83-6.94 (in, 311, H aroin.), 7.03-7.38 (in, 8H, H arom.), 7.46-7.80 (in, 4H, H arom.), 8.01 (br s, 1H1, minor isomer 8.5 5 (in, 111, H arom.), 8.72 (br s, I1H, maj or isomer 12.42 (s, 1H, minor isomer 13.86 111, major isomer (ESIT): 601.98. (ESI7): 604.06.

WO 02/32864 WO 0232864PCTIEP0I/1 1865 c-I 108- Example 65: General protocol C for the solution-phase synthesis of sulfanilide derivatives of general Formula flI with R 3 H (Schemes 3. ez. N-(4-chlorophenyl)-42-(4- 00 morpholinvl)eth llaminol f2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihvdro-3H-indol-3ylidene)hydrazinolethyllbnenslonamide a) Protocol for the formation of the N-aryl-benzenesulfonamide building block; XI (Scheme e.g. 4-fluoro-N-(4-chlorophenyl)benzenesulfonamide.

4-Chloroaniline (6.697 g, 52 mmol) was dissolved in pyridine (250 mL). The resulting mixture was cooled down to 0 0 C. 4-fluoro-benzenesulfonyl chloride (7.775 g, 40 rnnol) was added in portions. The mixture was stirred between 0 0 C and room temperature overnight. Solvents were evaporated to dryness. The crude oil was dissolved in ethyl acetate (150 mL) and washed with 10% HC1 (2 x 75 inL) and brine (I x 75 mL). Organic phase was dried over magnesium sulfate before filtering and removal of solvent. The resulting solid was recrystallized in cyclohexane/ethyl acetate 9: 1. The desired product, e.g.

4-fluoro-N-(4-chlorophenyl)benzenesulfonamfide (6.630 g, 5 was obtained as a colorless solid, in 97.3% purity by I{PLC (MaxPlot detection between 230 and 400 nin).

'H NMR (300 MHz, CDCl 3 7.05 (mn, 2H, H arom.), 7.15 (in, 2H, H arom.), 7.24 (in, 2H, H arom.), 7.81 (in, 2H, H aroin.); Mf(ESD: 284.12.

b) Protocol for the transformation of the N-aryl-benzenesulfonamide building blockXJI into XHI* by aromatic nucleophilic substitution with lithium amnide (Scheme e.g. N- (4-chlorophenyl)-4-[[2-(4-norpholinyl)ethyl]ainobenzelesufofamide.

WO 02/32864 PCT/EPO1/11865 S- 109- C N N-(2aminoethyl)morpholine (293 pL, 2.25 mmol) was dissolved in THF (7.5 mL) and was cooled down to -78 0 C. A 2.5N solution of nBuLi in hexane (1 mL, 2.5 mmol) was added in dropwise. After 5 min. at -78 0 C, the mixture was stirred Ih at -40 0 C. N-aryl-benzene- 00 sulfonamide building block XIII, e.g. 4-fluoro-N-(4-chlorophenyl)benzenesulfonamide S 5 (214 mg, 0.75 mmol), was added as a solid. The reaction mixture was stirred 2h at room temperature, then overnight at 60 0 C. The reaction was quenched at room temperature with 1 NH 4 C1 saturated solution in water (5 mL). The desired product was extracted with three portions of ethyl acetate (3x10 mL). Combined organic phases were dried over magnesium sulfate before filtering and removal of solvent. The crude product was purified by flash chromatography, using pure ethyl acetate as eluent. The desired product, e.g. N-(4chlorophenyl)-4- {[2-(4-morpholinyl)ethyl]amino}beenesulfonamide (184.2 mg, 62% yield) was obtained as a colorless oil, in 97% purity by HPLC (MaxPlot detection between 230 and 400 nm). This intermediate was used in the next step without further purification.

'H NMR (300 MHz, CDCl 3 2.30 4H), 2.46 2H), 3.00 2H), 3.55 4H), 4.74 (br s, 1H), 6.35 2H, H arom.), 6.51 (br s, 1H), 6.84 2H, H arom.), 7.01 2H, H arom.), 7.37 2H, H arom.); M-(ESr): 394.

c) Protocol for the formation of the acyl hydrazone, I1 (Scheme e.g. N-(4chlorophenyl)-4-{[2-(4-morpholinyl)ethyl]amino}-N-{2-oxo-2-[(2Z)-2-(2-oxo-1,2dihydro-3H-indol-3-ylidene)hydrazino]ethyl}benzenesulfonamide The crude N-aryl-benzenesulfonamide building block XIII* resulting from the precedent step, e.g. N-(4-chlorophenyl)-4- {[2-(4-morpholinyl)ethyl]amino}benzenesulfonamide (0.465 mmol), was submitted to the procedure described in the general protocol B point c).

Expected product, e.g. methyl {4-chloro[(4- morpholinyl)ethyl]amino}phenyl)sulfonyl]anilino} acetate, was obtained as a colorless oil, in 87% purity by HPLC (MaxPlot detection between 230 and 400 nm). This intermediate was used in the next step without further purification.

WO 02/32864 WO 0232864PCTIEP01/1 1865 -110- 'H NMIR (300 MHz, CDC1 3 2.48 (in, 4H), 2.64 (in, 2H), 3.18 (mn, 2H), 3.68 3H,

OCH

3 3.72 (mn, 4H1), 4.34 2H1, NCH 2 CO), 4.92 (br s, 1H, NH), 6.52 (in, 211, H arom.), 7.13 (in, 2H, H arom.), 7.23 (in, 2H1, H arom.), 7.42 (in, 2H, H arom.); Mi(ESr'): 468.3; Mr 00 (ESE): 466.3.

The crude carboxylic acid methyl ester resulting from the precedent step, e.g. methyl {4chloro {[2-(4-morpholinyl)ethyl] amnino} phenyl)sulfonyl]anilino acetate (0.465 minol), was transformed in the corresponding hydrazide following the procedure described in the general protocol B point Expected product, e.g. N-(4-chlorophenyl)-N-(2-hydrazino-2oxoethyl)-4- {[2-(4-morpholinyl)ethyl]amino~benzenesulfonamide, was obtained as a colorless oil, in 96% purity by HPLC (MvaxPlot detection between 230 and 400 nin). This.

intermediate was used in the next step without further purification.

M+(APCI

4 468.0; M-(APCD): 465.6.

Hydrazide obtained in the precedent step, e.g. N-(4-chlorophenyl)-N-(2-hydrazino-2oxoethyl)-4- {12-(4-morpholinyl)ethyl] amiino}benzenesulfonamide (0.465 minol), was dissolved in EtOHIS%AcOH (8 roL). Isatin (65 mg, 0.442 romol) was added. The reaction mixture was stirred overnight at 77'C. Temperature was cooled down to room temperature, and the desired product, e.g. N-(4-chlorophenyl)-4- [2-(4-morpholinyl)ethyl] amino} {2oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino]ethyl~benzenesulfonamide (220.9 mg, 84% yield), crystallised in the reaction mixture. It was isolated by filtration as an orange-yellow solid, in 98% purity by HPLC (MaxPlot detection between 230 and 400 rum).

'H NMvR (300 M&z, DMSO-d 6 2.9-3.78 (mn, 1 OR), 3.93 (in, 211), 4.40 (br s, 2K1

NCH

2 CO, major isomer 4.93 (br s, 211, NCH 2 CO, major isomer 6.64 (in, 211, H arom.), 6.77 (br s, 111, NH minor isomer 6.90 (in, 111, H arom.), 7.03 (in, 111, H arom.), 7.15-7.55 (in, 8HL H arom.), 11.38 111, NH, major isomer 11.22 WO 02/32864 WO 0232864PCTIEP01/11865 c-I 1H, Nil), 12.46 (br s, 1H, CONHN, minor isomer 13.60 (br s, 111, CONHN, major isomer MX(ESD-: 595.0.

00 Example 66: General protocol D for the solution-phase synthesis of sulfanilide derivatives of general Formula HI with R 3 H (Schemes 2 and exg. 3- f4-r(4-methyl {2-oxo-2-[(2z)- 2-(2-oxo-1,2-dihydro-3H-indol-3ylidene)hydrazinol ethyfl anln'slonylbbhenyllpropanamide.

a) Formation of the carboxylic acid methyl ester building block, Iff (Scheme e.g.

methyl {f(4-bromophenyl)sulfonylr4-methylanilinoOcetate.

Following the general protocol A as outlined in Example 1, points a) and starting from 4-bromobenzene-sulfonyl chloride, p-toluidine and methyl bromoacetate, the title compound was isolated as a light yellow oil (3.347 g, quantitative yield) in 98 purity by HPLC (MaxPlot detection between 230 and 400 nm).

'H NMR (300 Mi~z, DMSO-d 6 2.29 311), 3.63 311), 4.53 211), 7.07 (in, 211, H arom.), 7.17 (in, 2H, H arom.), 7.58 (in, 211. H arom.), 7.82 (in, 2H, H arom.); M+(APCI7): 400.0.

b) Protocolfor the transformation of the carboxylic acid methyl ester building block, III into 111* by Heck reaction followed by hydrogenation (Scheme e.g. methyl a mino-3 -oxqprqpy)phenyIsu6fony1)}-4-methylan iilo)a cetate WO 02/32864 PCT/EP01/11865 (N -112c- Sodium acetate was dissolved in water (0.5 mL). The carboxylic acid methyl ester builiding block II1, e.g. methyl {[(4-bromophenyl)sulfonyl]-4-methylanilino} acetate (398 mg, 1 t mmol), in DMF (3.5 mL) was added, followed by acrylamide (78 mg, 1.1 mmol), 00 triphenylphosphine (26.2 mg, 0.1 mmol, 10 mol%) and palladium diacetate (11.2 mg, 0.05

O

CN 5 mmol, 5 mol%). The resulting mixture was degazed for 5 min with argon and was heated at 080 0 C for 3h. It was filtrated through celite. Water (5 mL) was added and the desired C-I product was extracted with ethyl acetate (3x7 mL). Combined organic phases were dried over magnesium sulfate before filtering and removal of solvent. The desired product, e.g.

methyl E)-3-amino-3-oxo-1 -propenyl]phenyl} sulfonyl)-4-methylanilino] acetate was obtained as a colorless oil, in 88% purity by HPLC (MaxPlot detection between 230 and 400 nm). This intermediate was used in the next step without further purification.

'H NMR (300 MHz, CDCl 3 2.20 3H), 3.58 3H, OCH 3 4.29 2H), 5.60-5.90 (m, 2H, CONHz), 6.92-7.03 4H), 7.43 2H), 7.50-7.62 4H); M+(ES1): 389.2; M 387.1.

The crude product resulting from the precedent step, e.g. methyl [({4-[(1E)-3-amino-3-oxol-propenyl]phenyl} sulfonyl)-4-methylanilino]acetate (1 mmol) was dissolved in DMF mL). Palladium 10% on charcoal (100 mg, 0.09 mmol) was added. The mixture was heated 4 days under 45 bar ofH2 at 60 0 C. The solution was filtered through celite and solvents were evaporated. The desired product, e.g. methyl ({[4-(3-amino-3oxopropyl)phenyl]sulfonyl}-4-methylanilino)acetate (308 mg, 79% yield over two steps), was obtained as a colorless oil, in 79% purity by HPLC (MaxPlot detection between 230 and 400 nm). This intermediate was used in the next step without further purification.

'H NMR (300 MHz, CDC13): 2.25 3H), 2.47 2H, J 6.0 Hz), 2.97 2H, J Hz), 3.62 3H, OCH 3 4.31 2H), 5.33 (br s, 2H, CONH), 6.95-7.05 4H, H arom.), 7.21 2H, H arom.), 7.52 2H, H arom.); M+(ESI): 391.5; M"(EST): 389.2.

WO 02/32864 WO 0232864PCT/EPO 1/11865 (NI 113c-i c) Protocol for the formation of the acyl hydrazone, H! (Scheme e.g. -methyl [2oxo-2-[(2Z)-2-(2-oxo-J,2-dihydro-3H-indol-3ylidene)hydrazinojethyl~anilino)sulfonyljphenyl~propaniamide.

00 The crude carboxylic acid methyl ester resulting from the precedent step M*I, e.g. methyl r- 5 [4-(3-arnino-3-oxopropyl)phenyl] sulfonyl} -4-methylanilino)acetate (308 mng, 0.789 0 mrnol), was transformed in the corresponding hydrazide following the procedure described in the general protocol B point Expected product e.g. 3 {I(2-hydrazinio-2-oxoethyl)- 4-methylanilino]sulfonyl~phenyl)propanamide (197.3 mg, 64%) was obtained as a colorless oil, in 79% purity by 1{PLC (MaxPlot detection between 230 and 400 nm). This io intermediate was used in the next step without further purification.

1H NIMR (300 MHz, MeOH-d 4 2.21 3H, CHA) 2.44 2H, J 7.5 Hz), 2.90 2H, J= Hz), 4.13 2H, NCH 2 CO), 6.90 (in, 211, H arom.), 7.01 (mn, 2H, H arom.), 7.30 (mn, 2H1, H arom.), 7.41 (mn, 2H, H arom.); M 4 391.4; M-(Esr): 389.2.

Hydrazide obtained in the precedent step, e.g. 3 {[(2-hydrazino-2-oxoethyl).4methylanilino]sulfonyl}phenyl)propanamide (197 mg, 0.5 05 nirnol), was dissolved in (8 mL). Isatin (71 mng, 0.480 nimol) was added. The reaction mixture was stirred overnight at 771C. Solvents were evaporated and the crude product was recrystallized in EtOH. The desired product, e.g. 3- {4-[4-methyl {2-oxo-2-[(2Z)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3 -ylidene)hydrazino] ethyl) anilino)sulfonyl]phenyl~propanamnide (171.3 mng, 69% yield), was isolated by filtration as a yellow solid, in 94% purity by HIPLC (MaxPlot detection between 230 and 400 nin).

'H NMR (300 Miz, DMSO-d 6 2.25 3H, CH 3 2.38 2H1, J 7.5 Hz), 2.89 2K1 J Hz), 4.50 (br s, 211, NCH2CO, major isomer 4.97 (br s, 211, NCH 2 CO, minor isomer 6.80 (br s, 1H1), 6.94 (mn, 1M, H arom.), 7.03-7.17 (in, 5H1, H arom.), 7.30 (br, s 1Hf), 7.34-7.64 (in, 6H, H aroin.), 11.27 1H, NHl), 12.50 (br s, 111 CONIIN, minor WO 02/32864 WO 0232864PCT/EPO 1/11865 isomer 13.64 (br s, 1H, CONHN, major isomer 520.3; Ivf(ESF): 518.3.

00 Example 67: General protocol E for the solution-phase synthesis of sulfanilide derivatives of general Formula 11 with R 3 H (Schemes 1. 4. e.g. N-(4-chlorophenyl)-44[3- (dimethylamino)Rrop2oxvl-N- 12-oxo-2-[(2Z)-2-(2-oxo- 1.2-dihydro-3H-indol-3ylidene')hydrazinolethyllbnenslonamide a) Protocol for the transformation of the N-aryl-benzenesulfonamide building block- XM! into XI* by aromatic nucleophilic substitution with sodium alcoholate (Scheme S); e.g. N-(4-chlorophenyl)-4-f3-(dimethylamino)propoxyjbenzenesufonamide.

To a suspention of NaH (100 mmol, 55-65% in oil) in dry dioxane (140 ML) was added 3dimnethylarnino-1-propanol (11.90 mL, 100 mmol). Thenmixture was stirred 1h at roomn temperature. A solution of 4-fluoro-N-(4-chlorophenyl)benzenesulfonamide (9.53 g, 33.35 mmol, preparation described in example 66) in dry dioxane (35 mL) was added. The resulting mixture was heated 24h at 100 0 OC. Solvents were evaporated. NH 4 C1 saturated solution in water (75 mL) was added and the desired product was extracted with three portions of ethyl acetate (3x100 mL). Combined organic phases were dried over magnesium sulfate before filtering and removal of solvent. The desired product, e.g. N-(4chiorophenyl)-4-[3-(dimethylamino)propoxy]benzenesulfonamide was obtained as a colorless oil, in 96% purity by 1{PLC (MaxPlot detection between 230 and 400 um). This intermediate was used in the next step without further purification.

WO 02/32864 WO 0232864PCTJEP0I/1 1865 'H NMR (300 M&z, CDC1 3 1.99 (mn, 2H, CH 2

CH

2

CH

2 2.29 6H, N(CH 3 2 2.50 (mn, 2H, NCH 2

CH

2 4.01 (mn, 2H, OCH 2

CH

2 6.84 (mn, 2H, H atom.), 7.01 (in, 2H1, H atom.), 'n 7.14 (in, 211, H atom.), 7.65 (mn, 2H, H atom.); MW(ESI+): 369.17; M7(ESIF): 366.86.

00 b) Protocol for the Mitsunobu reaction (Scheme e.g. methyl [4-chloro({4-[3- (dimethylamino)propoxyjphenyl~sulfonyl)anililolacetate.

The crude N-aryl-benzenesulfonainide building block XMf* resulting from the precedent step, e.g. N-(4-chlorophenyl)-4-[3-(diethylamflno)popoxy]belzeesulfoflamfide (33.35 mmol), was dissolved in dry THF (500 ruL). Triphenyl phosphine (33.689 g, 128.44 imol) was added, and the resulting mixture was cooled down to 0 0 C. Diethyl azodicarboxylate (19.97 inL, 128.44 inmol) was added dropwise. After 15 min at room temperature, methyl glycolate in TEF (100 inL) was added dtopwise. The mixture was stirred 30 min. at room temperature. Solvents were evaporated and th resulting crude oil was dissolved in ethyl acetate (100 inL). It was extracted with 30% citric acid solution in water (2x70 mL).

Combined aqueous layers were extracted with diethyl ether (2x50 mL). They were then basified with NaOH 2M until pH 10, and extracted with EtOAc (3x70 inL). Combined organic layers were dried over magnesium sulfate, filtrated and evaporated. The desired product, e.g. methyl [4-chloro({4-13- (diinethylainino)propoxy]phenyl) sulfonyl)anilino] acetate (12.23 5 g, 83% yield over 2 steps) was obtained as a colorless oil, in 90% purity by HTPLC (MaxPlot detection between 230 and 400 nin). This intermediate was used in the next step without further purification.

'H NMR (300 Iv]Hz, CDCl 3 2.03 (in, 211, CH 2

CH

2 CH), 2.29 611, N(CHD)),2.49 (in, 211, NCH 2

CH

2 3.72 311, OCR' 3 4.09 (in, 211, OCH 2

CH

2 4.3 9 211), 6.93 (in, 2H, H arom.), 7.16 (in, 2H, H atom.), 7.28 (in, 211, H atom.), 7.60 (in, 2H1, H atom.); M 4 441.09.

WO 02/32864 WO 0232864PCTIEP0 1/11865 116c) Protocol for the transformation of the carboxylic acid ester into the hydrazide (Scheme e.g. N-(4-chlorophenyl)-4-[3-(dimethylamino)propoxy]-N-(2-hydrazino-2oxoethyl)benzenesulfonamide.

The crude carboxylic acid methyl ester resulting from the precedent step, e.g. methyl [4cbloro( {4-[3-(dimethylamlino)propoxy]phenyl} sulfonyl)anilino] acetate (12.235 g, 27.75 mmol), was dissolved in MeGH (95 mL). Hydrazine hydrate was added (10 mL). The reaction mixture was stirred lh at room temperature. Solvents were evaporated. The crude product was dissolved in ethyl acetate (50 mL) and It was extracted with 30% citric acid solution in water (2x70 rnL. Combined aqueous layers were extracted with diethyl ether (2x50 niL. They were then basi fled with NaOH 2M until pH 10, and extracted with EtOAc (3x70 niL). Combined organic layers were dried over magnesium sulfate, filtrated and evaporated. The desired product e.g. N-(4-chlorophenyl)-4-[3-(dimethylamino)propoxy]- N-(2-hydrazino-2-oxoethyl)benzenesulfonamide (8.772 g, 72% yield) was obtained as a colorless solid, in 87% purity by HPLC (MaxP lot detection between 230 and 400 rum).

A fr-action of this crude intermediate (842 mng) was recrystallized in EtOH. The expected product, e.g. N-(4-chlorophenyl)-4-[3-(dimethylamino)propoxy.]-N-(2-hydrazino-2oxoethyl)benzenesulfonanaide (283 mg, 34% yield) was was isolated as a colorless solid, in 97% purity by HPLC (MaxPlot detection between 230 and 400 rum).

'HNMR (300 M~z, CDC1 3 1.79 (mn, 2H, CH 2 CH2CH 2 2.07 611 N(CH 3 2 2.28 (mn, 2HL NCH 2

CH

2 3.24 211), 4. 00 (in, 211, OCH2CH2), 4.09 21-1), 4.12 (br s, 1H1), 7.01 (in, 211,11 aroin.), 7.10 (in, 2H, H arom.), 7.33 (mn, 2H, H arom.), 7.45 (mn, 2H, H aroin.); M+(ESI 441.12; 439.12.

d) Protocol for the formation of the acyl hydrazone, II (Scheme e.g. N-(4chlorophenyl)-4-f3- (dim ethylam inq)propoxy] (2-oxo-2-[(2Z) (2-oxo- 1, 2-dihydro- 3H-indol-3 -ylidene)hydrazino] ethyl) benzenesufonam ide.

WO 02/32864 WO 0232864PCT/EPOI/1 1865 Hydrazide obtained in the precedent step, e.g. N-(4-chlorophenyl)-4-[3- (dimethylamnino)propoxy]-N-(2-hydrazino-2-oxoethyl)benzenesulfolalide, was dissolved in EtOH 5 AcOH (40 mL). Isatin (2.029 g, 13.8 mmol) was added. The reaction 00 mixture was stirred overnight at 75TC. Solvents were evaporated and the desired product was purfied by flash chromatography using a mixture methylene chloride MeOH 40:1 to 40:3 as eluent. Two fractions of the expected product, e.g. N-(4-chlorophenyl)-4-[3- (dimethylamnino)propoxy] {2-oxo-2-[(2Z)-2-(2-oxo-1 ,2-dihydro-3H-indol-3ylidene)hydrazino~ethyl~benzenesulfonamnide (855 mg in 92.2% purity and 5.14 1 g in 74% purity by HIPLC ((MaxPlot detection between 230 and 400 nm) were isolated as a yellow solid (61% yield).

One fraction of the final product (5.141 g, 9.018 romol, 74% pure) was transformed in the corresponding HCI salt, by dissolution in methylene chloride (120 mL) and addition of one equivalent of a IN HCl solution in diethyl ether (9.5 m1L). After evaporation of the solvents, the crude salt was recrystallized in EtGH. The expected product, e.g. HCl salt of N-(4-chlorophenyl)-4-II3-(dimethylamino)propoxy]-N- {2-oxo-2-II(2Z)-2-(2-oxo-1 ,2dihydro-3H-indol-3-ylidene)hydrazino]ethyl~benzenesulfonamide (1.734 g, 32% yield), was isolated as a yellow solid, in 98% purity by HIPLC (MaxPlot detection between 230 and 400 nm).

M.p. 232 IR (neat) v 3060,1694,1596,1467, 1353, 1267, 1158 cm-1; 'H NMR (300 MvHz, DMSO-d 6 2.16 (in, 2H), 2.77 6H1, N(CH) 2 3.20 (in, 2ff, 4.15 (in, 211, 4.54 (br s, 2H, NCH 2 CO, major isomer 5.03 (br s, 2H, NCH 2 CO, minor isomer 6.96 (mn, I H, H aroin.), 7.03-7.17 (in, 3H, H aroin.), 7. 10 (mn, 211, H aroin.), 7.33 -7.74 (mn, 6H, H aroin.), 10.55 (hr s, 11H), 11.35 1H1), 12.52 (hr s, 1H, CONHN, minor isomer 13.61 (hr s, 111, CONHN, major isomer M+(APC17': 570.2; M(APCI-): 568.0. Analysis calculated for C 27

H

29

C

2

N

5 0 5 S0.5 H 2 0: C, 52.69; H, 4.91; N, 11.38; Cl, 11.52. Found: C, 53.01; H, 4.95; N, 11.45; Cl, 11.57.

WO 02/32864 PCT/EP01/11865 -118- Example 68: N-(4-chlorophenl)-4-[3-(dimethylamino)propoxly]-N- {2-oxo-2-r(2Z)-2-(2oxo-1, .2-dihydro-3H-prrolor3,2-clpvridin-3-vlidene)hvdrazinolethylbenzenesulfonamide 00 Following the general method as outlined in Example 67, starting from 4-chloroaniline, 3dimethylamino-propan- 1 -ol, methyl bromoacetate and 1H-pyrrolo[3,2-c]pyridine-2,3dione, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a mixture methylene chloride/MeOH 10:1 to 5:1 as eluent. A light yellow powder (296.4 mg, 43%) was obtained in 94% purity by HPLC (MaxPlot detection between 230 and 400 nm). It was further purified by preparative HPLC with a gradient of

H

2 0/0.1%TFA and MeCN/1%TFA as eluent. A beige powder. (234.4, O/o) was obtained in 99.68% purity by HPLC (MaxPlot detection between 230 and 400 nm).

IR (neat) v 1718, 1674, 1651, 1487, 1195, 1123 'H NMR (DMSO-d, 300 MHz) 8 2.11 2H), 2.82 3H, N(CH3)2), 2.22 2H), 4.01 (br s, 2H, major isomer 4.13 2H), 4.70 2H, minor isomer 7.00 2H, H arom.), 7.17-7.34 3H, H arom.), 7.43 2H, H arom.), 7.59 2H), 8.57 1H, H arom.), 9.49 1H), 11.06 (br s, 1H), 12.19 1H, major isomer 13.38 1H, minor isomer (ES): 569.48. (ES1): 571.47.

WO 02/32864 WO 0232864PCTIEP0 1/11865 ExaMple 69: f r4-chloro(LL- F3- (dImtlamino)propoxylphenvfl slonyR niio aevhydazono)-2-oxo-23dhdo 00 IH-indole-7-carboxylic acid Following the general method as outlined in Example 67, starting from 4-chioroaniline, 3dimethylamino-propan-1 -ol, methyl bromoacetate and 2,3-dioxo-2,3-dihydro- 1H-indole-7carboxylic acid, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a mixture methylene chloride/MeOH 10: 1 to 5:1 as eluent.

A yellow solid. (39.7 mg, 35%) was obtained in 92.02% purity by HPLC (MaxPlot detection between 230 and 400 un).

'H NMR (DMSO-4,, 300 MHz) 5 1.94 (mn, 2ff), 2.23 3H, N(CH3)2), 2.60 (in, 2H), 4.09 (mn, 2H), 4.54 (br s, 2H, major isomer 5.01 (in, 2H, minor isomer 7.02-7.13 (in, 4H, H arom.), 7.28 (in, 2H1, H aroin.), 7.40 (in, 2H, H arom.), 7.46-7.67 (mn, 3Hf), 7.79 (mn, 1H), 11.06 (br s, 1H1), 12.51 1H, minor isomer 13.60 1H, major isomer is (ESE): 611.89. (ESfr): 614.03.

Example 70: meth I 4-chloro(144[3- (dimethylamino)propoxylphenvl slonyl ailio aev}hrzoo-2-oxo-2,3-dihydro- 1H-indole-7-carboxylate WO 02/32864 PCT/EP01/11865 (N -120- 00 cI Following the general method as outlined in Example 67, starting from 4-chloroaniline, 3dimethylamino-propan- 1-ol, methyl bromoacetate and 2,3-dioxo-2,3-dihydro- 1H-indole-7carboxylic acid methyl ester, the title compound was isolated by evaporation of the solvents and purified by flash chromatography, using a mixture methylene chloride/MeOH 20:1 as eluent. A yellow solid. (83.8 mg, 77%) was obtained in 92.52% purity by HPLC (MaxPlot detection between 230 and 400 nm).

'H NMR (DMSO-d 6 300 MHz) 8 1.85 2H), 2.13 3H, N(CH3)2), 2.34 2H), 3.89 3H, OCH3), 4.07 2H), 4.57 (br s, 2H, major isomer 5.02 2H, minor to isomer 7.03-7.15 2H, H arom.), 7.17-7.33 3H, H arom.), 7.37-7.46 2H, H arom.), 7.55 2H, H arom.), 7.81 1H, H arom.), 7.89 1H, H arom.), 11.17 (br s, 1H), 12.45 (br s, 1H, minor isomer 13.58 (br s, 1H, major isomer (ESI): 626.15. (ESI): 628.22.

WO 02/32864 WO 0232864PCTIEP01/1 1865 ExaMple 71: General protocol F for the solution-phase synthesis of sulfanilide derivatives of general Formula HI with R 3 H (Schemes 3. e.g. 3-f 4-[(4-chloro f 2-oxo-2-[(2Z)-2-2- 00 oxo-1 .2-dihvdro-3H-indol-3-vylidene)hydrazinolehvl I ilino)sulfonyllphenvl}-N-r3- (dimethylamiino)propyllpropanamide a) Protocol for the formation of the N-aryl-benzenesulfonamide building block; XI (Scheme e.g. methyl 3-(4-[(4-chloroanilino)sulfonyqjphenyl~propanoate 4-Chloroaniline (957 mg, 7.5 nunol) was dissolved in pyridine (25 mL). The resulting mixture was cooled down to O'C. Methyl 3-(4-chlorosulphonyl)phenylpropionate (1.3 14 g, 5.0 mmol) was added in portions. The mixture was stirred between OTC and room temperature overnight. Solvents were evaporated to dryness. The crude oil was dissolved in ethyl acetate (30 mL) and washed with 10% HC1 (2 x 15 mL) and brine (lx 15 ML).

Organic phase was dried over magnesium sulfate before filtering and removal of solvent.

The desired product, e.g. methyl 3- {4-[(4-chloroanilino)sulfonyljlphenyl~propanoate (1.458 g, was obtained as a colorless solid, in 98.5% purity by J{PLC (MaxPlot detection between 230 and 400 u).

1HNMR (300 MIHz, CDCI 3 2.65 2H, J 7.0 Hz), 3.00 2H, J 7.0 Hz), 3.67 3H,

OCH

3 6.91 (br s, 1H, NIH), 7.04 (in, 2H, H arom.), 7.22 (in, 2H, H arom.), 7.30 (in, 2H, H arom.), 7.70 (in, 2H, H aromn.); Mf(ESD): 351.4.

WO 02/32864 PCT/EP01/11865 -122c b) Protocol for the transformation of the N-aryl-benzenesulfonamide building block: XII into XII* by saponification followed by amide bond formation (Scheme e.g. 3-{4lt [(4-chloroanilino)sulfonyl]phenyl}-N-[3-(dimethylamino)propyl]propanamide.

00 O A solution of sodium hydroxide (560 mg, 14.0 mmol) in water (7.0 mL) was added to the 5 intermediate resulting from the precedent step, e.g. methyl chloroanilino)sulfonyl]phenyl}propanoate (1.458 g, 4.12 mmol) in 3:1 dioxane:water The resulting mixture was stirred overnight at room temperature. The reaction mixture was acidified to pH 2 with 2N solution of HC1 in water. It was extracted with ethyl acetate (3x30 mL). Combined organic phases were dried over magnesium sulphate, filtered and evaporated. The expected product, e.g. 3-{4-[(4-chloroanilino)sulfonyl]phenyl}-N-[3- (dimethylamino)propyl]propanamide (1.410 g, quantitative yield) was obtained as a colorless oil, in 95% purity by HPLC (MaxPlot detection between 230 and 400 nm). This intermediate was used in the next step without further purification.

'H NMR (300 MHz, DMSO-ds): 2.53 2H, J 7.0 Hz), 2.84 2H, J 7.0 Hz), 7.08 (m, 2H, H arom.), 7.28 2H, H arom.), 7.40 2H, H arom.), 7.64 2H, H arom.), 10.40 1H), 12.16 1H); M 340.11; M'(ESI): 338.10.

Intermediate resulting from the precedent step, e.g. 3- chloroanilino)sulfonyl]phenyl}-N-[3-(dimethylamino)propyl]propanamide (2.06 mmol) was dissolved in THF (10 mL) and cooled down to -25 0 C. N-methyl morpholine (0.57 mL, 5.15 mmol) and isobutylchloroformate (0.29 mL, 2.27 mmol) were added successively. The resulting mixture was stirred at -25 0 C for 30 min. N,N-dimethyl-1,3-propanediamine (316 mg, 3.09 mmol) was added and the mixture was allowed to gradually warm to room temperaure. After 16h, solvents were removed. The crude residue was dissolved in EtOAc and washed with water and with a 10% solution of NaHCO 3 in water. Organic layer was dried over Na 2

SO

4 filtrated and evaporated. The desired product, e.g. 3- chloroanilino)sulfonyl]phenyl}-N-[3-(dimethylamino)propyl]propanamide (816.2 mg, WO 02/32864 WO 0232864PCT/EPO1/1 1865 -123was obtained as a colorless oil, in 94.3% purity by HPLC (MaxPlot detection between 230 and 400 urn).

00 'H NIMR (300 MFz, CDC1 3 1.61 (in, 2H1), 2.23 6H, N(CH 3 2 2.35 (in, 2H1), 2.42 (in, 211), 2.96 (in, 2H), 3.26 (in, 2H1), 7.04 (n-4 211, H arom.), 7.16 (mn, 2H, H arom.), 7.24 (in, 2H, H arom.), 7.64 (in, 2H, H1 aroin.); Mi(ES 4 424.22; MF(ESDI: 422.16.

c) Protocol for the formation of the acyl hydrazone, 11 (Scheme e.g. 3-{4-[(4--chloro (2oxo-2-[(2Z)-2-(2-oxo-J, 2-dihydro-3H-indol-3-ylidene)hydrazinojethyl~anilino)sulfonyl]phenyl}-N-[3-(dimethylamino)propyljpropanamide The crude N-aryl-benzenesulfonamide building block XIII* resulting from the precedent step, e.g. 3- {4-[(4-chloroanilino)sulfonyl]phenyl} -N-[3-(dimethylamino)propyl]ipropanamide (1.925 mmol), was submitted to the Mitsunobu reaction following the procedure described in the general protocol C point Expected product, e.g. methyl (4chloro [3-(dimethylainino)propyl] amnino) -3-oxopropyl)phenyl]sulfonyl} anilino)acetate (664.5 mg, 69% yield) was obtained as a colorless oil, in 84% purity by HPLC (MaxPlot detection between 230 and 400 urn). This intermediate was used in the next step without further purification.

1H1 NUiR (300 MHz, CDC1 3 1.57 (in, 211), 2.20 6H, N(CH 3 2 2.29 (in, 211), 2.38 (in, 211), 2.94 (in, 2M1, 3.22 (in, 2H), 3.61 311, OCH 3 4.29 2E), 7.06 (in, 211, H aroin.), 7.14-7.29 (in, 411, H1 aroin.), 7.48 (in, 211, H arom.); Mi(APCfr): 496.2.

The crude carboxylic acid methyl ester resulting from the precedent step, e.g. methyl (4chloro {[3-(dimethylaniino)propyl] amino -3 -oxopropyl)phenyl]sulfonyl} anilino)acetate (0.70 inmol), was transformed in the corresponding hydrazide following the procedure described in the general protocol C point Expected product, e.g. 3-(4-114chloro(2-hydrazino-2-oxoethyl)anilino]sulfonyl}phenyl)-N-[3-(dimethylaniino)propylpropanamide (170.2 ing, 49% yield) was obtained as a colorless oil, in 75% purity by WO 02/32864 WO 0232864PCTJEPO1/1 1865 -124- CI HPLC (MaxPlot detection between 230 and 400 This intermediate was used in the next step without further purification.

00 'H MR (300 MiHz, MeO11-d 4 1.64 (in, 2H1), 2.24 611, N(CH 3 2 2.29 (mn, 2H), 2.54 0(mn, 211, 3.03 (in, 2H), 3.18 (in, 211), 4.28 211, 7.18 (mn, 2H, H arom.), 7.34 (in, 211 H 5 atom.), 7.42 (mn, 2H, H atom.), 7.56 (in, 211,11 atom.); M+(APCL+): 496.

Hydrazide obtained in the precedent step, e.g. {14-chloro(2-hydrazino-2-oxoethyl)anilino]sulfonyl~phenyl)-N-1j3-(dimnethylamino)propyl]propanamide (170 mg, 0.34 inmol), was dissolved in AcOH (3.5 inL). Isatin (48 ing, 0.33 mmol) was added. The reaction mixture was stirred lh at 100'C. Solvents were evaporated and the desired product was purfied by preparative IWLC (reverse phase, 1120 0.1 %TFAI MeCN 0. 1 %TFA gradient between 100: 1 and 45:5 After lyophilisation, the TFA salt of the expected product e.g.

3- {4-[(4-chloro {2-oxo-2-II(2Z)-2-(2-oxo- 1 ,2-dihydro-3H-indol- 3-ylidene)hydrazino] ethyl) anilino)sulfonyl]phenyl}-N-113-(diinethylainino)propyl]propanainide (107.9 ing, 44% yield), was isolated as a yellow solid, in 98% purity by J{PLC (Maxilot detection between 230 and 400 nin).

111 NMR (300 MHz, DMSO0-d 6 1.68 (in, 211), 2.42 (in, 211), 2.73 3K1 N(CH 3 2 2.88- 2.96 (in, 411), 3.06 (in, 211), 4.56 (br s, 2H, NCH 2 CO, major isomer 5.05 (br s, 211, NCH 2 CO, minor isomer 6.95 (in, 111, H1 atom.), 7.09 (in, 111, H1 atom.), 7.25 (in, 2H, H atom.), 7.34-7.68 (in, 811), 8.00 (in, 111H), 9.19 (br s, 111,), 11.28 111H), 12.52 (br s, 111, CONHN, minor isomer 13.58 (br s, 1H1, CONHN, major isomer M+(APCI+): 625.2 M-(APCF): 623.0. Analysis calculated for C 30 11 3 3 C1N 6 0 5 S 1120 1.7 TFA: C, 48.45; H1, 4.35; N, 10.15. Found: C, 48.39; 11, 4.64; N, 10.33.

WO 02/32864 WO 0232864PCT/EPO 1/11865 -125- Example 72: N-(4-chlorophenyl)-4-[3-(4-methl-l1 piperazinvl')-3-oxopropyll-N- f2-oxo-2- [(2Z)-2-(2-oxo-1 .2-dihydro-3H-indol-3-lidene)h drazinoeth lbezeulfofamide 00 Following the general method as outlined in Example DI, starting from methyl 3-(4chlorosulphonyl)phenylpropionate, 4-chloroaniline, 1 -methylpiperazine, methyl. glycolate and isatine, the title compound was isolated by evaporation of the solvents and purified by preparative HPLC (reverse phase, H 2 0 0.1%/TFA/ MeCN 0. 1%TFA gradient between 100: 1 and 45:5 After lyophilisation, the TFA salt of the expected product, e.g. N-{4chlorophenyl)-4-[3-(4-methyl-1 -piperazinyl)-3-oxopropyl]-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2dihydro-3H-indol-3-ylidene)hydrazino]ethylbelzeesulfoflam-ide (68.9 mg, 27.5% yield), was isolated as a yellow solid, in 98% purity by J{PLC (MaxP lot detection between 230 and 400 n).

1 H NMIR (300 DMSO-d 6 2.65-3.05 (in, 8H), 2.79 3'H, NCH 3 3.25-3.45 (in, 2M, 4.05 (in, 1H1), 4.43 (in, 1H), 4.57 (br s, 2H, NCH 2 CO, major isomer 5.06 (br s, 2H, NCH 2 CO, minor isomer 6.95 (in, 1H, H arom.), 7.09 (in, 1H, H arom.), 7.28 (in, 2H, H arom.), 7.34-7.72 (in, 8H, H arom.), 9.79 (br s, 1WH), 11.29 1H), 12.52 (br s, 1H, CONHN, minor isomer 13.57 (br s, 1H, CONIIN, major isomer IMi(ESI 4 623.12; IvfESfl: 621.18.

WO 02/32864 PCT/EPO1/11865 -126- Example 73: General protocol for the solution-phase synthesis of sulfanilide derivatives of general Formula II with R 3 Me (Schemes 1 2. e.g. 4-ethoxy-N- {1-methyl-2-oxo-2- [(2Z)-2-(2-oxo-1,2-dihydro-3H-indol-3-vlidene)hvdrazinolethyll -N-(4-methlphenl)- 00 benzene-sulfonamide a) Protocolfor the displacement of the leaving group in X (Scheme e.g. methyl ethoxyphenyl)sulfonyl]-4-methylanilino)propanoate.

The crude N-aryl-benzenesulfonamide building block XII, e.g. 4-ethoxy-N-(4methylphenyl)benzenesulfonamide (204 mg, 0.70 mmol, preparation described in example 1, step was dissolved in DMF (5 mL). Methyl-2-bromopropionate (0.117 mL, 1.05 mmol) and potassium carbonate (193 mg, 1.40 mmol) were added. The mixture was heated overnight at 60 0 C. Solvents were evaporated. The crude residue was suspended in ethyl acetate (10 mL) and was washed with IN HCI solution (7 mL) and with brine (7 mL).

Organic phase was dried over MgSO 4 fltrated and evaporated. The desired product, e.g. methyl 2- [(4-ethoxyphenyl)sulfonyl]-4-methylanilino}propanoate (276 mg, quantitative crude yield) was isolated as a light yellow oil, in 94.3 purity by HPLC (MaxPlot detection between 230 and 400 nm).

'H NMR (300 MHz, CDCl 3 1.42 3H, J= 7.1 Hz), 2.30 3H), 3.65 3H), 4.01-4.17 3H), 6.85 2H, H arom.), 6.98-7.10 4H, H arom.), 7.58 2H, H arom.); M(APCI): 378.

WO 02/32864 WO 0232864PCT/EPOI/1 1865 -127b) Protocol for the transformation of the carboxylic acid ester into the hydrazide (Scheme e.g. 4-ethoxy-N-(2-hydrazino-1-methyl-2-oxoethyl)-N-(4-methylphenyl)benzenesulfonamide.

The crude carboxylic acid methyl ester, e.g. methyl 2- {[(4-ethoxyphenyl)sufonyl]-4- 5 methylanilino~propanoate (264 mg, 0.70 mmol), was dissolved in MeGH (2 mL).

Hydrazine hydrate was added (0.44 rnL). The reaction mixture was stirred overnight at Solvents were evaporated. The crude mass was redissolved in MeOH and solvents were evaporated again. This process was repeated three times. The desired product, e.g. 4ethoxy-N-(2-hyclrazino- 1-methyl-2-oxoethyl)-N-(4-methylphenyl)benzenesulfonanude (138.4 mg, 52%) was isolated as a colorless solid in 91.1 purity by HPLC (MaxPlot detection between 230 and 400 nm).

1 H NMR (300 MIHz, CDCl 3 1.13 3H, J =7.2 Hz), 1.45 3H, J 7.0 Hz), 2.36 (s, 3H), 3.34 (in, 1H), 4.15 2H, J= 7.0 Hz), 7.03 (in, 2H, H arom.), 7.09 (mn, 21-, H arom.), 7.15 (in, 2H, H aroin.), 7.63 (in, 2H, H arom.); M 4 (APCIi): 378.0; M-(APCD): 376.0.

c) Protocol for the formationi of the acyl hydrazone. If (Scheme e.g. 4-ethoxy-N-(1miethyl-2-oxo-2-[(2Z)-2-(2-oxo-1, 2-dihydro-3H-indol-3-ylidene)hydrazinolethyl)-N-(4methylphenyl)benzenesulfonamide.

Hydrazide obtained in the precedent step, e.g. 4-ethoxy-N-(2-hydrazino-1I-methyl-2oxoethyl)-N-(4-methylphenyl)benzenesulfonanide 4-ethoxy-N-(2-hydrazino-l1-methyl-2..

oxoethyl)-N-(4-methylphenyl)benzenesulfonainide (138 mg, 0.37 nimol), was dissolved in EtOH 5 AcOH (8 niL). Isatin (54 mg, 0.37 nimol) was added. The reaction mixture was stirred overnight at 76*C. Solvents were evaporated and the crude mixture was purified by flash chrmatography, using a mixture cyclohexane ethyl acetate 6:4 as eluent. The desired product, e.g. 4-ethoxy-N- 1-methyl-2-oxo-2-[(2Z)-2-(2-oxo-1 ,2-dihydro-3H-indol- 3-ylidene)hydrazino] ethyl) -N-(4-inethylphenyl)benzenesulfon amide (86 mig, was WO 02/32864 WO 0232864PCT/EP01/l 1865 128- NI isolated as a yellow solid in 89% purity by HPLC (Max.Plot detection between 230 and 400 nm).

00 'H NMIR (300 MMz, CDCI 3 1.28 J= 7.2 Hz, 3H1), 1.41 (in, 3HK OCH 2

CH

3 4.04 (in, 2K1 OCH 2

CH

3 ),5.05 (in, 1H, NCHCO, major isomer 6.11 (DI, 1H, NCHCO, minor r- 5 isomer 6.72-6.95 (in, 3H, H arom.), 6.98-7.22 (in, 5H1, H arom.), 7.29 (in, 1H, H arom.), 7.52-7.80 (in, 3K1 H arom.), 8.23 (br s, 111, CONHN, minor isomer 8.67 (br s, 1H1, CONHN, major isomer 12.40 (br s, 1H1, CONHN, minor isomer 13.83 (br s, 111, CONHN, major isomer M+(APC~I): 507; M-(APCf): 505.

ExaMle 74: General protocol for the solution-phase synthesis of sulfanilide derivatives of general Formula II with R 3 CH20H (Schemes 1. e. 4-eth oxy N- f I-(hydrox3Meth I 2-oxo-2-i(2Z)-2-(2-oxo- 1.2-dihvdro-3H-indol-3-ylidene)hydrazinolethyll inethylphenvl~benzenesulfonamide r a) Protocol for the preparation of intermediate.Xf with R3 CH 2 OBu (Scheme e.g. 2bromo-3-tert-butoxypropanoic acid.

A mixture of potassium bromide (6.830 g, 57.39 mmol) and 0.75 M HBr solution (91 inL, 68.24 inmol) was cooled down to Sodium nitrite (2.093 g, 29.47 inmol) and L-serine tert-butyl ether (2.50 g, 15.51 mmol) were added successively and the mixture was stirred 3h at room temperature. The mixture was cooled down to 0 0 C, and was extracted with ethyl acetate (3x 100 inL). Combined organic phases were washed with brine (2x 180 inL), dried WO 02/32864 PCT/EP01/11865 -129over MgSO 4 filtrated and evaporated. The expected product, e.g. 2-bromo-3-tertbutoxypropanoic acid (3.481 g, quantitative yield), was isolated as a light yellow oil. This t intermediate was used in the next step without further purification.

oO O 'H NMR (300 MHz, MeOH-d 4 1.21 9H), 3.68 1H), 3.84 1H), 4.22 1H-); M+(APCI): 168.4.

0 The bromo acid isolated in the precedent step, e.g. 2-bromo-3-tert-butoxypropanoic acid (1.276 g, 5.67 mmol), was dissolved in a 3:1 chloroform MeOH mixture (81 mL).

Tirmethylsilyl diazomethane (8.505 mL, 17.01 mmol) was added dropwise. The yellow resulting mixture was stirred overnight at room temperature. The solvents were evaporated at atmospheric pressure, affording the desired product, e.g. methyl 2-bromo-3-tertbutoxypropanoate (1.482 in quantitative yield. This intermediate was used in the next step without further purification.

1 H NMR (300 MHz, CDC13): 1.01 9H), 3.51 1H), 3.67 3H, OCH 3 3.69 1H), 4.05 1H); M+(APCI): 240.

b) Protocol for the displacement of the leaving group in X with R 3

CH

2 O'Bu (Scheme e.g. methyl 3-tert-butoxy-2-{[(4-ethoxyphenyl)sulfonyl]-4-methylanilino}propanoate The crude N-aryl-benzenesulfonamide building block XIII, e.g. 4-ethoxy-N-(4methylphenyl)benzenesulfonamide (388 mg, 1.33 mmol, preparation described in example 1, step was dissolved in DMF (5 mL). Intermediate XI with R--CH 2 0 t Bu, e.g. methyl 2-bromo-3-tert-butoxypropanoate (478 mg, 2 mmol) and potassium carbonate (368 mg, 2.66 mmol) were added. The mixture was heated overnight at 60 0 C. Solvents were evaporated. The crude residue was suspended in ethyl acetate (10 mL) and was washed with IN HCI solution (7 mL) and with brine (7 mL). Organic phase was dried over MgSO4, fltrated and evaporated. The crude mixture was purified by flash chromatography, using a 8:2 mixture cyclohexane ethyl acetate as eluent. The desired product, e.g. methyl 3-tert-butoxy-2- {[(4-ethoxyphenyl)sulfonyl]-4-methylanilino}propanoate (157 mg, 26.3%) WO 02/32864 WO 0232864PCTIEPOI/1 1865 -130was isolated as a light yellow oil, in 96.4 purity by L{PLC (MaxPlot detection between 230 and 400 run).

00 1H NMIR (300 MHz, CDCl 3 1.28 911), 1.61 311, J= 7.1 Hz), 2.49 311), 3.50 (t, 1H, J= 9.4 Hz), 3.85 (dd, 1H, J= 4.9, 9.4 Hz), 3.92 311), 4.25 2H1, J= 7.1. Hz), 5.33 (dd, I1H, J 4.9, 9.4 Hz), 7.03 (in, 211, H arom.), 7.23 (in, 2H, H atom.), 7.28 (mn, 211, H atom.), 7.87 (mn, 211,1H atom.); M+(APCI 4 450.

c) Protocol for the transformation of the carboxylic acid ester into the hydrazide (Schemne e.g. NJJI-(tert-butoxymethyl)-2-hydrazino-2-oxoethYl-4-ethoxy-N-(4- ,nethylphenyl)benzenesulffonamide.

The crude carboxylic acid methyl ester, e.g. methyl 3-tert-butoxy-2- ethoxyphenyl)sulfonyl]-4-nethylanilino~propaloate (157 mg, 0.35 inmol), was dissolved in MeOH (1 mL). Hydrazine hydrate was added 11 mL). The reaction mixture was stirred 3 days at 60*C. By cooling down the reaction mixture, the desired product, e.g. N- [1 -(tert-butoxyinethyl)-2-hydrazino-2-oxoethyl] -4-ethoxy-N-(4methylphenyl)benzenesulfonamide (40.5 mng, 25%) crystallised. It was isolated by filtration as a colorless solid in 86 purity by HPLC (MaxPlot detection between 230 and 400 nm).

1H NMR (300 NMz, MeOH-d 4 1.21 911), 1.60 3H, J= 7.1 Hz), 2.51 311), 3.43 (mn, 111), 3.53 211), 3.62 (in, 111), 3.79 (in, 111), 4.29 211, J= 7.1 Hz), 7.15 (mn, 211, H atom.), 7.29 (mn, 4H, H atom.), 7.82 (mn, 2H1, H atom.); Mf+(APCli): 450.2.

d) Formation of the acyl hydrazone, II (Scheme e.g. 4-ethoxy-N-(1-(hydroxymethiyl)-2oxo-2-(2Z)-2-(2-oxo-J,2-dihydro-3H-indol-3-ylidene)hydrazinojethyl}-N-Y4met hyiphenyl) benzenesulffonamide Hydrazide obtained in the precedent step, e.g. N.{1-(tert-butoxymethyl)-2-hydrazino-2oxoethyl]4ethoxy-N(4-methylphenyl)benzeesulfonaflhde (40 mng, 0.09 innol), was dissolved in EtOH 5 AcOH (2 miL). Isatin (13 mg, 0.09 inmol) was added. The reaction

I

WO 02/32864 PCTIEP01/1 1865 CK1 -131mixture was stirred overnight at 76 0 C. Solvents were evaporated and the crude mixture was dissolved in methylene chloride (1 mL). Trifluoroacetic acid (0.5 mL) was added at 0 0

G.

The reaction mixture was stirred 3 days at room temperature and the solvents were 00 evaporated. The crude product was purified by flash chromatography, using a mixture cyclohexane ethyl acetate 1: 1 as eluent. The desired product, e.g. 4-ethoxy-N- 1- (hydroxymnethyl)-2-oxo-2-[(2Z)-2-( 2 -oxo- 1,2-dihydro-3H-indol-3ylidene)hydrazino]ethyl-N-(4-methylphenyl)belzefesulfoInflide (17.2 mg, 36%) was isolated as an orange solid in 90% purity by HPLC (MaxPlot detection between 230 and 400 nm).

1 H NMR (300 MHz, MeOH-d 4 1.16 (in, 3K OCH 2

CH

3 2.20 3H, CH 3 ),3.56 (in, 1lH), 3.64-3.81 (in, 1H), 3.84-4.02 (mn, 2H), 4.86 (in, 1H, NCHCO, major isomer 5.22 (in, 1H, NCHCO, minor isomer 6.77-6.87 (in, 3H, H 7.93-7.04 (in, 5H, H aroin.), 7.26 (mn, 1ff), 7.44-7.72 (in, 3K H arom.). Ivf(APCr-): 521.

Example 75: General protocol for the solid-phAse synthesis of sulfanilide derivatives of general Formula I with RW H (Scheme 10): 3-(3.4-Dichlorophenvl)-2-({r4fluoro(phenylsulfonl)anilinolacetl} amino)propanamide a) Protocol for the preparation of the Rink amnine resune, MV7T, by Fmoc deprotection of Fmoc-Rink amide resin.

Finoc-Rink amide resin 84 mmollg) was suspended in 10 inL/g of 20% piperidine in DMF and was shaken for 30 min. The resin was filtered and washed with DMF, DCMv, WO 02/32864 PCT/EP01/11865 C( -132ci DMF, DCM, MeOH and twice with Et 2 O. It was finally dried on sinter. The disappearance of the C-O stretch in the IR indicated a complete deprotection of the Fmoc-Rink amide.

00 b) Protocol for the loading of, fmoc-protected amino acids on Rink amine resine, XXV, 0 e.g. loading of N-fmoc-2-amino-3-(3,4-dichloro-phenyl)-propionic acid.

O 5 The resin resulting from the precendent step, the Rink amine resine, XXIV, was suspended C in DMF (10 ml/g) fmoc-protected amino acid (3 eq) was added, together with diisopropylcarbodiimide (3 eq). The suspention was shaken overnight at room temperature.

The resin was washed with DMF, DCM, DMF, DCM, MeOH and twice with Et 2 O. It was finally dried on sinter. The formation of this new amide bond could be checked by negative ninhydrin test and the apparition of new C=O stretches in IR.

c) Protocol for fmoc deprotection of the amino acid loaded on Rink resine, XXV.

Fmoc-protected amino acid loaded on Rink resin (0.84 mmol/g) was suspended in 10 mU/g of 20% piperidine in DMF and was shaken for 30 min. The resin was filtered and washed with DMF, DCM, DMF, DCM, MeOH and twice with Et20. It was finally dried on sinter.

The lost of the C=O stretch in IR indicated a complete deprotection of the amino acid.

d) Protocol for amide bond formation between amino acid and Xa with R 3 H (Scheme formation of XVI.

Resin amine recovered from the precendent step was suspended in DMF (10 mL/g).

Carboxylic acid XIa (3 eq), e.g. bromoacetic acid, and diisopropylcarbodiimide (3 eq) were added and the mixture was shaken overnight at room temperature. The resin was washed with DMF, DCM, DMF, DCM, MeOH and twice with Et 2 0. It was finally dried on sinter.

The formation of this new amide bond could be checked by negative ninhydrin test and the apparition of new C=O stretches in IR.

WO 02/32864 PCT/EP01/11865 C- 133- C e) Protocol for the displacement of the leaving group in Xla with R 3 H with XII (Scheme formation ofXXVII.

0 o Amine XII, e.g. 4-fluoroaniline (25 eq), was dissolved in DMSO (10 mL/g of resin). This Ssolution was added to the resin resulting from the precendent step and the mixture was shaken overnight at room temperature. The resin was recovered and washed with DMF, SDCM, DMF, DCM, MeOH and twice with Et 2 0. It was finally dried on sinter. The formation of this new amide bond was checked on a sample of resin which was suspended in 50%TFA/DCM for 10 min at room temperature. The resulting solution was analysed by LC-MS and 1 H NMR.

f) Protocol for the sulfonylation of XVII (Scheme 10); formation ofXXVII.

Sulfonyl chloride VII, e.g. benzenesulfonyl chloride (5 eq), was dissolved in dichloroethane mL/g of resin) and N-methylmorpholine (5 eq) was added. This solution was added on the resin resulting from the precedent step. The whole mixture was shaken overnight at 0 C. The resin was recovered and washed with DMF, DCM, DMF, DCM, MeOH and twice with Et 2 0. It was finally dried on sinter.

g) Protocol for the cleavage from the resin XXVI of sulfanilide derivatives of general Formula I with R 3 H (Schemes 10); e.g. 3-(3,4-Dichlorophenyl)-2-({[4fluoro(phenylsulfonyl)anilino]acetyl}amino)propanamide.

A 50% TFA in DCM solution (3 x 0.5 mL) was allowed to drip through the resin resulting from the precedent step. This procedure was repeated twice. The combined filtrate was evaporated and analyzed by LC-MS and 'H NMR. Through this procedure, the desired product, e.g. 3-(3,4-Dichlorophenyl)-2-( fluoro(phenylsulfonyl)anilino]acetyl}amino)propanamide, was isolated in >60% purity by LC/MS. 525.

WO 02/32864 WO 0232864PCTJEP01/1 1865 -134- Exaple76:3-(enzlox)-2-[( 14-chloro[(3,4-dimethoxyphenvlI)sulfonvlIanio} acetyl)aniinolpropanamide 00 >0)Y 0 Following the general method as outlined in Example 75, starting from N-fnioc-2-amino-3benzyloxy-propionic acid, methyl bromoacetate, 4-chioro aniline and 3,4-dimethoxybenzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS.

(ESIi): 563.

Examp~le 77: 3-(Benzvloxy)-2-( 414-chloro(phenylsulfonvl)an linolacetvll amino)propaiamide 100 Following the general method as outlined in Example 75, starting from N-frnoc-2-amino-3benzyloxy-propionic acid, methyl bromoacetate, 4-chloroaniline and benzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS. (ESIi): 502.

WO 02/32864 WO 0232864PCT/EP01/1 1865 -135- Example 78: [(4-Ethoxvhenyl)sulfonyll-4-metwlanilinoi acetyl')axminol-2phenyacetamide Following the general method as outlined in Example 75, starting from N-finoc-aminophenyl-acetic acid, methyl bromoacetate, 4-toluidine and 4-ethoxy-benzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS. (ES1 4 482.

Example 79: 3-(3,4-Dichlorophenyl)-2-r( ([(4-fluo ohenyl)sulfonyll-4-methoxyanilino 1acetvl~aminolvrovanamide Following the general method as outlined in Example 75, starting from N-fmoc-2-aniino-3- (3,4-dichloro-phenyl)-propionic acid, methyl bromoacetate, 4-methoxy-aniline and 4fluoro-benzenesulfonyl chloride, the title compound was obtained in >60% purity by LG/MS. (ESf): 555.

WO 02/32864 WO 0232864PCTIEPOI/1 1865 -136- Example 80: ([(4-Ethoxyphenyl)sulfonl]l-4-methoxyanhlinol acetvl)-1 .2.3,4tetahydro-3-isociuinolinyllacetamide 00 0J Following the general method as outlined in Example 75, starting from N-finoc-(l,2,3,4tetrahydro-isoquinolin-3-yl)-acetic acid, methyl bromoacetate, 4-methoxy-aniline and 4ethoxy-benzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS. 538.

Example 81: Fr(4-EthoxyphevlI)sulfonyll-4-methoxvanhliol acetyl)-l1-isoindolinecarboxamide Following the general method as outlined in Example 75, starting from N-finoc-2,3dihydro-1H-isoindole- 1-carboxylic acid, methyl. bromoacetate, 4-methoxy-aniline and 4ethoxy-benzenesulfonyl chloride, the title compound was obtained in >60% purity by LCIMS. 5 WO 02/32864 WO 0232864PCTIEP01/1 1865 137- Example 82: f(3.4-DimethoxyphenyIlsulfonvll -4-methoxyanhlino I acetvl)- 1 2.3 .4tetrahvdro-3-isouuinolinvllacetamnide Following the general method as outlined in Example 75, starting from N-fmoc-(1,2,3,4tetrahydro-isoquinolin-3-yl)-acetic acid, methyl bromoacetate, 4-methoxy-aniline and 3,4dimnethoxy-benzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS. (ES1I): 554.

Example 83: {4-Chloro r(4-etlioxypheny1~sulfonyllanilino} acetyl)valine Following the general method as outlined in Example 75, starting from N-finoc-3-methyl- 2-methylamino-butyric acid, methyl bromoacetate, 4-chloroaniline and 4-ethoxybenzenesulfonyl chloride, the title compound was obtained in >60% purity by LCIMS.

(EST): 483.

WO 02/32864 WO 0232864PCTIEP01/1 1865 -138- ExaMpie 84: 2-r( fr(4-Ethoxyhenl)sufonll-4-fluoroaniino1 acetyl)aminol-3-(lH-indol- 3-yl)prop~anamide Following the general method as outlined in Example 75, starting from N-finoc-2-amino-3- (1H-indol-3-yl)-propionic acid, methyl bromoacetate, 4-fluoro aniline and 4-ethoxybenzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS.

539.

Example 85: il(4-Ethoxyphenl)sulfonyll-4-fluoroanilinol~acetyflaniinol-2phgnvlacetamide Following the general method as outlined in Example 75, starting from N-fmnoc-aminophenyl-acetic acid, methyl. bromoacetate, 4-fluoroaniline and 4-ethoxy-benzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS. 486.

WO 02/32864 WO 0232864PCT/EP0 1/11865 (Nj -139- Example 86: J1(A.-Dimethoxyphen l)sulfonll-4-fluoroaniinol~acetvl)valine 00 Following the general method as outlined in Example 75, starting from N-finoc-3-methyl- 2-methylamino-butyric acid, methyl bromoacetate, 4-fluoroaniline and 3,4-diinethoxybenzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS.

(ESOi: 483.

ExaMle 87: 1 -(f{[(4-Ethoxyphenvl)sulfonvfl-4-methlanilinolacetvl)-5-phenvl-2pyrolidinecarboxamide rJ Following the general method as outlined in Example 75, starting from pyrrolidine-2-carboxylic acid, methyl bromoacetate, 4-toluidine and 4-ethoxybenzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS.

(Esfr): 522.

WO 02/32864 WO 0232864PCTIEP0 1/1 1865 -140- Exmple 88: 2-r2-( {r(4-Ethoxyphenyl)sulfonvll anilino~ acetyl)- 1,2,3.4-tetrahydro-3isoginolinyll acetaniide 00 Following the general method as outlined in Example 75, starting from N-finoc-(l,2,3,4tetrahydro-isoquinolin-3-yl)-acetic acid, methyl bromoacetate, aniline and 4-ethoxybenzenesulfonyl chloride, the title compound was obtained in >60% purity by LG/MS.

(ES

4 7J: 508.

ExMle 89: 2-r2-({fr(4-Ethoxyphyl)sulfonl-4-methylanilinoI acetyl)-1 2.3,4tetrahydro-3-isoauinolinyllacetamide Following the general method as outlined in Example 75, starting from N-fmnoc-(1,2,3,4tetahydro-isoquinolin-3-yl)-acetic acid, methyl bromoacetate, 4-toluidine and 4-ethoxybenzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS.

(ESr): 522.

WO 02/32864 WO 0232864PCT/EPO 1/11865 -141- Example 90: 2-r( f r4-EthoxyhenDsulfonyll-4-methoxaru l1acetyl)aniinol-4phenylbutananiide Following the general method as outlined in Example 75, starting from N-fioc-2-amino-4phenyl-butyric acid, methyl. bromoacetate, 4-methoxy-aniline and 4-ethoxybenzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS.

526.

ExaMple 91: 2-(f {(4-Ethoxyphenv1-)sulfony11-4-methoxyanilino1 acetyl)- 1.2,3,4-tetahydro- 3-isoguinolinecarboxamide

NJ

100 Following the general method as outlined in Example 75, starting from N-finoc-1,2,3,4tetrahydroisoquinoline-3-carboxylic acid, methyl bromoacetate, 4-methoxy-aniline and 4ethoxy-benzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS. (ESe): 524.

WO 02/32864 WO 0232864PCTIEP0 1/11865 -142- Exavl 92 2[((F(-Ehoxphnv)sulfonvll-4-methoxvanhliol acetvl)aniinol-3-(1Hindol-3-Yl)propanamide Following the general method as outlined in Example 75, starting from N-fmoc-2-amino-3- (1H-indol-3-yl)-propionic acid, methyl bromoacetate, 4-methoxy-aniline and 4-ethoxybenzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS.

551.

ExajMple 93: 1 I[r4-Ethoxvhenvl)sulfonll-4-fluoroanilino }acetfl-5-nhenvl-2pRMolidinecarboxamide Following the general method as outlined in Example 75, starting from pyrrolidine-2-carboxylic acid, methyl bromoacetate, 4-fluoroaniline and 4-ethoxybenzenesulfonyl chloride, the title compound was obtained in >60% purity by LC/MS.

(Esid): 526.

WO 02/32864 PCT/EP01/11865 (N -143- CI Example 94: Preparation of a pharmaceutical Formula tion The following Formula tion examples illustrate representative pharmaceutical compositions 00 according to the present invention being not restricted thereto.

Formulation 1 Tablets A sulfanilide compound of Formula I is admixed as a dry powder with a dry gelatin binder C in an approximate 1:2 weight ration. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 240-270 mg tablets (80-90 mg of active sulfanilide compound per tablet) in a tablet press.

Formulation 2 Capsules A sulfanilide compound of Formula I is admixed as a dry powder with a starch diluent in an approximate 1:1 weight ratio. The mixture is filled into 250 mg capsules (125 mg of active sulfanilide compound per capsule).

Formulation 3 Liquid A sulfanilide compound of Formula I (1250 mg), sucrose (1.75 g) and xanthan gum (4 mg) are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously prepared solution of microcrystalline cellulose and sodium carboxymethyl cellulose (11:89, mg) in water. Sodium benzoate (10 mg), flavor, and color are diluted with water and added with stirring. Sufficient water is then added to produce a total volume of 5 mL.

Formulation 4 Tablets A sulfanilide compound of Formula I is admixed as a dry powder with a dry gelatin binder in an approximate 1:2 weight ratio. A minor amount of magnesium stearate is added as a lubricant. The mixture is formed into 450-900 mg tablets (150-300 mg of active sulfanilide compound) in a tablet press.

WO 02/32864 PCT/EP01/11865 C( -144- CN Formulation 5 Injection A sulfanilide compound of Formula I is dissolved in a buffered sterile saline injectable I aqueous medium to a concentration of approximately 5 mg/ml.

00 Example 95: Biological assays C The compounds according to Formula I may be subjected to the following assays: a) In vitro competition binding assay on hOT receptor with Scintillating Proximity Assay (Pharmaceutical Manufacturing International, 1992, p.

4 9 5 3 by Cook, N.D. et al) This assays allows to determine the affinity of the test compounds for the OT receptor.

Membranes from HEK293EBNA cells expressing the hOT receptor were resuspended in buffer containing 50 mM Tris-HCI, pH 7.4, 5 mM MgC12 and 0.1 BSA The membranes (2-4 jig) were mixed with 0.1 mg wheat-germ aglutinin (WGA) SPA bead (type A) and 0.2 nM of the radiolabel [125I]-OVTA (OVTA being Omithin Vasoactive and is an analogue of OT for competition binding experiments). Non-specific binding was determined in the presence of 1 jiM Oxytocin. The total assay volume was 100 pl. The plates (Coming NBS plate) were incubated at room temperature for 30 min and counted on a Mibrobeta plate counter. The tests compounds were used in concentrations of 30 pM, pM, 1 pM, 300 nM, 100 nM, 10 nM, 1 nM, 100 pM, 10 pM. The competition binding data were analysed using the iterative, nonlinear, curve-fitting program, "Prism".

The binding affinities to the oxytocin receptor of the sulfanilide derivatives claimed in the formula I were assessed using the above described in vitro biological assay. Representative values for some example compounds are given in Table 1 below. The values refer to the binding affinity (ICso; tM) of the example compounds according to formula I to the WO 02/32864 PCT/EP01/11865 145- Oxytocin receptor. From the values shown in Table 1 it can be derived that said test compounds according to formula I do show a significant binding to the oxytocin receptor.

WO 02/32864 WO 0232864PCT/EP01/1 1865 -146- Table 1.

N-(4-chlorophenyl)-4-[3-(dimethylaminio)popoxyl-N-2oxo-2-f(2Z)-2-(2-axo-1 ,2-dihydro-SH-ndol-3- 0.0006 ylidene)hydrazlno]ethyl)benzenesilforiamlde 3-{4-[(4-chloro{2-ox-2-[(2Z)-2-(2-cxo-1 .2-dihydlD-3Hindod-3-y4idene)hydrazino]ethyalino)sufonylp~eny)4 0.0007 [3-(dimethytamino)propyljpropanamlde

-O

N-{4-chlomophenyl)-(2-(4-morphlnyl)ethoxy--2-oxo- 2-{2-(2-oxo-i ,2-dlhydro-31-I-ndal-3ylidene)hydrazinolethyl~benzenesulfonamlde 0.0008 N-(4-chloropheryl)-4-{2-(dimethytamino)ethoxy-N-{2oxo-2-[(2Z)-2-(2-oxo-1 ,2-dlhydro-3H-indol.3ylidene)hydrazlnolethyl)benizenesulfornamkle 0.0018 -4 4-4-chlorophenyl)-N-{2-oxo-2-j(2Z)-2-(2-oxo-1,2dihydro-3H-ndol-3-ylldene)hydrazino]ethyl)-4-[3-(3pyridinyl)propoxy~benzernesulfonamlde 0.0028 N-(4-chlorophenyl)-4-f-(2-methoxyethoxy)ethoxy]-N-2oxo-2-[(2Z)-2-(2-oxo1 .2-dihydro-3H-Indol-3ylldene)hydrazlno]ethl)bermenestilforiamlde 0.0029 -h WO 02/32864 WO 0232864PCT/EPO 1/11865 147- Table 1 (cont.) 4-[3-(dimethylamino)propoxy-N-(4-methylphenyl)-N-2oxo-2-(2Z)-2-(2-oxo-1 .2-dihydro-3H-Indol-3- 0.003 J ylidene)hydrazino]ethylqbenzenesulfonamde 3-{4-[(4-methol(2.oxo-2-[(2Z)-2-(2-oxo-1 ,2-dihydro-3H- Indol-3ylidene)hydrazinoethyoanilino)sulfonylqphenyl)propana mide 0.0034 N-(4-chlorophenyl)-4-etioxy-N-{2-oxo-2-[(2Z)-2-(2-oxo- I .2-dihydro-3H-indo4-3- 0.004 ylidene)hydrazino]ethyl~benzenesulfonamide N-(4-chlorophenyl)-4--a2-(4-morphollnyl)ethyljamino)-N- (2-oxo-2-[(2Z)-2-(2-axo-l ,2-dihydro-3H-Indol-3- 0.0069 ylidene)hydrazmno]ethylbenzenesulfornamide 4-ethoxy-N-{2-[(2Z)-2-(2-hydroxybenzylidene)hydrazno]- 0.1 2-oxoethyl)-N-{4-methylphenyl)benzenesulfonamide 0.2 N-(4-chlorapheny)-4-thoxy-N-(2-[(2E)-2-(2hydroxybenzyIldene)hydrazino]-2- 0.0148 oxoethyl)berizenesulfonamide WO 02/32864 WO 0232864PCT/EPOI/1 1865 -148- Table 1 (cont.) 4-ethoxy-N-(4-methyphy)N-(xo-2-[(2Z2-(2-oxo- 1 ,2-dlhydro-3H-Indol-3- 0.0173 ylldene)hydrazlno~ethylqbenzenesulfonamide N-(4-.chlarophenyl)-N-f2-oxo-2-(2Z)-2-(2-oxo-1 ,2- 0±08dlhydro-3H-Indol-3-ylldene)hydrazno]ethyl)-2- 0.0293 thlophenesulfonlamlde N-(4-chloropheny)-N-{2-oc-2-[(2Z)-2-(2-oxo-1 ,2dlhydro-3H-indol-3-ylldene)hydrazinio]ethyl-4-C2- 0.0533 tlerimethoxy)benzenesulfonamlde N-(4-chloropheny)-4-ethoxy-N-{2-oxo-2-f(2Z)-2-(2-oxo- I ,2-dihydro-3H-pyrrolop,2-c]pyidln-3- 0.0571 ylldene)hydrazlno]ethyl)benzenesulfanaMlde N-(4.-doraphenyl)-4[3-(dlmethylamno)propoxy]-N-2axo-2-f(2Z)-2-(2.axa-1 ,2-dlhydro-3H-pyrrala[3,2-c]pyrldln 0.0781 3-yldene)hydrazlno]ethyl)benzenesulfonamlde methyl (3Z)-3-(f14-chloro({4-[3- (dlmethylamlno)propoxylphenylsulanyl)anllnojacetlh 0.1081 ydrazano)-2-oxo-2,3-dlhydro-IH-Indole-7-cartbaxylate WO 02/32864 PCTIEP01/I 1865 149- Table 1 (cont.) I I WO 02/32864 PCT/EP01/11865 (1 -150- 0 Nc b) In vitro competition binding assay on hVla receptor with Scintillating Proximity Assay This assays allows to determine the affinity of the test compounds for the V1a receptor.

00 Membranes from CHO cells expressing the hVla receptor were resuspended in buffer 0 containing 50 mM Tris-HC1, pH 7.4, 5 mM MgC12 and 0.1 BSA The membranes 5 (5-10 p.g) were mixed with 0.2 mg wheat-germ aglutinin (WGA) SPA bead (type A) and 0.03 nM of the radiolabel [12I]-LVA LVA being Linear Vasopressin Antagonist and is an analogue of AVP for competition binding experiments). Non-specific binding was determined in the presence of 1 |tM AVP. The total assay volume was 100 tl. The plates (Coring NBS plate) were incubated at room temperature for 2 hours and counted on a Mibrobeta plate counter. The tests compounds were used in concentrations of 30 tM, pM, 1 pM, 300 nM, 100 nM, 10 nM, 1 nM, 100 pM, 10 pM. The competition binding data were analysed using the iterative, nonlinear, curve-fitting program, Graph pad "Prism".

The binding affinities to the Via receptor of the sulfanilide derivatives claimed in the formula I were assessed using the above described in vitro biological assay. Representative values for some example compounds are given in Table 1 below. The values refer to the binding affinity (ICso; pM) of the example compounds according to formula I to the Via receptor. From the values shown in Table 1 it can be derived that said test compounds according to formula I do show a significant binding to the Vi receptor.

WO 02/32864 WO 0232864PCT[EPOI/1 1865 -151- Table 2 :H miO N-(4-Brmo-phenyl)-N-f1-(2-hydroxy-phenyl)-ettiylidene .9 hydrazinocarbonylmethyt}.benzenesulfonainide039 N-(3-Bromo-phenyl)-N-ydroxy-benzylldene-0.3 hydrazlnocarbonylmethyl)-benzenesulfonanide0.3 N-(4-Chloro-phenyl)-N-(2-hydroxy-benzylldenehydrazlnocarbonylmethyl)-3,4-dimethoxy- 0.55 "a benzenesulfonamlde 4-Etthoxy-N-{2-axo-1 ,2-dihydro-~ndol-3-ylidenehydrazI nocarb nym ethiyl Y"--tolyl- 0.75 benzenesulfonamide N (-Chloro-phenyl)-N-2-hydroxy-benzylidene- 07 hydraJnocarboiylmethyl-benzenesufonamide N-(4-Brom o-phenyi)-N-[l -(2-hydroxy-ph enyl)-ethyl idene. hydrazlnocarboriylmettiyIJ-benzenesulfonamide08 WO 02/32864 WO 0232864PCT/EPOI/1 1865 152- Table 2 (cont.) n~48Idl ftty II U grin~ 2-[BereesulfonyH44-methoxy-phenyl-arrno-N(2.4- 0.045 d~methyl,-phenyl)-acetaide N-(4-ronio-phenyl)-N-[2-(3,4-dhydro-1 H-~soquinolIn-2- y1-2-oxo-ethyJ]-enzenesUforwr~de0.5 2-(3,4Uethoxyernsulfonyl-4-netoxy-henyl) 0.3 amrna1-N-(2,4-dlmethyt-pheny4)-aoetamIde 0.3 N-(2-Hydroxy-2-phaiyethyl)-2-[(toluene-4-sufonyl).p- 0.37 tolyl-amlnol-acetamlde N-J2-(3,4-Dlhydm-1H-Isoquinain-2-yt).2-oxo-ethy]-4- 0.375 ettioxy-N-p-tolyl-benzernesulfaoamlde C) 2-[(4-Methoxy-phny)-toluene-4-sufonA4)amno-N- 0.43 (pyridin-2-ytsulfanyl)-ethy].etamlde WO 02/32864 PCT/EP01/11865 C 153c-i c) Functional assay No. 1: Inhibition of oxytocin mediated Ca 2 +-mobilization by FLIPR (Fluorescent Imaging Plate Reader) 00 FLIPR is a machine for fluorescence imaging using a laser that is capable of illuminating a 0 96-well plate and a means of simultaneously reading each well thus enabling rapid 5 measurements on a large number of samples.

NC This assay intends to show the inhibition of the OT OT-R mediated calcium mobilisation being necessary to cause uterine contractions by using test compounds of formula Preparing the plates: FLIPR-plates were pre-coated with PLL (Poly-L-Lysine) 10pg/ml 0.1% gelatine to attach the HEK (Human Embryonic Kidney) cells for 30min up to 2 days at 37 The cells were plated out into 96-well plates (60000 cells/well).

Labelling with fluo-4: 501tg fluo-4 (fluorescent marker) were dissolved in 20pl pluronic acid (20% in DMSO). The dissolved fluo-4 was then diluted in 10ml DMEM (Dubecco's Minimal Essential Medium-F12 medium without FCS (Fetal Calf Serum). The medium was removed from the plates, followed by one wash with DMEM-F12 medium. Now, 100pl of the DMEM-F12 medium containing fluo-4 were added and the cells incubated for 1.5-2h (HEK-cells). The cells now contain the fluorescent marker.

Buffer: 145mM NaCI, 5mM KC1, ImM MgC 2 10mM Hepes, 10mM Glucose, EGTA (Ethylene-bis oxyethylene nitrilo tetraacetic acid). Adjust to pH 7.4.

Performance of the assay: A minimum of 80pl/well of antagonists (5x) in the above buffer (lx) were prepared (96-well plates). The antagonists were added to the well-plates at different concentrations (30 pM, 10 pM, 1 [tM, 300 nM, 100 nM, 10 nM, 1 nM, 100 pM, pM).

OT is added at a concentration of 40 nM.

The fluorescent marker being sensitive to the amount ofCa2+ mobilized within the cell may be quantified by the FLIPR machine.

WO 02/32864 PCT/EP01/11865 -154- S The activities of the sulfanilide derivatives according to formula I were assessed using the above described in vitro biological assay. Representative values for some example tI compounds are given in Table 3 below. The values refer to the capacity of the example 00 Scompounds according to formula I to effectively antagonize oxytocin-induced intracellular

O

N 5 Ca2+-mobilization mediated by the oxytocin receptor. From the values shown in Table 3 it 0can be derived that said example test compounds according to formula I do exhibit a C significant activity as oxytocin receptor antagonists.

WO 02/32864 PCTIEPO 1/1 1865 -155- Table 3 WO 02/32864 WO 0232864PCT[EPOI/1 1865 (Nj -156- Table 3 (cont.) (1 3-(4+f4-methyI(2-cxo 2-((2Z)-2 dihydro-3H-indol-3yllderne)hydrazinajethylanlina)su propnamlde WO 02/32864 WO 0232864PCTIEPO 1/11865 157- Table 3 (cont.) -b b 7 2-EBenzenesulfonyl-(4-metloxy-phelyamilo]- .4 o~o N-(3-chloro-2-methyl-phenyl)-acetamide 2-[Benzenesulfonyl-4-bromo-pheny)-aminoJ-t 0.353 (3-chloro-2-methy-phenyI)actamide "a oN 2-Benzenesulfonyl-(4-metoxy-pheny)-amiflol- 0.363 N-naphthalen-1 -y-acetamide ON~y 2.[Benzenesulfonyl{4-methoxy-pheny)-aminol- 0.392 N-(3-methoxy-phenyl)-acetamlde O~~O2.jBenzenesulfonyl-(4-chlaro-phenyl-amino]-N- 0.443 (3-chloro-2-methy-pheny)-acetamide N-{2,4-Dichloro-benzy!)-2-((toluene-4-sulfony)- 0.595 p-toli-amilno-acetamide WO 02/32864 PCT/EP01/11865 -158- C, d) Functional assay No. 1: Inhibition of vasopressin-mediated Caz+-mobilization by FLIPR (Fluorescent Imaging Plate Reader) 00 FLIPR is a machine for fluorescence imaging using a laser that is capable of illuminating a 0 96-well plate and a means of simultaneously reading each well thus enabling rapid S 5 measurements on a large number of samples.

This assay intends to show the inhibition of the AVP Via-R mediated calcium mobilisation being necessary to cause uterine contractions by using test compounds of formula Preparing the plates: FLIPR-plates were pre-coated with PLL (Poly-L-Lysine) 10g/ml 0.1% gelatine to attach the CHO cells (expessing hVia) for 30min up to 2 days at 37 oC.

The cells were plated out into 96-well plates (60000 cells/well).

Labelling with fluo-4: 50ftg fluo-4 (fluorescent marker) were dissolved in 20l pluronic acid (20% in DMSO). The dissolved fluo-4 was then diluted in 10ml DMEM (Dubecco's Minimal Essential Medium-F12 medium without FCS (Fetal Calf Serum). The medium was removed from the plates, followed by one wash with DMEM-F12 medium. Now, 100gl of the DMEM-F12 medium containing fluo-4 were added and the cells incubated for 1-1.5h (CHO-cells). The cells now contain the fluorescent marker.

Buffer: 145mM NaCI, 5mM KC1, 1mM MgC12, 10mM Hepes, 10mM Glucose, EGTA (Ethylene-bis oxyethylene nitrilo tetraacetic acid). Adjust to pH 7.4.

Performance of the assay: A minimum of 80dl/well of antagonists (5x) in the above buffer (Ix) were prepared (96-well plates). The antagonists were added to the well-plates at different concentrations (30 pM, 10 pM, 1 pM, 300 nM, 100 nM, 10 nM, 1 nM, 100 pM, pM).

AVP is added at a concentration of 40 nM.

WO 02/32864 PCT/EP01/11865 <N -159- C The fluorescent marker being sensitive to the amount of Ca2+ mobilized within the cell may be quantified by the FLIPR machine.

00 The activities of the sulfanilide derivatives according to formula I were assessed using the O above described in vitro biological assay. Representative values for some example 5 compounds are given in Table 4 below. The values refer to the capacity of the example O compounds according to formula I to effectively antagonize AVP-induced intracellular Ca2+-mobilization mediated by the Via-receptor. From the values shown in Table 4 it can be derived that said example test compounds according to formula I do exhibit a significant activity as Via receptor antagonists.

WO 02/32864 PCT[EP01/11865 -160- Table 4 WO 02/32864 PCT/EP01/11865 L' -161c' e) Functional assay No. 2: Inhibition of P3 (Inositol Tri-Phosphate)-Synthesis in HEK/EBNA-OTR cells 00 This assay intends to show the inhibition of the OT OT-R mediated IP3 synthesis being O necessary to cause uterine contractions by using test compounds of formula Stimulation of the cells: HEK/EBNA OTR(rat or human) cells were plated out into costar 12-well plates, and equilibrated for 15-24h with 3 H]-inositol radiolabel in medium without inositol supplement, with 1% FCS (0.5ml/well). 4 p.Ci/ml were used. After this, the medium containing the label was aspirated. Then was added DMEM (without FCS, inositol), 20mM Hepes (4-(2-hydroxyethyl)-1-piperazine-ethatie-sulphonic acid), Img/ml BSA containing 10mM LiCl (freshly prepared), for 10-15min at 37°C. The agonist (i.e.

oxytocin used at a concentration of 10 nM) and the antagonists the tests compounds of formula used in a concentration of 10 pM, 1pM, 300 nM, 100 nM, 10 nM, 1 nM, 100 pM, 10 pM, 3 pM) were added for the time required (15-45min), followed by aspiration of the medium. Due to the antagonization of the OT receptor, the radiolabeled inositol is phosphorylated to yield IP3, the amount of the radiolabeled IP3 may be determined through the ensuing work-up. The reaction was stopped with Iml STOP-solution 0.4 M perchloric acid), and let sit for 5-10min at Room Temperature. Then, 0.8ml were transferred into tubes containing 0.4ml of neutralizing solution (0.72 M KOH/0.6M

KHCO

3 and the tubes vortexed and kept in the cold at least for 2h.

Separation of IP's: The samples were spun in a table top centrifuge at 3000-4000 rpm for 1ml of the supernatant was transferred to new tubes containing 2.5ml H 2 0. Packed resin (0.8ml) was equilibrated with 20ml H 2 0, and the whole samples poured onto the chromatography columns, thus separating the mixture. To discard free inositol, two washes with 10ml H 2 0 were carried out.

WO 02/32864 PCT/EP01/11865 CN -162- Elution of total IP's: The elution was achieved using 3ml 1M ammonium formate/0.1M formic acid. The eluant was collected in scintillation counting tubes, followed by addition ttn of 7ml of scintillation liquid. The amount of IP3 is determined by a scintillating counter.

00 The activities of the sulfanilide derivatives claimed in the formula I were assessed using the above described in vitro biological assay. Representative values for some example Scompounds are given in Table 5 below. The values refer to the capacity of the example compounds according to formula I to effectively antagonize oxytocin-induced IP3synthesis mediated by the oxytocin receptor. From the values shown in Table 5 it can be derived that said example test compounds according to formula I do exhibit a significant activity as oxytocin receptor antagonists.

WO 02/32864 PCT/EPO1/1 1865 -163- Table WO 02/32864 PCT/EP01/11865 -164- CI J) In vivo model for inhibtion of uterine contractions The assay intends to show the biological effect of tested compounds in an in vivo model of 00 preterm labor, premature birth.

c Non-pregnant Charles River CD(SD) BR female rats (9-10 weeks old, 200-250g) were treated at 18 and 24 hours before the experiment with 250 pg/kg, i.p. diethylstilbestrol S (DES). For the assay, the animal was anaesthetised by urethane (1.75 g/kg, and placed on an homeothermic operating table. The trachea was isolated and cannulated with a suitable polyethylene (PE) tubing. A midline incision at the hypogastrium level was made and one uterine horn exposed, its cephalic end cannulated with a PE240 tubing and, after filling the internal cavity with 0.2 ml of sterile physiological saline, connected to a "Gemini" amplifying/recording system via a P23ID Gould Statham pressure transducer.

For the i.v. route of administration of the test compounds, one jugular vein was isolated and cannulated with a PE60 tubing connected to a butterfly needle to allow the administration by a dispensing syringe. In the case ofintraduodenal administration of the test compounds, the duodenum was isolated and similarly cannulated through a small incision in its wall.

One carotid artery was also isolated and cannulated with PE60 catheter and connected to a suitable syringe for blood sample collection (see below). After a stabilization period, the same dose of oxytocin was repeatedly injected intravenously at 30-min intervals. When comparable contractile responses of the uterus to the selected dose of oxytocin were obtained, the dose of the test or reference compound was administered. Further injections of the same dose of oxytocin were then made for a suitable time after treatment to assess inhibitory effects of the compounds under study. The contractile response of the uterus to oxytocin was quantified by measuring the intra-uterine pressure and the number of contractions. The effect of the reference and test compounds were evaluated by comparing pre- and post-treatment pressure values. In addition, at 2, 30, 90 and 210 minutes after test compound administration, a 0.5-ml blood sample was withdrawn from the cannulated WO 02/32864 PCT/EP01/11865 CN -165c carotid artery of each experimental animal. Plasma was obtained by standard laboratory procedure and the resulting samples were stored at -20 0

C.

00 The activities of the sulfanilide derivatives claimed in the Formula I were assessed using O the above described in vivo biological assay. Representative values for one example 5 compound are given in Table 4 below. The values refer to the capacity of the example O compound according to Formula I to effectively antagonize oxytocin-induced uterine contractions in the rat. From the values shown in Table 6 it can be derived that said example test compound according to Formula I does exhibit a significant activity as tocolytic, i.e. uterine-relaxing, agent.

WO 02/32864 WO 0232864PCT/EPO 1/11865 -166- Table 6 N-(4-chlorophenyl)-4-{2-(4-morpholinyl)ethoxy]- N-{2-oxo-2-[2-(2-axo-1 ,2-dihydro-3H-indol-3ylidene)hydrazino]ethyl~benzenesutfonamide 4.3±1.7 0.3 118.2 ±3.7 1 39.8±5.1 3 41.7± 12.5 N-(4chlorophenyl)-43- (dimethylamino)propoxy-N-{2-oxo-2-[(2Z)-2-(2- .2-dihydro-3FHindolylidene)hydrazino]ethyl~benzenesulfonamide -9.±2503 :20.8 ±2.2 1 '34.4 ±3.9 3 .57.1±4.8 67.4 7.1 4-ethoxy-N-(4-methylphenyl)-N-{2-oxo-2-[(2Z)- 2-(2-oxo-1 ,2-dihydro-3Ht-indol-3ylidene)hydrazino]ethyl~benzenesulfonamide 23.9 4.0 :40.3 4.2 62.6 ±5.0

Claims (4)

1. Use of a sulfanilide derivative of Formula I: 0 1 R 2 0 its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein: R' and R 2 are "aryl" or "heteroaryl" which may be fused with 1-2 further cycloalkyl or aryl or heteroaryl groups; R 3 is selected from the group consisting of H, "Ci-C 6 -alkyl", "Ci-C6-alkyl aryl","C-C 6 alkyl heteroaryl", "C 2 -C 6 -alkenyl", "C 2 -C 6 -alkynyl"; R 4 and R 5 are independently selected from the group consisting of hydrogen, "CI-C 6 alkyl", "C 2 -C 6 -alkenyl", "C 2 -C 6 -alkynyl"; saturated or unsaturated 3-8-membered "cycloalkyl" which may contain 1 to 3 heteroatoms selected from N, O, S, "aryl", "heteroaryl", "C 1 -C 6 -alkyl aryl"," C 1 -C 6 -alkyl heteroaryl", or R 4 and R 5 may form together with the N atom to which they are attached a 3-8 membered saturated or unsaturated heterocyclic ring which may contain 1-2 further heteroatoms selected from N, S and O and which is optionally fused with an aryl, heteroaryl or 3-8 membered saturated or unsaturated cycloalkyl ring; or R 4 can be H or CI-C 6 alkyl, and R 5 can be -N=CR 6 R 7 wherein: WO 02/32864 WO 0232864PCTIEPOI/1 1865

168- R 6 is an "aryl" or a "heteroaryl" ring carrying 1 to 5 substituents selected from the group consisting of H, "Cl-C 6 -allcYl", "Cl-C 6 -alkyl aryl", "Cl-C 6 -alkyl heteroaryl", "C 2 OC) C 6 -alkenyl", "C 2 -C 6 -alkynyl", primary, secondary or tertiary amino groups, "acyl", C)"acyloxy", "acylamnino", "ammnocarbonyl", "alkoxycarbonyl", "aryl", "heteroaryl" N 5 carboxyl, cyano, halogen, hydroxy, mercapto, nitro, sulfoxy, sulfonyl, "Cl-C 6 -alkoxY", thioalkoxy, 2-alkoxyethoxy, 2-(2-alkoxyethoxy)ethoxy, 2-hydroxyethoxy, 2-(2- N hydroxyethoxy)-ethoxy, 2-(dimethylaniino)ethoxy, 2-(2-(dimethylaxnino)ethoxy)- ethoxy, 2-carboxyethoxy, 2-(2-carboxyethoxy)ethoxy, carboxymethoxy, 2-sulfoxy- ethoxy, 2-(2-sulfoxyethoxy)ethoxy, 2-[(2-methoxyethyl)sulfanyl]ethoxy, hydroxyethyl)-sulfanyl]ethoxy, 2-[(2-carboxyethyl)sulfanyl]ethoxy, carboxymethyl)sulfanyl]-ethoxy, 2-[(2-sulfoxyethyl)sulfanyl] ethoxy; R7 is selected from the group consisting of H, "Cl-C 6 -allcyl", "C 1 -C 6 -alcYl aryl", "C 1 C 6 -alkyl heteroaryl", "C 2 -C 6 -alkenyl", "C 2 -C 6 -alkYnYl", "acyl", "aminocarbonyl", "calkoxycarbonyl", "aryl", "heteroaryl", carboxyl, cyano, sulfonyl; or R 6 and R 7 form together with the C atom to which they are attached a 3-8 membered saturated or unsaturated heterocyclic ring which may contain 1-2 further heteroatoms selected from N, S and 0 and which is optionally fused with an aryl, heteroaryl or 3-8 membered saturated or unsaturated cycloalkyl ring; for the preparation of a medicament for the treatment of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nepbrotic syndrome and ocular hypertension. 2. Use according to claim 1, wherein R' and/or R? are substituted with from 1 to substituents independently selected from the group consisting Of "C 1 -C 6 -alkyl","CI-C6- alkyl aryl", "C 1 -C 6 -alkl heteroaryl", "C 2 -C 6 -alkenyl", "C 2 -C 6 -alkynyl", primary, secondary or tertiary amino groups or quartemnary ammonium moieties, "acyl", ccacyloxy", "acylamino", "aininocarbonyl", "alkoxycarbonyl", "4aryl"C, "heteroaryl"c, WO 02/32864 WO 0232864PCTIEPO 1/11865 -169- CI carboxyl, cyano, halogen, hydroxy, mercapto, nitro, sulfoxy, sulfonyl, alkoxy, thioalkoxy, 2-alkoxyethoxy, 2-(2-alkoxyethoxy)ethoxy, 2-hydroxyethoxy, 2-(2- hydroxyethoxy)ethoxy, 2-(dimethylamiino)ethoxy, 2-(2-(dimethylamino)ethoxy)- 00 ethoxy, 2-carboxyethoxy, 2-(2-carboxyethoxy)ethoxy, carboxymethoxy, 2- N- 5 sulfoxyethoxy, 2-(2-sulfoxyethoxy)ethoxy, 2-[(2-methoxyethyl)sulfanyljethoxy, 0 hydroxyethyl)sulfanyl]ethoxy, 2-[(2-carboxyethyl)sulfanyl] ethoxy, CI carboxymethyl)sulfanyl]ethoxy, 2-[(2-sulfoxy-ethyl)sulfanyl]ethoxy. 3. Use according to claim 1 or 2, wherein R' and W? are aryl and heteroaryl rings whereby either or both of said rings are substituted with 1 or 2 sub stituents selected from the group consisting of halogens, cyano, CI-C 6 -alkyl, primary, secondary amines or C 1 -C 6 -alkoxy groups. 4. Use according to claim 3, wherein the CI-C 6 -alkoxy groups are selected from the group consisting of methoxy, ethoxy groups and substituted ethoxy groups such as, for example, 2-alkoxyethoxy, 2-(2-alkoxyethoxy)ethoxy, 2-hydroxy-ethoxy, 2-(2- hydroxyethoxy)ethoxy, 2-(dimethylamino)ethoxy, 2-(2-(dimethylamino)- ethoxy)ethoxy, 2-carboxyethoxy, 2-(2-carboxyethoxy)ethoxy, carboxymethoxy, 2- sulfoxyethoxy, 2-(2-sulfoxyethoxy)ethoxy, 2-[(2-methoxyethyl)sulfanyl]ethoxy, hydroxyethyl)sulfanyllethoxy, 2-[(2-caboxyethyl)sulfanyl]ethoxy, 2-[(2-carboxy- methyl)sulfanyl]ethoxy, 2-I(2-sulfoxyethyl)sulfanyl]ethoxy. 5. Use according to any of the preceding claims, wherein R 1 and W 2 are unsubstituted or substituted phenyl. 6. Use according to any of the preceding claims, wherein R 4 and R 5 are independently selected from the group consisting of hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, carboxymethyl, (aminocarbonyl)methyl, 2-carboxyethyl, 2-aminocarbonylethyl, 3- arninopropyl, 4-aminobutyl, 3-guanidinopropyl, phenylmethyl, 2-phenylethyl, hydroxy(phenyl)mnethyl, (imnidazol-4-yl)methyl, (indol-3-yl)methyl, (pyrid-2- WO 02/32864 WO 0232864PCTIEP01/1 1865 (NI -170- (1 yl)methyl, (pyrid-3-yl)methyl, (pyrid-4-yl)methyl, (thien-2-yl)methyl, (thien-3- yl)methyl. 00 7. Use according to any of the preceding claims, wherein R? and R 4 are H, and R5 is a group N=CR 6 R 7 according to Formula Il: R 8H N, N R (I its tautomeric forms, such as, for example, the keto-enol form of the carbonyl group or the different forms of the group N==CR 6 R 7 its geometrical isomers, its optically active forms as enantiomers, diastereomners and its racemnate forms, as well as pharma- ceutically acceptable salts thereof, wherein: R 6 is an "aryl" or "heteroaryl" group; R' is selected from the group consisting of H, "Cj-C 6 -alkyl', "CI-C-allcYl aryl" "C 1 C 6 -alkyl heteroaryl","Cl-C 6 -alcyl cycloalkyl", "C 2 -C 6 -alkenyl", "C 2 -C 6 -alkynyl", "acyl", "aminocarbonyl", "alkoxycarbonyl", "aryl", "heteroaryl", carboxyl, cyano, sulfonyl; or R 6 and R 7 form together with the C atom to which they are attached a 3-8 membered, saturated or unsaturated heterocyclic ring which may contain 1-2 further heteroatoms selected from N, S and 0 and which is optionally fused with an aryl, heteroaryl or 3-8 me mbered saturated or unsaturated cycloalkyl ring; I WO 02/32864 WO 0232864PCT/EP01/1 1865 171 R 8 and R? are selected from the group consisting Of "C 1 -C 6 alkYl", "Cl-CO-alkyl aryl", "Cl-C 6 -alkyl heteroaryl","C1-C6-alkYl cycloalkyl", "C 2 -C 6 -allcenyl", "C 2 -C 6 -allcynyl", primary, secondary or tertiary amino groups or quartemnary ammonium moieties, "acyl", "acyloxy", "acylamino", "aminocarbonyl", "alkoxycarbonyl", "aryl", "heteroaryl", carbonyl, carboxyl, cyano, halogen, hydroxy, mercapto, nitro, sulfoxy, sulfonyl, Cl-C 6 -alkoxy, thioalkoxy; or 2 substituents of R 8 and/or of R? undergo ring closure, n and n' are independently selected from 1 to 8. Use according to claim 7, wherein R 6 and W 7 form an oxindole ring. 9. Sulfanilide derivatives of Formula (Ha): NN NN.KRT 07:: ZO 0 (Ila) R 9 wherein: W? is H or "Cl-C 6 -allcyl"; R 6 R7 are independently selected from the group consisting of H, "C 1 -C 6 -alkyl", "C 1 C 6 -alkYl aryl", "Cl-C 6 -alkyl heteroaryl","Cl-C 6 -alkyl cycloalkyl", "C 2 -C 6 -alkenyl", "C 2 -C 6 -alkYnYl", "acyl, "aminocarbonyl", "alkoxycarbonyl", "aryl", "heteroaryl", carboxyl, cyano, sulfonyl; or, R 6 and R 7 form together with the C atom to which they are attached a 3-8 membered saturated or unsaturated (cyclic or) heterocyclic ring which may contain 1-2 WO 02/32864 WO 0232864PCT/EP01/1 1865 (NI -172- CI further heteroatorns selected from N, S and 0 and which may be fused with an aryl, heteroaryl or 3-8 membered cycloalkyl ring; 00 R 8 is H, halogen or "CI-C 6 -alkyl"; CI R 9 is selected from the group consisting Of -X-(CI-C 6 -alkyl)-Y, whereby X is a bond, 0, NR, -CONR; Y is a 3-8-membered cycloalkyl, a 3-8-membered cycloalkyl containing 1-3 heteroatoms selected from N, 0, S, aryl, heteroaryl, OR, NRR', NRR', with R, R' independently being H, "Cl-C 6 -alkyl", "C-C 6 -afkyl aryl", "CI-C 6 alkyl heteroaryl","Cl-C 6 -alkyl cycloalkyl", "Cl-C 6 -alkoxy"' or R, R' form together with the N atom to which they are attached a 3-8 membered saturated or unsaturated heterocyclic ring which may contain 1-2 further heteroatoms selected from N, S and 0 and which may be fused with an aryl, heteroaryl or 3-8 membered cycloalkyl ring. Sulfanilide derivatives according to claim 9, wherein W 3 is H, R 6 is phenyl and R 7 is H or CI-C 6 -alkyl. 11. Sulfanilide derivatives according to claim 9, wherein R 6 and R 7 form together an tetrahydroisoquinoline or an oxindole ring. 12. Sulfanilide derivatives of Formula Th R R N NR O :ZO V (Ib) wherein, ffi WO 02/32864 WO 0232864PCT[EP01/1 1865 (Nj -173- R 8 and R 9 are independently selected from H, halogen, "C 1 -C 6 -alkoxy" or "CI-C 6 alkyl"; 00 R 4 is H or "Cl-C 6 -alkyl" and W( is an acetaniide, a propionic amide, a propionic acid 0 moiety, being substituted by "Cl-C 6 -alkyl", "Cl-C 6 -alkyl aryl", "CI-C 6 -alkyl 5 heteroaryl", "Cl-C 6 -allcoxy"; or R 4 and W 5 form together with the nitrogen atom to which they are attached a pyrrolidine, piperidine, tetrahydroisoquinoline, isoindole or indole ring carrying an acetamide, propionic amide or propionic acid moiety, said acetamide, propionic amnide or propionic acid moiety may be substituted by "Cl-C 6 -alkyl", "CI-C 6 -alkyl aryl", "C 1 -C 6 -alkyl heteroaryl", "Cl-C 6 -alkoxy". 13. A sulfanilide derivative according to any of the preceding claims selected from the following group: 4-ethoxy-N-(2- 1-(2-hydroxyphenyl)ethylidene]hydrazino) -2-oxoethyl)-N-(4- methylphenyl)benzenesulfonamnide 4-ethoxy-N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl) benzenesulfonamide 4-ethoxy-N- {2-oxo-2-II(2E)-2-(2-oxo-l ,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl} -N-phenylbenzenesulfonamide 4-ethoxy-N-[2-((2E)-2- {5-Ilhydroxy(oxido)amino]-2-oxo- 1 ,2-dihydro-3H-indol-3- ylidene~hydrazino)-2-oxoethyl]-N-phenylbenzenesulfonamide 4-ethoxy-N- {2-I(2E)-2-(5-iodo-2-oxo-1 ,2-dihydro-3H-indol-3-ylidene)hydrazino]-2- oxoethyl} -N-phenylbenzenesulfonaniide 4-ethoxy-N-(2-hydrazino-2-oxoethyl)-N..{4-methylphenyl)benzenesulfonamide WO 02/32864 WO 0232864PCT/EPO 1/11865 -174- N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3- ylidene)hydrazino]ethyl} -1 -naphthalenesulfonamide 00 N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo-1 ,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl) -2-naphthalenesulfonamide 4-cbloro-.N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo.1 ,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl) benzenesulfonamide 4-methoxy-N-(4-methylphenyl)-N- {2-oxo-2- I ,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl} benzenesulfonamide 4-methyl-N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl} benzenesulfonainide 4-cyano-N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl) benzenesulfonanide 4-ethoxy-N- {2-[(2Z)-2-(2-fluorobenzylidene)hydrazino]-2-oxoethyl} methylphenyl)benzenesulfonamide {[(4-ethoxyphenyl)sulfonyl]-4-methylanilino} acetyl)hydrazono]-2-oxo-2,3- dihydro-1 H-indole-5 -sulfonic acid N-(4-methylphenyl)-N- {2-oxo-2-[X2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl} 1[1,1 '-biphenyl] -4-sulfonamide N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl) -4-phenoxybenzenesulfonamide 4-ethoxy-N- [(2Z)-2-(2-hydxoxybenzylidene)hydrazino]-2-oxoethyl) methylphenyl)benzenesulfonamide WO 02/32864 WO 0232864PCT/EPOI/1 1865 CK1 175- {(2Z)-2-[4-(diethylamino)-2-hydroxybenzylidene]hydrazino} -2-oxoethyl)-4- ethoxy-N-(4-methylphenyl)benzenesulfonamide 00 4-ethoxy-N-(2- {(2Z)-2-[(2-hydroxy-l1-naphthyl)methylene]hydrazino} -2-oxoethyl)-N- 0 (4-methylphenyl)benzenesulfonamide 4-ethoxy-N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(3-oxo-2,3-dihydro-1H-inden- 1- ylidene)hydrazino] ethyl} benzenesulfonamide 4'-methoxy-N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl) [1,1 '-biphenyl]-4-sulfonaniide 4-ethoxy-N- -methyl-2-oxo-1 ,2-dihydro-3H-indol-3-ylidene)hydrazino] 2-oxoethyl} -N-(4-methylphenyl)benzenesulfonamide {(2E)-2-[l1-(2,4-dihydroxyphenyl)ethylidene]hydrazino) -2-oxoethyl)-4-ethoxy- N-{4-methylphenyl)benzenesulfonaniide 3,4-dimethoxy-N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-{2-oxo- 1,2-dihydro-3H-indol- 3-ylidene)hydrazino]ethyl}benzenesulfonamide 4-ethoxy-N-(2- 1-(2-hydroxy-l1-naphthyl)ethylidene]hydrazino} -2-oxoethyl)- N-(4-methylphenyl)benzenesulfonaniide 4-ethoxy-N-(2- 1-(1 -hydroxy-2-naphthyl)ethylidene]hydrazino} -2-oxoethyl)- N-(4-methylphenyl)benzenesulfonamide 4-tert-butyl-N-(4-chlorophenyl)-N- {2-oxo-2-II(2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl) benzenesulfonamide N-(4-chlorophenyl)-3,4-dimethoxy-N- {2-oxo-2-[(2E}-2-(2-oxo- 1,2-dihydro-3H-indol- 3-ylidene)hydrazinollethyllbenzenesulfonamide WO 02/32864 WO 0232864PCTIEP01/1 1865 (NI -176- N1 4-tert-butyl-N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo- 1,2-dihydro-3H-indol-3- ylidene)hydrazino]ethyl}benzenesulfonamide 00 N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl)}-4-propylbenzenesulfonaniide 4-butoxy-N-(4-methylphenyl)-N- {2-oxo-2-[(2E)-2-(2-oxo- I ,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl) benzenesulfonamide 4-butoxy-N-(4-chlorophenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3- ylidene)hydrazino]ethyl}benzenesulfonamide N-(4-chlorophenyl)-N- {2-oxo-2- 1 ,2-dihydro-3H-indol-3- ylidene)hydrazinolethyl) 4-propoxybenzenesulfonamide N-(4--methylphenyl)-N- {2-.oxo-2-[(2Z)-2-(2-oxo-1 ,2-dihydro-3H-indol-3- ylidene)hydrazino]ethyl} 4-tert-pentylbenzenesulfonamnide N-(4-methylphenyl)-N- {2-oxo-2-[(2Z}-2-(2-oxo- 1,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl} -4-propoxybenzenesulfonamide N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl) -2-thiophenesulfonamide N-QI-chlorophenyl)-N- {2-oxo-2-II(2Z)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3- ylidene)hydrazino]ethyl} -2-thiophenesulfonamide N-(4-chlorophenyl)-N- {2-[(2E)-2-(2-hydroxybenzylidene)hydrazino] -2-oxoethyl) -3,4- dimethoxybeuzenesulfonamide N-(4-chlorophenyl)-4-ethoxy-N- {2-I[(2E)-2-(2-hydroxybenzylidene)hydrazino]-2- oxoethyl~benzenesulfonanmide WO 02/32864 WO 0232864PCT/EPO 1/11865 -177- N-(4-chlorophenyl)-N- {2-oxo-2-II(2Z)-2-(2-oxo-1 ,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl}I -4-tert-pentylbenzenesulfonamide 00 N-(4-chlorophenyl)-4-ethoxy-N- 1,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl} benzenesulfonamnide N-(4-chlorophenyl)-N- {2-oxo-2-II(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl) benzenesulfonamnide N-(4-chlorophenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl} -4-propylbenzenesulfonanuide 4-ethoxy-N- 1-methyl-2-oxo-2-[X2Z)-2-(2-oxo-1 ,2-dihydro-3H-mndol-3- ylidene)hydrazino] ethyl} -N-(4-methylphenyl)benzenesulfonaniide 4-ethoxy-N- I -(hydroxymethyl)-2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl} -N-(4-methylphenyl)benzenesullonamide N-(4-chlorophenyl)-4-ethoxy-N- {2-[(2E)-2-(lH-imidazol-2-ylmethylene)hydrazino]- 2-oxoethyl}benzenesulfonaniide N-(4-chlorophenyl)-4-ethoxy-N- pyridinyhnethylene)hydrazino] ethyl} benzenesulfonamide 4-fluoro-N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-{2-oxo- 1,2-dihydro-3H-indol-3- ylidene)hyclrazino]ethyl}benzenesulfonaniide 4-fluoro-N- {2-[(2E)-2-(2-hydroxybenzylidene)hydrazino]-2-oxoethyl} methylphenyl)benzenesulfonaxnide 4-ethoxy-N-[2-((2E)-2- {2-[hydroxy(oxido)amino]benzylidene}hydrazino)-2- oxoethyl]-N-(4-methylphenyl)benzenesulfonaniide WO 02/32864 WO 0232864PCT/EPOI/1 1865 -178- N- {2-I(2E)-2-(2-aniinobenzylidene)hydrazino]-2-oxoethyl} -4-ethoxy-N-(4- methylphenyl)benzenesulfonamide 00 {[(4-ethoxyphenyl)sulfonyl] -4- methylanilino} acetyl)hydrazono]methyl} phenyl)acetamide N-(4-chlorophenyl)-4-[2-(4-morpholinyl)ethoxy]-N- {2-oxo-2-[2-(2-oxo- 1,2-dihydro- 3H-indol-3 -ylidene)hydrazino] ethyl) benzenesulfonaniide N-(4-methylphenyl)-4-[2-(4-morpholinyl)ethoxy]-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2- dihydro-3H-indol-3-ylidene)hydrazino] ethyl} benzenesulonanide N-(4-clorophenyl)-4-112-(dimethylamino)ethoxy]-N- {2-oxo-2-[(2Z)-2-(2-oxo-1 ,2- dihydro-3 H-indo1-3 -ylidene)hydrazino] ethyl)}benzenesulfonamide 4-[2-(dimethylaznino)ethoxy]-N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2- dihydro-3 H-indol-3-ylidene)hydrazino] ethyl} benzenesulfonaniide 4-[3-(dimethylamnino)propoxy]-N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo-1 ,2- dihydro-3H-indol-3-ylidene)hydrazino] ethyl} benzenesulfonamide N-(4-chlorophenyl)-4-[3 -(dimethylamino)propoxy] {2-oxo-2-II(2Z)-2-(2-oxo-1 ,2- dihydmo-3H-indol-3-ylidene)hydrazino] ethyl) benzenesulfonaniide N-(4-chilorophenyl)-4-ethoxy-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-pyrrolo[3,2- c]pyridin-3 -ylidene)hydrazino] ethyl) benzenesulfonarnide N-(4-.chlorophenyl)-4- {[2-(4-morpholinyl)ethyl] amino)} {2-oxo-2-II(2Z)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3 -ylidene)hydrazino] ethyl} benzenesulfonaniide 3- {4-[(4--methyl {2-oxo-2- 1,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl) anilino)sulfonyl]phenyl) prop anamide WO 02/32864 WO 0232864PCT/EPO 1/11865

179- CI N-(4-chlorophenyl)-N- {2-oxo-2-II(2Z)-2-(2-oxo-1I,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl} -4-(2-thienylmethoxy)benzenesulfonamide 00 N-(4-chlorophenyl)-.4-[2-(2-methoxyethoxy)ethoxy]-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2- 0 ~dihydro-3H-indol-3-ylidene)hydrazino] ethyl) benzenesulfonamide N-(4-chlorophenyl)-4-(2-methoxyethoxy)-N- 1 ,2-dihydro-3H- indol-3-ylidene)hydrazino]ethyl~benzenesulfonainide N-(4-chlorophenyl)-N- {2-oxo-2-IX2Z)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl} [3 -pyridinyl)propoxy]benzenesulfonaniide N-(4-chlorophenyl)-N- {2-oxo-2-II(2Z)-2-(2-oxo- 1 ,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl} -(2-pyridinyl)propoxy]benzenesulfonamide 4-(2-methoxyethoxy)-N-(4-methylphenyl)-N- {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro- 3H-indol-3 -ylidene)hydrazino] ethyl} benzenesulfonamide 4-ethoxy-N- {2-[(2E)-2-(1H-indol-3-ylmethylene)hydrazino]-2-oxoethyl} methylphenyl)benzenesulfonamide 4-ethoxy-N-(2- {(2E)-2-[(2-methyl- 1H-indol-3-yl)methylene]hydrazino}-2-oxoethyl)- N-(4-methylphenyl)benzenesulfonamide N-(4-chlorophenyl)-4- [3 -(dimethylamino)propoxy] {2-oxo-2-II(2Z)-2-(2-oxo- 1,2- dihydro-3H-pyrrolo[3,2-c]pyridin-3-ylidene)hydrazino] ethyl) benzenesulfonainide {[4-chloro( (dimethylamino)propoxy]phenyl} sulfonyl)anilino] acetyl}hydrazono)-2-oxo-2,3- dihydro- 1H-indole-7-carboxylic acid WO 02/32864 PCTIEPO 1/11865 C1 -180- C1 methyl {[4-cbloro( (dimethylamiino)propoxy]phenyl) sulfonyl)anilino]acetyl}llydrazono)-2-oxo-2,3- dihydro-lH-indole-7-carboxylate 00 4-ethoxy-N- {2-oxo-2-[(2Z)-2-(2-oxo-1 ,2-dihydro-3H-indol-3- 5 ylidene)hydrazinol ethyl} -N-(2-pyrimidinyl)benzenesulfonamide Cl 3- {4-[(4-cbloro {2-oxo-2-[(2Z)-2-(2-oxo- 1,2-dihydro-3H-indol-3- ylidene)hydrazino] ethyl} anilino)sulfonyl]phenyl} (dimethylan-ino)propyl]propanamide N-(4-chlorophenyl)-4-13-(4-methyl-1 -piperazinyl)-3-oxopropyl] {2-oxo-2-[(2Z)-2- (2-oxo- 1,2-dihydro-3H-indol-3-ylidene)hydrazino]ethyl}benzenesulfonamnide 3-(benzyloxy)-2-[( {4-chloro[(3,4- dimethoxyphenyl)sulfonyl] anilino} acetyl)amino]propanamide 3-(benzyloxy)-2-( {[4-chloro(phenylsulfonyl)anilinolacetyl} amino)propanamide {[(4-ethoxyphenyl)sulfonyl]-4-methylanilino} acetyl)anino]-2-phenylacetamide 3-(3,4-dichlorophenyl)-2-[( {[(4-fluorophenyl)sulfonyl] -4- methoxyanilino} acetyl)amino]propanamide {[(4-ethoxyphenyl)sulfonyl]-4-methoxyanihno} acetyl)- 1 ,2,3,4-tetahydro-3- isoquinolinyl] acetamide {[(4-ethoxyphenyl)sulfonyl]-4-niethoxyanilino} acetyl)-l1-isoindolinecarboxamide {[(3,4-dimethoxyphenyl)sulfonyl]-4-methoxyanilino} acetyl)-1 ,2,3,4-tetrahydro- 3-isoquinolinyl]acetamide {4-chloro[(4-ethoxyphenyl)sulfonyl]anilino} acetyl)valine WO 02/32864 WO 0232864PCTJEPOI1/11865 IND-81 CI {[(4-ethoxyphenyl)sulfonyl]-4-fluoroanilino} acetyl)aniino]-3-(1 H-mndol-3- yl)propanamide 00 {[(4-ethoxyphenyl)sulfonyl]-4-fluoroanilino Iacetyl)amnino]-2-phenylacetamide {[(3,4-dimethoxyphenyl)sulfonyl]-4-fluoroanilino} acetyl)valine N 5 1 {[(4-ethoxyphenyl)sulfonyl]-4-methylanilino} acetyl)-5-phenyl-2- pyrrolidinecarboxaniide 2-112-( {[(4-ethoxyphenyl)sulfonyl]anilino} acetyl)- 1,2,3,4-tetrahydro-3- isoquinolinyl] acetamide {[(4-ethoxyphenyl)sulfonyl]-4-methylanilino} acetyl)-1 ,2,3 ,4-tetrahydro-3- isoquinolinyl] acetamide {[(4-ethoxyphenyl)sulfonyl]-4--methoxyanilino} acetyl)amino]-4-phenylbutananiide {I(4-ethoxyphenyl)sulfonyl] -4-methoxyanilino} acetyl)-1 ,2,3,4-tetrahydro-3- isoquinolinecarboxamide {[(4-ethoxyphenyl)sulfonyl]-4-methoxyanilino} acetyl)amino] -3-(l1H-indol-3- yl)propanamide 1 {[(4-ethoxyphenyl)sulfonyl]-4-fluoroanilino} acetyl)-5-phenyl-2- pyrrolidinecarboxamide 3-(3,4-dichlorophenyl)-2-( fluoro(phenylsulfonyl)anilino] acetyl} anino)propanamnide 14. Sulfanilide derivatives according to any of claims 9 to 13 for use as a medicament. WO 02/32864 PCT/EP01/11865 (N -182- C1 15. Use of a sulfanilide derivatives according to any of claims 9 to 13 for the preparation of a medicament for the treatment of preterm labor, premature birth, dysmenorrhea, V) inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, oO Sliver cirrhosis, nephrotic syndrome and ocular hypertension. O r- 5 16. Use of a sulfanilide derivatives according to any of claims 9 to 13 for the preparation of 0 a medicament for the treatment ofpreterm labor, premature birth, dysmenorrhea 17. Use according to claim 15 or 16, wherein such treatment and/or prevention is associated with the modulation of the oxytocin and/or vasopressin receptor. 18. Use according to claim 17, wherein said modulation consists in the blocking of the oxytocin and/or vasopressin receptor or in antagonising the binding of oxytocin and/or vasopressin to its receptor. 19. Use of a sulfanilide derivative according to any of claims 9 to 13 for the preparation of a pharmaceutical composition. A pharmaceutical composition containing at least one sulfanilide derivative according to any of claims 9 to 13 and a pharmaceutically acceptable carrier, diluent or excipient thereof. 21. Process for the preparation of a sulfanilide derivative according to any of claims 9 to 13, wherein one of the following reactions are performed: WO 02/32864 WO 0232864PCT/EPOI/1 1865 -183- H IV I peptide coupling agent R 1 0 0i1 Z S OR A 2 R 1) H 2 N-NH 2 R8~ R 9 F R' 0 4 0' 4 0 =SN, NYRa R 2 3 R F II whereby n is an integer from 1 to 3, R is H or CI-C 6 -alkyl and the substituents R'-R 9 are as above defined. 21. Process for the preparation of a sulfanilide derivative according to any of claims 9 to 13, wherein one of the following reactions are performed WO 02/32864 WO 0232864PCT/EP01/1 1865

184- H 0 P N OR H 0 4 R 3 R MVI 2 k 3 R 11 (R 4 -N=CR 8 R 9 0 0 z kOR zY N' W R 3 Rk =VI1 whereby P is a protecting group, Z is a leaving group, ni is an integer from 1 to 3, R is H or CI-C&-alkyl and the substituents are as above defined.